US20120237485A1 - Trabecular Meshwork Stem Cells - Google Patents

Trabecular Meshwork Stem Cells Download PDF

Info

Publication number
US20120237485A1
US20120237485A1 US13/361,908 US201213361908A US2012237485A1 US 20120237485 A1 US20120237485 A1 US 20120237485A1 US 201213361908 A US201213361908 A US 201213361908A US 2012237485 A1 US2012237485 A1 US 2012237485A1
Authority
US
United States
Prior art keywords
cells
stem cells
cell
multipotent stem
isolated population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/361,908
Inventor
Yiqin Du
James L. Funderburgh
Joel Steven Schuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/361,908 priority Critical patent/US20120237485A1/en
Assigned to UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION reassignment UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DU, YIQIN, FUNDERBURGH, JAMES L., SCHUMAN, JOEL STEVEN
Publication of US20120237485A1 publication Critical patent/US20120237485A1/en
Priority to US14/605,216 priority patent/US10004766B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF PITTSBURGH
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/07—Coculture with; Conditioned medium produced by endocrine cells
    • C12N2502/076—Coculture with; Conditioned medium produced by endocrine cells pituitary cells

Definitions

  • the trabecular meshwork is a region of spongy tissue in the eye located around the base of the cornea and near the ciliary body.
  • the TM functions to drain the aqueous humor from the eye into the circulatory system via the anterior chamber and a series of tubes called Schlemm's canal.
  • cells of the TM i.e., TM cells
  • TM cells phagocytose extracellular debris to prevent blockage of Schlemm's canal.
  • TM cellularity and impaired TM function lead to the pathogenesis of glaucoma, a medical condition of the eye in which aqueous humor outflow is decreased and/or levels of aqueous are increased, either or both of which ultimately lead to an elevation in intraocular pressure.
  • Laser trabeculoplasty is a surgery in which a laser makes tiny, evenly spaced burns in the TM to re-stimulate its drainage function. Laser trabeculoplasty surgery increases cell division in the TM, thereby increasing TM cellularity. Within days of the procedure, cells found in the anterior, non-filtering region of the TM, called the insert area, migrate out of this region and repopulate the laser-burned sites. While laser trabeculoplasty is a quick, easy, convenient, and relatively low-risk procedure, there are drawbacks to this technique. For example, about half of the patients require further medical or surgical treatment within two to five years.
  • the procedure has a relatively small effect on lowering the eye pressure and repeat treatments are usually not very effective.
  • the procedure has no benefit and can even worsen the glaucoma.
  • Surgical treatment options for glaucoma also have risks.
  • the glaucoma operation fails and requires glaucoma medication or another glaucoma operation.
  • the eye pressure becomes severely reduced immediately after surgery. While this is harmless over a short period of time, this can lead to vision changes if the reduced eye pressure continues over a long period of time.
  • surgery treatment most often requires general anesthesia. Further, a leak from the surgery, bleeding in the eye, or infection of the eye can occur post-surgery.
  • the application or administration of stem cells that have the potential to differentiate into TM cells is an attractive means of treating or preventing glaucoma. It has been postulated that the insert area contains stem-like cells that serve as a source of TM cell renewal, and some groups report attempts to isolate such cells through surgical dissection of the TM insert area. However, Kelley et al., Exp Eye Res 88(4); 747-751 (2009) argue that this method represents a difficult technique. Other groups have cultured TM cells or have produced neurospheres from human TM cultures with an aim to isolate multipotent progenitor cells from the TM. While these groups report the expression profiles of the isolated cells, none have demonstrated that the isolated cells are capable of differentiating into TM cells.
  • multipotent stem cells exist throughout the TM and are not limited to the insert area (also known as “insert region”) of the TM.
  • the multipotent stem cells can be cultivated and passaged in vitro, undergoing multiple cellular divisions without losing their likeness to stem cells, are capable of differentiating into functional trabecular meshwork (TM) cells, and are capable of localizing to the TM after injection into the eye.
  • TM functional trabecular meshwork
  • the present disclosures provide isolated populations of multipotent stem cells which are capable of differentiating into TM cells.
  • the isolated population comprises multipotent stem cells isolated from a TM, e.g., a TM obtained from a tissue bank.
  • the TM is a TM of a mammal, e.g., a human, pig, horse, cow, dog, monkey, and the like.
  • the isolated population comprises multipotent stem cells isolated from a filtering region of a TM, and in some embodiments, the isolated population comprises multipotent stem cells isolated from both a filtering region and non-filtering region of the TM.
  • the isolated population comprises multipotent stem cells isolated from a region other than the insert area of the TM, and in other embodiments, the isolated population comprises multipotent stem cells isolated from the insert area of the TM and from a region other than the insert area.
  • the isolated population represents a highly purified population of multipotent stem cells, wherein, for example, at least 90% of the cells of the population are multipotent stem cells.
  • at least 90% of the cells of the population express a stem cell marker selected from the group consisting of ABCG2, Pax6, Nestin, Ankyrin G, Mucin 1, CD73, CD90, CD 166, Bmi-1, CD 117, Notch 1, Oct4, KLF4, and a combination thereof.
  • at least 90% of the cells of the population express Ankyrin G and Mucin 1.
  • the stem cells are multipotent insofar as the multipotent stem cells are capable of differentiating into TM cells (e.g., phagocytic TM cells), corneal keratocytes, neural cells, and adipocytes.
  • the multipotent stem cells represent a single type of precursor cells or progenitor cells that has the capacity to become TM cells (e.g., phagocytic TM cells), the capacity to become corneal ketocytes, the capacity to become neural cells, and the capacity to become adipocytes.
  • An exemplary method comprises obtaining an isolated population of multipotent stem cells and culturing the isolated population of multipotent stem cells in a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor, to induce differentiation of the multipotent stem cells into TM cells.
  • the isolated population of multipotent stem cells is any one of the presently disclosed isolated populations of multipotent stem cells, e.g., those isolated from a trabecular meshwork.
  • the isolated population of multipotent stem cells is obtained by side population cell sorting of cells of a trabecular meshwork.
  • the isolated population of multipotent stern cells is obtained by clonal expansion of cells of a trabecular meshwork.
  • the isolated population of multipotent stem cells is obtained by selective expansion of stem cells of a trabecular meshwork.
  • the isolated populations of TM cells obtained therefrom are moreover provided.
  • compositions comprising the presently disclosed isolated population of multipotent stem cells or the presently disclosed isolated population of TM cells.
  • the composition comprises a pharmaceutically acceptable carrier, diluents, or excipient, such that the composition may be considered as a pharmaceutical composition.
  • the composition comprises a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor.
  • the cells are from a human and the aqueous humor is from a non-human.
  • the cells are in solution.
  • the cells are cryopreserved.
  • the compositions are formulated for administration to a subject by implantation or injection.
  • the compositions are formulated for sustained, continuous release.
  • the cells are in a matrix, capsule, or gel.
  • kits and devices comprising the compositions of the present disclosures.
  • the kits comprise instructions for use, e.g., instructions for administration of the composition to a subject, and/or comprise a device for administration of the composition to a subject.
  • the device is a syringe, a matrix, a capsule, or an intravenous bag.
  • the composition is used in a method of decreasing intraocular pressure in an eye.
  • the method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to decrease the intraocular pressure in the eye.
  • the composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures is used in a method of increasing cell density in a trabecular meshwork of an eye.
  • the method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to increase cell density in the trabecular meshwork of an eye.
  • the composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures is used in a method of increasing outflow of aqueous humor from an eye.
  • the method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to increase outflow of aqueous humor from the eye.
  • the present disclosures furthermore provide a method of treating or preventing a medical condition.
  • the medical condition is caused by or associated with decreased cell density in a trabecular meshwork, increased intraocular pressure in an eye, decreased outflow of aqueous humor from an eye, or a combination thereof.
  • the method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to treat or prevent the medical condition.
  • the medical condition is glaucoma.
  • FIG. 1 demonstrates an exemplary distribution of stem cells in trabeculate meshwork.
  • A Immunofluorescent staining on cryosections of human anterior segment shows the distribution of cells positive to stem cell markers ABCG2, Pax6, Muc1 or AnkG (Red) in human TM tissue which is outlined by the TM cell markers AQPI, MGP, CHI3L1, TIMP3 (Green). The cells positive to stem cell markers spread through the TM tissue and are not limited to a specific region.
  • TM trabecular meshwork
  • ABCG2 ATP-binding cassette sub-family G member 2
  • Mud mucin 1
  • AnkG ankyrin G
  • MGP matrix gla protein
  • AQPI aquaporin 1
  • CH13L1 chitinase 3-like 1
  • TIMP3 tissue inhibitor of metalloproteinases-3
  • qPCR quantitative reverse transcription-polymerase chain reaction, Kera, keratocan.
  • FIG. 2 demonstrates an exemplary isolation and characteristics of Side Population cells.
  • A The SP cells were isolated by fluorescence activated cell sorting (FACS) from cultured human TM cells. Passage-three TM cells stained with DyeCycle Violet Dye (DCV) were analyzed using violet 405-nm excitation with blue (450/40) and red (620 LP) emission. Cells showing reduction of both blue and red fluorescence (SP cells) were collected as defined by the box outlined on the left (arrow) which can be eliminated by preincubation with ABCG2 inhibitor fumitremorgin C (FTC).
  • FACS fluorescence activated cell sorting
  • FIG. 3 demonstrates exemplary expression of stem cell markers in passaged TM stem cells.
  • Different expression of stem cell markers ABCG2, Pax6, Ankyrin G, Mucin1 and TM differentiation markers CHI3L1, AQPI, MGP, TTMP3 as well as glaucoma related marker myocilin was detected by immunofluorescent staining on TMSC (A-E) and primary TM cells (F-J).
  • a and F show double-stain of ABCG2 and Pax6,
  • B and E are stains of Ankyrin G and CHI3L1, C and H are Mucin 1 and AQPI, D and I are MGP and Myocilin, E and J are T1MP3 stain.
  • DAPI stains nuclei as blue.
  • FIG. 4 demonstrates an exemplary induction of TMSC differentiation into TM cells.
  • A Double fluorescent staining compares the different expression of the TMSC cultured in SCGM (the first column: A, E, I, M, Q) and the induced TM cells in SCGM and AH (the second column: B, F, 3, N, R), in AH only (the third column: C, O, K, 4, 5), or in 10% FBS (the fourth column: D, H, L, P, T).
  • A-D show double-stain of ABCG2 and Pax6, E-H are stains of Ankyrin G and CHI3L1, I-L are Mucin 1 and AQP1, M-P are MGP and Myocilin, Q-T are TIMP3 stain.
  • U mRNA pools for stem cell makers ABCG2, Pax6, Muc1, AnkG; TM markers AQP1, MGP; and glaucoma markers myocilin were quantified by qPCR to compare the differences between the passaged TMSC and the induced TM cells in different media. Error bars show SD of triplicate analyses.
  • TMSC stem cell growth medium
  • 5CGM/AH 50% stem cell growth medium+50% aqueous humor
  • AH aqueous humor
  • FBS fetal bovine serum
  • FIGS. 4V-4X demonstrate differential gene expression among passaged TMSC and differentiated TM cells.
  • V mRNA pools for stem cell makers ABCG2, Pax6, CD73, CD90, CD 166, CD 117, Bmi 1, OCT4, Notch 1, KLF4, Muc1 and AnkG were quantified by qPCR to compare the differences between passaged TM stem cells and induced TM cells with aqueous humor at passage-two as well as passage-five. Error bars show SD of triplicate analyses. Asterisks indicate significant (p ⁇ 0.05) difference between passaged TMSC and induced TM cells.
  • FIG. 5 demonstrates an exemplary phagocytosis of TM cells induced from TMSC.
  • Passaged TMSC were induced to differentiate into TM cells by culturing in STCMIAH, in AH or in 10% FBS for one week. Phagocytic function was detected by incubating the cells with Staphylacoccus aureus bioparticles (Green) as described in Materials and Methods. Green particles in A-E are the ingested bioparticles by the cells and the yellow dots are not washed out free particles with conjugating with the red secondary antibody.
  • FIG. 6 demonstrates an exemplary induction of TMSC into neural cells, adipocytes and keratocytes.
  • the TMSC were cultured in NDM for neural induction and in ADM and AMM for adipogenic induction as described in the Materials and Methods.
  • the keratocyte differentiation was induced as three dimensional culture in KDM.
  • Immunofluorescent stain compares the cells in NDM (A-D) and in. SCGM (E-F).
  • A) and (E) are the stain of NF200;
  • B) and (F) are that of—tubulin HI;
  • C) and (G) are GFAP;
  • D and H are Mucin 1.
  • (I) and (7) show oil red O stain on cells induced in ADM and AMM (I) and cells in SCGM (J) as control.
  • TMSC trabecular meshwork stem cells
  • NDM neural differentiation medium
  • ADM adipogenic differentiation medium
  • AMM adipogenic maintenance medium
  • KDM keratocyte differentiation medium
  • NF200 neurofilament 200
  • GFAP glial fibrillary acidic protein
  • FIG. 7 demonstrates an exemplary injection of human TMSCs into mouse anterior chamber (AC).
  • Human TMSC were injected into normal mouse AC for 1 week, 2 weeks and 4 weeks.
  • the cryosections of the eyeballs were stained with TM marker AQPI (A) and TMSC marker AnkG (B), Schlemm's canal is labeled by the dashed arrows; the white solid arrows point to the injected green cells in the TM region; yellow arrows point out that the sclera is on the left and the cornea is on the right of the TM.
  • A TM marker AQPI
  • B TMSC marker AnkG
  • TM tissue whole mount stain was performed an TMSC injection at 1 week (D, I, N) and 4 weeks (F, K, P), on fibroblast injection at 1 week (E, 7, 0) and 4 weeks (G, L, Q) and on normal wild mouse tissue (C, H, M) as controls.
  • C-G are stains with anti-AQP1 antibody which reacts with both human and mouse antigen;
  • H-L are stains with anti-human specific CHI3L1 antibody;
  • M-Q are stains for Mud antibody which is not specific as AQP1.
  • FIG. 7M shows the sclera is over the left; cornea is over the right while the TM is in the middle which applies to all the whole mount stain in FIG. 7 .
  • TMSC human trabecular meshwork stem cells
  • AC Anterior chamber
  • TMSC-1w 1 week after trabecular meshwork stem cell injection
  • Fibro-1w 1 week after fibroblast injection.
  • FIG. 8A-C demonstrate isolation of TMSC as side population (SP) cells.
  • SP cells were isolated by FACS from passage-three human TM cells using DyeCycle Violet Dye. Cells showing reduction of both blue and red fluorescence (SP cells) were collected as defined by the box outlined on the left (arrow).
  • SP cells were collected as defined by the box outlined on the left (arrow).
  • RNAs extracted from dissected TM tissue and the adjacent corneal stroma tissue were compared on the expression of TM markers AnkG, CHI3L1; stromal marker KERA and the common marker for both TM and stroma AQP1 to assess if the dissected TM tissue contains corneal tissue.
  • SP side population
  • FACS fluorescence-activated cell sorting.
  • FIG. 9A-K demonstrate differential expression of stem cell- and TM-markers between TMSC and primary TM cells.
  • Clonal passaged TMSC (A-E) and primary TM cells (F-J) were double-stained with stem cell markers ABCG2 (green), Notch1 (red), OCT4 (red), AnkG (green), MUC1 (green); TM markers TIMP3 (green), CHI3L1 (red), AQP1 (red), MGP (green); and MYOC (red).
  • FIG. 10A-F demonstrates flow analysis of passage-four TMSC to assess the cell purity.
  • Stem cell markers (A) CD73, (B) CD90, (C) CD166, Bmi1 and TM cell markers (E) CHI3L1, AQP1 were analyzed by flow cytometry. The peak on the left in each histogram represents the isotype control for comparison with the cells labeled for each marker (on the right).
  • FIG. 11A-I demonstrate induction of neural cell differentiation from TMSC.
  • Immunofluorescent staining on neural markers neurofilament, ⁇ -tubulin III, GFAP and TMSC marker MUC1 shows different expression between TMSC in NDM (A-D) for neural induction and in SCUM (EH) to stem cell maintenance.
  • TMSC trabecular meshwork stem cells
  • NDM neural differentiation medium
  • SCUM stem cell growth medium
  • GFAP glial fibrillary acidic protein
  • NF neurofilament.
  • FIG. 12A-C demonstrate induction of adipocyte differentiation from TMSC.
  • TMSC were cultured in ADM and AMM alternately for adipogenic induction.
  • ADM adipogenic differentiation medium
  • AMM adipogenic maintenance medium
  • FIG. 13A-G demonstrate induction of corneal keratocyte differentiation from TMSC.
  • Cryosections of TMSC cultured as pellets in KDM (A-B) or in SCGM (C-D) were stained with keratan sulfate (A, C) and keratocan (B, D).
  • Human corneal stromal stem cells cultured as pellets in KDM served as positive control were also stained with keratan sulfate (E) and keratocan (F).
  • KDM keratocyte differentiation medium
  • KERA keratocan
  • ALDH aldehyde dehydrogenase
  • FIG. 14A-T demonstrate different protein expression of TMSC and induced TM cells.
  • Immunofluorescence compares different expression of stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; TM markers TIMP3, CHI3L1, AQP1, MGP and MYOC of TMSC cultured in SCGM (A-E), in 50% AH in SCUM (SCGM/AH) (F-J), in AH (K-O), or in 10% FBS (P-T).
  • Double-stain model is the same as FIG. 2 and the markers are labeled as green/red on top.
  • FIG. 15A-B demonstrate different gene expression of TMSC and induced TM cells by qRT-PCR and Western blotting.
  • A mRNA pools for stem cell makers ABCG2, Pax6, Notch1, MUC1, AnkG; TM markers AQP1, MGP; and MYOC and ELAM1 were quantified by qRT-PCR to compare the differences between TMSC and TM cells induced in different media. Error bars show SD of triplicate analyses.
  • ⁇ -tubulin serves as loading control. 1° TM, primary trabecular meshwork cells.
  • FIG. 16A-F demonstrate phagocytosis.
  • Figures A-E show phagocytosis assay to compare TMSC, induced and primary TM cells.
  • Green dots are phagocytosed fluorescently-conjugated S. aureus bioparticles. Yellow dots are unphagocytosed free bioparticles labeled with red secondary antibody.
  • the present disclosures provide isolated populations of multipotent stem cells which are capable of differentiating into TM cells (e.g., phagocytic TM cells).
  • TM cells e.g., phagocytic TM cells
  • multipotent refers to adult stem cells or somatic stem cells that can develop into two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) different differentiated cell types.
  • the multipotent stem cells of the isolated populations provided herein are not embryonic stem cells, and, therefore, are neither totipotent stem cells nor pluripotent stem cells, which stem cells are described in Kefley et al., Exp Eye Res. 88 (4): 747-751 (2009).
  • the stem cells are multipotent due to their potential for differentiating into any of TM cells, corneal ketocytes, neural cells, or adipocytes.
  • the multipotent stem cells represent a single type of precursor cell or progenitor cell that has the capacity to become TM cells, the capacity to become corneal ketocytes, the capacity to become neural cells, and the capacity to become adipocytes.
  • the multipotent stem cells of the isolated populations provided herein have only these four capacities (e.g., can only differentiate into one of TM cells, corneal ketocytes, neural cells, and adipocytes).
  • the multipotent stem cells of the isolated populations provided herein have the capacity to differentiate into additional cell types other than TM cells, corneal ketocytes, neural cells, and adipocytes.
  • the multipotent stem cells which are capable of differentiating into TM cells have the capacity to differentiate into phagocytic TM cells. Additional features and descriptions of the differentiated cells derived from the multipotent stem cells are provided below in the section entitled “Differentiated Cell Types.”
  • the multipotent stems cells of the isolated populations provided herein express one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more) stem cell markers.
  • a cell marker refers to a molecule, such as a polypeptide, protein, mRNA, that is expressed by the cells and assists scientists in the identification of that cell type (either alone, in the case of certain cell type-specific markers, or in combination with other markers or cellular characteristics.
  • a stem cell marker is a marker that is expressed by stem cells and is useful for distinguishing a stem cell from other types of cells, such as differentiated cells, e.g., a TM cell, a neural cell, a corneal keratocyte, corneal fibroblasts, a stromal cell, an adipocyte.
  • the stem cells marker is CD34, CD38, CD90, CD 133, CD105, c-kit, CD73, CD90, CD166, ABCG2, Pax6, Nestin, Ankyrin G, Mucin 1, bone morphogenetic protein receptor, Lineage surface antigen (lin), Stro-1 antigen, Oct4, or KLF4.
  • the multipotent stem cells express one or more stem cell markers selected from the group consisting of CD73, CD90, CD 166, Bmi-1, Oct4, KLF4, ABCG2, Pax6, Nestin, Ankyrin G, and Mucin 1.
  • the multipotent stem cells express two, three, four, five, six, seven, eight, nine, ten, or all of the stem cell markers CD73, CD90, CD166, Bmi-1, Oct4, KLF4, ABCG2, Pax6, Nestin, Ankyrin G, and Mucin 1.
  • the multipotent stem cells express Mucin 1 and Ankyrin G.
  • the multipotent stem cells express the stem cell marker at a level which is detectable by standard immunohistochemistry techniques, including but not limited to immunofluorescence, fluorescent activated cell sorting (FACS) analysis, and the like, or by polymerase chain reaction (PCR) based techniques, e.g., quantitative PCR.
  • the multipotent stem cells express the stem cell marker at an increased level, as compared to the expression level of the stem cell marker in a differentiated cell, e.g., a TM cell, a neural cell, a corneal keratocyte, corneal fibroblasts, a stromal cell, an adipocyte, and the like.
  • the multipotent stem cells of the isolated populations provided herein express one or more (e.g., one, two, three, four, five, or more) non-stem cell markers at reduced or undetectable levels.
  • the multipotent stem cells express at a reduced or undetectable level a marker that is characteristic of a differentiated cell which is derived from the stem cell.
  • the multipotent stem cells express one or more (e.g., one, two, three, four, five, or more) of TM cell markers at reduced levels or at undetectable levels as compared to that expressed by a TM cell (e.g., a differentiated TM cell, a mature TM cell).
  • the TM cell marker is selected from a group consisting of: AQP1, MGP, and CH13L1, NCAM, and TIMP3, or lack of detectable expression of MYOC, or a combination of these TM cell markers.
  • the multipotent stem cells express one or more keratocyte markers at reduced levels or at undetectable levels, as compared to that expressed by keratocytes.
  • the keratocyte marker is keratocan.
  • the multipotent stem cells express one or more neural cell markers at reduced levels or at undetectable levels, as compared to that expressed by neural cells.
  • the neural cell marker is GFAP, neurofilament, (3-tubulin III, or a combination thereof.
  • the multipotent stem cells express one or more adipocyte markers at reduced levels or at undetectable levels, as compared to that expressed by adipocytes.
  • the adipocyte marker is selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, and adipocyte lipid-binding protein (ALBP/ap2).
  • the adipocyte marker is formation of lipoid deposits, e.g., as detected by Oil Red O staining.
  • the multipotent stem cells of the isolated populations provided herein may be considered as tissue-specific stem cells that differentiate into the cells of the tissue from which the multipotent stem cells are isolated or obtained. Tissue-specific stem cells are further described in Kelley et al., supra. Accordingly, in some embodiments, the isolated population provided herein comprises multipotent stem cells isolated from the trabecular meshwork, e.g., TM of a mammal (e.g., rat, mouse, pig, cow, dog, chimpanzee, primate, human, and the like).
  • TM multipotent stem cells isolated from the trabecular meshwork
  • the isolated population comprises multipotent stem cells isolated from a filtering region of the TM, and in same embodiments, the isolated population comprises multipotent stem cells isolated from both a filtering region and non-filtering region of the TM. In some aspects, the isolated population comprises multipotent stem cells that are isolated only from a filtering region of the TM and not from a non-filtering region of the TM. In some aspects, the multipotent stem cells are cells isolated from a region of the TM other than the insert area. In some aspects, the multipotent stem cells are cells isolated from the insert area of the TM and from a region of the TM other than the insert area.
  • greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the multipotent stem cells of the isolated population are from a filtering region of the TM.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5% less than or about 2%, or almost 0%) of the multipotent stem cells of the isolated population are from a non-filtering region of the TM.
  • the isolated population lacks multipotent stem cells isolated from the insert area of the TM.
  • the isolated population of multipotent stem cells comprise the multipotent stem cells obtained in accordance with one of the methods of obtaining an isolated population of multipotent stem cells provided herein.
  • the multipotent stem cells of the isolated populations provided herein are not tissue-specific stem cells. Accordingly, in some aspects, the multipotent stem cells are isolated from a tissue other than the TM. In some aspects, the multipotent stem cells are isolated from a tissue other than a neural tissue. In some aspect, the multipotent stem cells are isolated from a tissue other than adipose. In some aspects, the multipotent stem cells are isolated from bone marrow, adipose tissue, skin, umbilical cord, amniotic fluid.
  • the term “isolated” means having been removed from its natural environment and separated from some or all of the coexisting materials in the natural environment. Accordingly, the isolated populations of multipotent stem cells are stern cells that have been removed from their natural environment and separated from some or all of the other cells and/or tissue of the origin of the multipotent stem cells. For example, an isolated population of multipotent stem cells from a TM represents multipotent stem cells removed from the TM and separated from some or all of the co-existing TM cells and fibroblasts (and connective tissue) found in a TM.
  • an isolated population of multipotent stem cells isolated from the filtering region of the TM represents multipotent stem cells removed from the filtering region of the TM and separated from other cells of the filtering region of the TM.
  • an isolated population of multipotent stem cells isolated from the filtering region and non-filtering region of the TM e.g., the insert area, represent cells removed from the filtering region and non-filtering region, e.g., the insert area, of the TM and separated from other cells of the filtering region and non-filtering region of the TM.
  • the isolated populations provided herein are purified, e.g., purified from other components (e.g., cells) of the natural environment from which the cells were isolated.
  • purified as used herein means having been increased in purity, wherein “purity” is a relative term, and not to be necessarily construed as absolute purity.
  • the purity can be greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%)
  • the isolated populations in some aspects may be purified of cells of the TM which are not stem cells, e.g., the isolated populations are purified from T1v1 cells.
  • the isolated population represents a substantially purified population of multipotent stem cells, wherein, for example, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the population are multipotent stem cells.
  • greater than or about 50% e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%
  • greater than or about 50% e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%
  • stem cell marker selected from the group consisting of ABCG2, Ankyrin 5 Pax6, Nestin, Mucin 1, CD73, CD90, CD166, Bmi-1, Oct4, CD117, Notch1, and KLF4.
  • the stem cell marker is expressed by greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the population at an increased level, as compared to cells which are known not to be stem cells, e.g., non-stem cells (e.g., TM cells, fibroblasts, keratocytes, neural cells, adipocytes, and the like).
  • non-stem cells e.g., TM cells, fibroblasts, keratocytes, neural cells, adipocytes, and the like.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of cells of the isolated population are cells other than multipotent stem cells.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are non-stem cells (e.g., TM cells, fibroblasts, keratocytes, neural cells, adipocytes, and the like).
  • the isolated populations are homogeneous populations consisting of only one type of cell, the multipotent stem cells. In some aspects, the isolated populations are substantially homogenous populations consisting essentially of multipotent stem cells. In exemplary embodiments, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated populations provided herein are multipotent stem cells, e.g., multipotent stem cells that express one or more stem cell markers, as described herein.
  • the isolated population is a clonal population of multipotent stem cells in which each cell of the population is genetically indistinct from another cell of the population.
  • the isolated population consists of only or consists essentially of multipotent stem cells, but the isolated population is not a clonal population of genetically indistinct multipotent stem cells.
  • the multipotent stem cells are from a TM.
  • the TM is a TM of a mammal, such as any mammal described herein, e.g., mouse, rat, pig, human, dog, cat, horse, cow, chimpanzee, primate.
  • the human is an adult (e.g., aged 18 years or more).
  • the human is a child or a fetus.
  • the human is living.
  • the human is deceased, e.g., recently deceased (e.g., deceased within 1 month, 2 weeks, 1 week, 3 days, 2 days, 1 day, 12 hours, 6 hours, from time of TM collection).
  • the cells of a trabecular meshwork are cells of an eye, or part thereof (e.g., cornea, sclera rim, TM) obtained from a tissue bank, e.g., a human tissue bank. Collection of TM tissue from a cornea obtained from a tissue bank and processing of the TM tissue to obtain cells are described herein (Example 1).
  • the multipotent stem cells are from a source other than a TM, e.g., bone marrow, adipose tissue, skin, umbilical cord, amniotic fluid.
  • a source other than a TM e.g., bone marrow, adipose tissue, skin, umbilical cord, amniotic fluid.
  • the isolated population of multipotent stem cells are obtained by side population cell sorting of cells of a TM.
  • Such cell sorting methods are described herein (e.g., Example 1) and, in the context of other cell types, in, e.g., Goodell, Curr Protocols in Cytometry 34: 9.18.1-9.18.11 (2005), Telford, “Stem Cell Side Population Analysis and Sorting Using DyeCycle Violet,” Current Protocols in Cytometry Unit 9.30 (2010), Telford et al., Stem Cells 25: 1029-1036 (2007), Telford, Applications of Flow Cytometry in Stem Cell Research and Tissue Regeneration, ed. Krishan et al., pages 25-44 (2010), and Camargo et al., Blood 107: 501-507 (2006).
  • the isolated population of multipotent stem cells which are capable of differentiating into TM cells are obtained through a side population cell sorting method comprising (i) contacting cells isolated from a trabecular meshwork with a dye which (a) is effluxed by an, ABCG2 protein and (b) emits a detectable signal at a known wavelength, (ii) isolating cells exhibiting a reduced emission of the detectable signal at the known wavelength from cells exhibiting an increased emission of the detectable signal at the known wavelength.
  • the dye used in the side population cell sorting method is a dye that intercalates into DNA.
  • the dye is a fluorescent dye.
  • the dye is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux, e.g., DyeCycle Violet.
  • ABCG2-mediated efflux e.g., DyeCycle Violet.
  • Such dyes are commercially available through vendors, such as Invitrogen (Carlsbad, Calif.).
  • the dye is Hoechst 33342, which is commercially available from Sigma-Aldrich, St. Louis, Mo.).
  • the isolated population of multipotent stem cells are obtained by clonal expansion of cells of a trabecular meshwork, which cells express stem cell markers.
  • Such methods are described herein (e.g., Example 1) and, in the context of other cell types, in, e.g., Halleux et al., J Musculoskele Neuron Interact 2(1): 71-76 (2001).
  • the isolated population of multipotent stem cells is obtained by selective expansion of stem cells of a TM in a culture medium which promotes growth of stem cells while preventing or inhibiting growth of non-stem cells of the TM (e.g., mature TM cells, fibroblasts).
  • the culture medium is a culture medium comprising growth factors and cytokines (e.g., IL-6, stem cell factor) suitable for the growth of stem cells.
  • the culture medium substantially lacks growth factors or cytokines necessary for the growth of TM cells or fibroblasts.
  • the isolated populations of multipotent stem cells may be cultured under any suitable culturing conditions known in the art, e.g., conditions which promote cellular growth and expansion. Suitable culturing conditions include those described herein (e.g., Example 1) and in Adult Stem Cells, Turksen, ed., Humana Press, 2004, and Stem Cells Handbook, Sell, ed., Humana Press, 2003, or conditions varied therefrom which conditions may be empirically determined.
  • the isolated populations of multipotent stem cells are cultured in a medium comprising serum, epidermal growth factor, pituitary extract, ascorbic acid, chondroitin sulfate, calcium chloride, or a combination thereof.
  • the medium comprises at least one antibiotic, e.g., penicillin, streptomycin, gentamicin, and the like.
  • multipotent stem cells can be induced to differentiate into functional trabecular meshwork cells, e.g., phagocytic TM cells.
  • the multipotent stem cells that have the capacity to differentiate into TM cells also are capable of differentiating into other cells types, including, but not limited to, keratocytes, neural cells, and adipocytes, thus, demonstrating the multipotent nature of the stem cells.
  • the present disclosures also provide methods of obtaining an isolated population of differentiated TM cells, differentiated keratocytes, differentiated neural cells, or differentiated adipocytes from multipotent stem cells.
  • the method comprises obtaining an isolated population of multipotent stem cells (e.g., from a TM) and culturing the isolated population of multipotent stem cells in a medium comprising factors sufficient and appropriate for induction of differentiation of the multipotent stem cell into the differentiated cell (e.g., TM cell, keratocyte, neural cell, adipocyte).
  • a medium comprising factors sufficient and appropriate for induction of differentiation of the multipotent stem cell into the differentiated cell (e.g., TM cell, keratocyte, neural cell, adipocyte).
  • the step of obtaining the isolated population of multipotent stem cells is preformed as described herein (e.g., the section entitled “Methods of obtaining isolated populations of multipotent stem cells”).
  • the isolated population of multipotent stem cells is obtained via side population cell sorting of cells of a TM, clonal expansion of cells of a TM, or selective expansion of stem cells of a TM in a culture medium which promotes growth of stem cells while preventing of inhibiting growth of non-stem cells of the TM.
  • the method provided herein is a method of obtaining an isolated population of differentiated TM cells.
  • the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting, clonal expansion of cells of a TM, selective expansion of stem cells of a TM).
  • the isolated population of multipotent stem cells is in accordance with the descriptions of isolated populations of multipotent stem cells described herein (see, e.g., “Isolated populations of multipotent stem cells”).
  • the isolated population of multipotent stem cells are cultured in a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor.
  • the medium comprises aqueous humor, fetal bovine serum, or both aqueous humor and fetal bovine serum.
  • the aqueous humor is obtained from a non-human mammal (e.g., cow, pig, horse, dog, cat, monkey) and the multipotent stem cells are human multipotent stem cells.
  • the medium comprises at least or about 25% (v/v) aqueous humor.
  • the medium comprises at least or about 30% (e.g., 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%) (v/v) aqueous humor.
  • the medium comprises at least or about 5% (v/v) fetal bovine serum.
  • the medium comprises at least or about 10% (e.g., 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%)) (v/v) fetal bovine serum.
  • the medium comprising fetal bovine serum comprises Dulbecco's Modified Eagle Medium (DMEM): Nutrient Mixture F-12 (DMEMIF'12)® (Invitrogen, Carlsbad, Calif.).
  • DMEM Dulbecco's Modified Eagle Medium
  • DMEMIF'12 Nutrient Mixture F-12
  • the multipotent stem cells used in the method of obtaining an isolated population of differentiated TM cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • the method provided herein is a method of obtaining an isolated population of differentiated keratocytes.
  • the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in a keratocyte differentiation medium (KDM).
  • KDM comprises fibroblast growth factor-2 and/or ascorbic acid-2-phosphate.
  • the KDM comprises Advanced® MEM (Invitrogen) supplemented with fibroblast growth factor-2 and/or ascorbic acid-2-phosphate.
  • the multipotent stem cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • the method provided herein is a method of obtaining an isolated population of differentiated neural cells.
  • the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in a neural differentiation medium (NDM).
  • NDM comprises epithelial growth factor, fibroblast growth factor, all-trans retinoic acid, or a combination thereof.
  • the NDM comprises penicillin, streptomycin, gentamicin, or a combination thereof.
  • the NDM comprises Advanced® DMEM (Invitrogen) supplemented with epithelial growth factor, fibroblast growth factor, all-trans retinoic acid, penicillin, streptomycin, gentaraicin, or a combination thereof.
  • the multipotent stem cells in the NDM are plated onto a dish (e.g., a plastic dish) coated with a medium which promotes attachment of cell to the dish, e.g., FNC Coating Mix® (AthenaES).
  • the multipotent stem cells used in the method of obtaining an isolated population of differentiated neural cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • the method provided herein is a method of obtaining an isolated population of differentiated adipocytes.
  • the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in an adipogenic differentiation medium (ADM).
  • ADM comprises fetal bovine serum, dexamethasone, methyl-isobutylxanthine, insulin, or a combination thereof.
  • the ADM comprises indomethacin, penicillin, streptomycin, gentamicin, or a combination thereof.
  • the ADM comprises DMEM-Law glucose (Invitrogen) supplemented with fetal bovine serum, dexamethasone, methyl-isobutylxanthine, insulin, indomethacin, streptomycin, gentainicin, or a combination thereof.
  • the multipotent stem cells in the ADM are plated onto a dish (e.g., a plastic dish) coated with gelatin (e.g., 1% (v/v) gelatin).
  • the multipotent stem cells used in the method of obtaining an isolated population of differentiated adipocytes are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • the present disclosures further provide the isolated populations of the differentiated cells obtained through these methods.
  • the differentiated cells e.g., the TM cells, corneal keratocytes, neural cells, or adipocytes
  • the differentiated cells express a stem cell marker at a reduced level or an undetectable level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated.
  • the stem cell marker is selected from the group consisting of ABCG2, Pax6, Nestin, AnkyriuG, Mucin1, CD73, CD9Q, CD166, Bmi-1,
  • CD117 Notch1, Oct4, KLF4, and a combination thereof. Further descriptions of each type of differentiated cells are provided below.
  • the TM cells when the differentiated cells are TM cells, the TM cells in some aspects express a TM cell marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated.
  • the TM cell marker is selected from the group consisting of MGP, AQP1, CHI3L1, NCAM, TIMP3, and a combination thereof.
  • the differentiated TM cells are phagocytic TM cells.
  • the TM cells of the isolated populations provided herein are capable of phagocytosing extracellular debris, such that the TM cells function to prevent blockage of Schlemm's canal in an eye.
  • the present disclosures further provide isolated populations of TM cells, e.g., phagocytic TM cells, which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells.
  • the isolated populations of TM cells are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells.
  • the isolated population of TM cells is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are TM cells.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a TM cell, e.g., a multipotent stem cell, a keratocyte, a neural cell, adipocyte.
  • a TM cell e.g., a multipotent stem cell, a keratocyte, a neural cell, adipocyte.
  • the corneal keratocytes in some aspects express a keratocyte marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated.
  • the keratocyte marker is keratocan.
  • the present disclosures provides isolated populations of corneal keratocytes which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells.
  • the isolated populations of corneal keratocytes are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells.
  • the isolated population of corneal keratocytes is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g—greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are corneal keratocytes.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a corneal keratocyte, e.g., a multipotent stem cell, a TM cell, a neural cell, an adipocyte.
  • a corneal keratocyte e.g., a multipotent stem cell, a TM cell, a neural cell, an adipocyte.
  • the neural cells when the differentiated cells are neural cells, the neural cells in some aspects express a neural cell marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated.
  • the neural cell marker is selected from the group consisting of GFAP, neurofilament, and J3-tubulin III, and a combination thereof.
  • the present disclosures provides isolated populations of neural cells which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells.
  • the isolated populations of neural cells are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells.
  • the isolated population of neural cells is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are neural cells.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a neural cell, e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, an adipocyte.
  • a neural cell e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, an adipocyte.
  • the adipocytes in some aspects express an adipocyte marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated.
  • the adipocyte marker is selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, ALBP/ap2, and a combination thereof.
  • the adipocytes exhibit an increased level of lipoid deposits, as compared to the multipotent stem cells from which the adipocytes originated.
  • the present disclosures provides isolated populations of adipocytes which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells.
  • the isolated populations of adipocytes are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells.
  • the isolated population of adipocytes is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are adipocytes.
  • less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than an adipocyte, e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, a neural cell.
  • adipocyte e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, a neural cell.
  • the present disclosures furthermore provides the cells in singular form. Accordingly, the present disclosures provides an isolated multipotent stem cell capable of differentiating into a TM cell, as well as an isolated differentiated cell e.g., an isolated TM cell, an isolated corneal keratocyte, an isolated neural cell, an isolated adipocyte.
  • the isolated cell exhibits a marker expression profile in accordance with the teachings of the corresponding isolated population provided herein.
  • the isolated multipotent stem cell provided herein expresses a stem cell marker selected from the group consisting of ABCG2, Ankyrin 5 Pax6, Nestin, Mucin 1, CD73, CD9Q, CD166, Bmi-1, CD117, Notch1, Oct4, KLF4, and a combination thereof.
  • the isolated TM cell provided herein expresses a TM cell marker selected from the group consisting of MGP, AQP1, CHI3LI, NCAM, TIMP3, and a combination thereof, at an increased level, as compared to the multipotent stern cell from which the TM cell originated.
  • the isolated corneal keratocyte expresses keratocan at an increased level, as compared to the multipotent stem cell from which the keratocyte originated.
  • the isolated neural cell expresses a neural cell marker selected from the group consisting of GFAP, neurofilament, ( ⁇ -tubulin III and a combination thereof, at an increased level, as compared to the multipotent stem cell from which the neural cell originated.
  • the isolated adipocyte exhibits an increased level of lipoid deposits, or an increased level of an adipocyte marker selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, ALBP/ap2, and a combination thereof, as compared to the multipotent stem cell from which the adipocyte originated.
  • the multipotent stem cells or the differentiated cells of the present disclosures are genetically modified to contain a recombinant nucleic acid.
  • nucleic acid includes “polynucleotide,” “oligonucleotide,” and “nucleic acid molecule,” and generally means a polymer of DNA or RNA, which can be single-stranded or double-stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered inter-nucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide.
  • the term “recombinant” refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above.
  • the replication can be in vitro replication or in vivo replication.
  • the recombinant nucleic acid encodes a protein and the cell expresses the protein.
  • the recombinant nucleic acid inhibits or prevents expression of a protein by the cell in which the recombinant nucleic acid resides.
  • the protein may be any protein, e.g., an enzyme, signaling protein, a ligand binding protein, a structural protein, a cell surface receptor, a cytokine, a growth factor, a signal transduction factor, a transcription factor, and the like.
  • the protein in some aspects is a protein which is naturally expressed by the cell in which the recombinant nucleic acid resides. In some aspects, the protein is one which is not naturally expressed by the cell in which the recombinant nucleic acid resides. In exemplary aspects, the protein is selected from the group consisting of the proteins listed in Table A set forth below.
  • the isolated populations or isolated cells of the present disclosures are optionally formulated into a composition, such as a pharmaceutical composition.
  • a pharmaceutical composition comprising any of the presently disclosed isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising an isolated multipotent stem cell, an isolated TM cell, an isolated corneal keratocyte, an isolated neural cell, or an isolated adipocyte, of the present disclosures and a pharmaceutically acceptable carrier.
  • the carrier is any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the cells, and by the route of administration.
  • the pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public.
  • the pharmaceutically acceptable carrier is one which is chemically inert to the cells, and one which has no detrimental side effects or toxicity under the conditions of use.
  • the choice of carrier will be determined in part by the particular agents comprising the pharmaceutical composition, as well as by the particular route used to administer the pharmaceutical composition. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of the present disclosures.
  • the pharmaceutical composition may comprise additional pharmaceutically acceptable ingredients, including, for example, one or more of additives, adsorbents, anticoagulants, antimicrobial preservatives, antioxidants, buffering agents, cryoprotectant, diluents, preservatives, stabilizing agents, therapeutic agents, tonicity agents, toxicity agents, viscosity-increasing or -decreasing agents.
  • additional pharmaceutically acceptable ingredients including, for example, one or more of additives, adsorbents, anticoagulants, antimicrobial preservatives, antioxidants, buffering agents, cryoprotectant, diluents, preservatives, stabilizing agents, therapeutic agents, tonicity agents, toxicity agents, viscosity-increasing or -decreasing agents.
  • the pharmaceutical composition comprises any one or more of the components in the Handbook of Pharmaceutical Excipients, Third Edition, A. H.
  • Kibbe Patent Application Laidge (Phaniaceutical Press, London, UK, 2000), which is incorporated by reference in its entirety.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety, discloses various components used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof, provided that the component does not adversely affect the viability or functionality of the cells.
  • Supplementary active ingredients also can be incorporated into the compositions.
  • the composition in some aspects comprises a cryoprotectant.
  • the cryoprotectant is a glycol, e.g., ethylene glycol, propylene glycol, glycerol, DMSO, formamide, 2-methyl, ⁇ 2,4-pentadiol, sucrose, trehalose, and colloid.
  • Methods of cryopreservation are known in the art and include, but not limited to those described in Lee et al., Ferl Steri193 (3): 976-985 (2008); Berz et al., Am J Hernatal 82(6): 463-472 (2007); Watt et al., Methods Ml. Biol.
  • the compositions of the present disclosures comprises a cell culture medium suitable for the viability and functionality of the cells.
  • the composition comprises one or more growth factors and/or cytokines, optionally selected from the group consisting of: platelet derived growth factor (PDGF), a fibroblast growth factor (FGF), transforming growth factor (TGF), epidermal growth factor (EGF), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), c-Kit, tumor necrosis factor (TNF), stromal cell-derived factor (SDF), granulocyte colony stimulating factor (G-CSF), interferon, bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), and K1f4.
  • PDGF platelet derived growth factor
  • FGF fibroblast growth factor
  • TGF epidermal growth factor
  • IL-2 interleukin-2
  • IL-6 interleukin-6
  • GM-CSF granulocyte
  • the composition comprises a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor.
  • the compositions comprise growth factors and/or cytokines found in aqueous humor.
  • the compositions comprise a medium comprising serum or components thereof, e.g., fetal bovine serum, human serum albumin.
  • the compositions are serum-free.
  • the composition comprises a medium comprising fetal bovine serum and/or aqueous humor.
  • the aqueous humor is from a non-human (e.g., cow, pig, horse, mouse, rat, dog, cat, monkey) and the cells of the composition are from a human.
  • the foregoing component(s), e.g., fetal bovine serum, aqueous humor, may be present in the pharmaceutical composition at any concentration, such as, for example, at least A, wherein A is 0.0001% w/v, 0.001% o w/v, 0.01% w/v, 0.1% w/v, 1% w/v, 2% w/v, 5% w/v, 10% w/v, 20% w/v, 30% w/v, 40% w/v, 50% w/v, 60% w/v, 70% w/v, 80% w/v, or 90% w/v.
  • A is 0.0001% w/v, 0.001% o w/v, 0.01% w/v, 0.1% w/v, 1% w/v, 2% w/v, 5% w/v, 10% w/v, 20% w/v, 30% w/v, 40% w/v, 50% w/v, 60% w/
  • the foregoing component(s) may be present in the pharmaceutical composition at any concentration, such as, for example, at most B, wherein B is 90% w/v, 80% w/v, 70% w/v, 60% w/v, 50% w/v, 40% w/v, 30% w/v, 20% w/v, 10% w/v, 5% w/v, 2% w/v, 1% w/v, 0.1% w/v, 0.001% w/v, or 0.0001%.
  • the foregoing component(s) may be present in the pharmaceutical composition at any concentration range, such as, for example from about A to about B. In some embodiments, A is 0.0001% and B is 90%.
  • the pharmaceutical compositions may be formulated to achieve a physiologically compatible pH.
  • the pH of the pharmaceutical composition may be at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, at least 8, at least 8.5, at least 9, at least 9.5, at least 10, or at least 10.5 up to and including pH 11, depending on the formulation and route of administration.
  • the pharmaceutical compositions may comprise buffering agents to achieve a physiological compatible pH.
  • the buffering agents may include any compounds capable of buffering at the desired pH such as, for example, phosphate buffers (e.g., PBS), triethanolamine, Tris, bicine, TAPS, tricine, HEPES, TES, MOPS, PIPES, cacodylate, MES, and others.
  • the strength of the buffer is at least 0.5 mM, at least 1 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 30 mM, at least 40 mM, at least 50 mM, at least 60 mM, at least 70 mM, at least 80 mM, at least 90 mM, at least 100 mM, at least 120 mM, at least 150 mM, or at least 200 mM.
  • the strength of the buffer is no more than 300 mM (e.g., at most 200 mM, at most 100 mM, at most 90 mM, at most 80 mM, at most 70 mM, at most 60 mM, at most 50 mM, at most 40 mM, at most 30 mM, at most 20 mM, at most 10 mM, at most 5 mM, at most 1 mM).
  • the cells of the composition are in solution, e.g., aqueous solution, In some aspects, the cells of the composition are cryopreserved.
  • the pharmaceutical composition comprising the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes is formulated for parenteral administration, intraanterior chamber administration, intraschlemm's canal administration, intravitreous administration, subconjunctival administration, subcutaneous administration, intravenous administration, intramuscular administration, or intra-arterial administration.
  • the pharmaceutical composition is formulated for implantation or injection.
  • the pharmaceutical composition is administered via nasal, spray, oral, or aerosol administration.
  • parenteral administration includes, but is not limited to, intravenous, intraanterior chamber administration, intraschlemm's canal administration, intravitreous administration, subconjunctival administration, intraarterial, intramuscular, intracerebral, intracerebroventricular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal, intravesical, and intracavernosal injections or infusions.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the pharmaceutical composition are in various aspects administered via a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2-dimethyl-1,3-dioxalane-4-methanol, ethers, polyethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
  • Oils which are optionally used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral.
  • suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearie acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • the parenteral formulations in some embodiments contain preservatives or buffers.
  • such compositions optionally contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17.
  • HLB hydrophile-lipophile balance
  • suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • parenteral formulations are in various aspects presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a cryopreserved condition along with a freezing agent, e.g., dimethyl sulfoxide (DMSO).
  • a freezing agent e.g., dimethyl sulfoxide (DMSO).
  • Injectable formulations are in accordance with the invention.
  • the requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Company, Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)).
  • the cells of the isolated populations are administered via a cell delivery matrix.
  • the cell delivery matrix in certain embodiments comprises any one or more of polymers and hydrogels comprising collagen, fibrin, chitosan, MATRIGEL, polyethylene glycol, dextrans including chemically crosslinkable or photocrosslinkabie dextrans, and the like.
  • the cell delivery matrix comprises one or more of: collagen, including contracted and non-contracted collagen gels, hydrogels comprising, for example, but not limited to, fibrin, alginate, agarose, gelatin, hyaluronate, polyethylene glycol (PEG), dextrans, including dextrans that are suitable for chemical crosslinking, photocrosslinking, or both, albumin, polyacrylamide, polyglycolyic acid, polyvinyl chloride, polyvinyl alcohol, poly(n-vinyl-2-pyrollidone), pmy(2-hydroxy ethyl methacrylate), hydrophilic polyuretlianes, acrylic derivatives, pluronics, such as polypropylene oxide and polyethylene oxide copolymer, or the like.
  • the fibrin or collagen in certain embodiments are autologous or allogeneic with respect to the patient.
  • the matrix in some instances comprises non-degradable materials, for example, but not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polyethyleneterephthaiate (PET), poly(butylenes terephthalate (PBT), polyurethane, polyethylene, polycabonate, polystyrene, silicone, and the like, or selectively degradable materials, such as poly (lactic-co-glycolic acid; PLGA), PLA, or PGA.
  • ePTFE expanded polytetrafluoroethylene
  • PTFE polytetrafluoroethylene
  • PET polyethyleneterephthaiate
  • PBT poly(butylenes terephthalate
  • polyurethane polyethylene, polycabonate, polystyrene, silicone, and the like
  • selectively degradable materials such as poly (lactic-co-glycolic acid; PLGA), PLA, or PGA.
  • the cells are in a matrix, capsule or gel.
  • the matrix, capsule or gel is implantable.
  • the pharmaceutical composition comprising the isolated populations of multipotent stern cells, TM cells, corneal keratocytes, or neural cells, in certain embodiments, comprises any of the components of a cell delivery matrix, including any of the components described herein.
  • the amount or dose of the pharmaceutical composition administered to a subject are sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject or animal over a reasonable time frame,
  • the dose of the pharmaceutical composition is sufficient to treat or prevent a medical condition as further described herein (e.g., glaucoma), in a period of from about Ito 4 days or longer, e.g., 5 days, 6 days, 1 week, 10 days, 2 weeks, 16 to 20 days, or more, from the time of administration. In certain embodiments, the time period is even longer.
  • Cell based therapies of the present disclosures have potential to provide sustained or permanent benefit.
  • the dose is determined by the efficacy of the particular pharmaceutical composition and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.
  • an assay which comprises comparing the extent to which multipotent stem cells are localized to the TM of an eye upon administration of a given dose of such multipotent stem cells to a mammal among a set of mammals of which is each given a different dose of the multipotent stem cells is used to determine a starting dose to be administered to an animal.
  • the extent to which multipotent stem cells are localized to a TM upon administration of a certain dose can be assayed by methods known in the art, including, for instance, the methods described herein.
  • an assay which comprises comparing the extent to which a particular dose of multipotent stem cells cause attenuation of a medical condition as further described herein (e.g., glaucoma), a decrease in intraocular pressure, an increase in TM cellularity, or increase in aqueous humor outflow from the eye, can be used to determine a starting dose to be administered to a mammal.
  • the dose of the pharmaceutical composition also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular pharmaceutical composition. Typically, the attending physician will decide the dosage of the pharmaceutical composition with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, therapeutic agent(s) of the pharmaceutical composition to be administered, route of administration, and the severity of the condition being treated.
  • the dose of the pharmaceutical composition can be such that at least about 0.5 ⁇ 106 (e.g, at least or about 104, 105, 106, 107, 108) multipotent stem cells are administered to the patient.
  • the pharmaceutical composition are in certain aspects modified into a depot form, such that the manner in which the pharmaceutical composition is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Pat. No. 4,450,150).
  • Depot forms are in various aspects, an implantable composition comprising the therapeutic or active agent(s) and a porous or non-porous material, such as a polymer, wherein the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes are encapsulated by or diffused throughout the material and/or degradation of the non-porous material.
  • the depot is then implanted into the desired location within the body and the cells are released from the implant at a predetermined rate.
  • the pharmaceutical composition in certain aspects is modified to have any type of in vivo release profile.
  • the pharmaceutical composition is an immediate release, controlled release, sustained release, extended release, delayed release, or bi-phasic release formulation.
  • the pharmaceutical composition is formulated for sustained, continuous release, e.g., formulated for continuous release of the (same amount of) cells over a sustained period of time, including but not limited to at least 103, 104, 105, 106, 107, 108, 109, 1010, 10′′, 1012 cells released from the composition and into the subject over 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 48 hours, 36 hours, 72 hours, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month.
  • the cells or the isolated populations of cells are attached or linked to a second moiety, such as, for example, a therapeutic agent or a diagnostic agent.
  • the cells e.g., multipotent stem cells
  • the present disclosures provide in one aspect a composition comprising a conjugate comprising multipotent stem cells attached to a therapeutic agent or a diagnostic agent.
  • Suitable therapeutic agents and diagnostic agents for purposes herein are known in the art and include, but are not limited to, any of those mentioned herein.
  • the cells are conjugated into a matrix and the matrix is conjugated to a second moiety, such as, for example a therapeutic or diagnostic agent.
  • the multipotent stem cells, T1 Vi cells, corneal keratocytes, neural cells or adipocytes of the isolated populations provided herein are administered alone, and in alternative embodiments, the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes of the isolated populations provided herein are administered in combination with another therapeutic agent, e.g., another cell of the present disclosures but of a different type (e.g., a combination of multipotent stem cells, TM cells, corneal keratocytes, neural cells and/or adipocytes), or another therapeutic which is known to achieve the same effect as the cells of the isolated populations or which are known to aid in the growth, survival, expansion, localization, stability, prevention of rejection, therapeutic index, bioefficacy, of the cells of the isolated population.
  • the cell or isolated population provided herein is administered simultaneously as the other therapeutic agent.
  • the cell or isolated population provided herein is administered either before or after the other therapeutic agent.
  • the other therapeutic agent is an anti-glaucoma agent, including, but not limited to: a beta blocker (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol); an alpha-2-agonist (e.g., apraclonidine, brimonidine); a carbonic anhydrase inhibitor (e.g., acetazolamide, methazolamide, brinzolamide, dorzolamide), a prostaglandin (e.g., bimatoprost, latanoprost, travoprost, unoprostone); a miotic (e.g., carbachol, echothiophate, and pilocarpine), a combination medication (e.g., Cosopt (timolol and dorzolamide)).
  • a beta blocker e.g., betaxolol, carteolol, levobunolol
  • the isolated populations or cells are administered in conjunction with an anti-glaucoma therapeutic procedure, including a laser surgery, e.g. laser trabeculoplasty, or a glaucoma surgery, e.g., incisional glaucoma surgery, or implantation of a glaucoma drainage device (e.g., glaucoma implant).
  • the laser trabeculoplasty in some aspects is a selective laser trabeculoplasty, a laser peripheral iridotomy, a laser peripheral iridoplasty, or a laser cyclophotocoagulation.
  • the present disclosures additionally provide uses of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes.
  • the isolated populations, or composition comprising the same wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of decreasing intraocular pressure in an eye.
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to decrease the intraocular pressure in the eye.
  • Methods of assaying intraocular pressure in an eye are known in the art, and include, but not limited to, measurement of pressure with a tonometer, e.g., a Goldmann tonometer.
  • the isolated populations, or composition comprising the same wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of increasing cell density in the trabecular meshwork of an eye.
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to increase cell density in the trabecular meshwork of an eye.
  • Methods of assaying cell density or cellularity in the TM of an eye are known in the art.
  • Suitable methods include, but not limited to, immunohistochemistry, microscopy (e.g., confocal), and the methods described in Alvarado et al., Invest Ophthamol V is Sci 21(5): 714-727 (1981), Alvarado et al ., Ophthamology 91(6): 564-579 (1984); and Murphy et al., Invest Ophthamol V is Sci 25(3): 312-322 (1984).
  • the isolated populations, or composition comprising the same wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of increasing outflow of aqueous humor from the eye.
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to increase outflow of aqueous humor from the eye.
  • Methods of assaying outflow of aqueous humor from an eye are known in the art and include but not limited the tonographic technique described in Grant, Arch Ophthal 44(2): 204-214 (1950), Toris et al., GlaucomA Today, pages 15-22 (September/October 2007), and Brubaker, Trans Am Ophthalmol Soc 80: 391-474 (1982).
  • the increase or decrease achieved upon administration of the cells of the isolated populations, or compositions comprising the same may be any level of increase or decrease.
  • the method of decreasing intraocular pressure in some aspects achieves at least or about a 10% decrease (e.g., at least or about a 20% decrease, at least or about a 30% decrease, at least or about a 40% decrease, at least or about a 50% decrease, at least or about a 60% decrease, at least or about a 70% decrease, at least or about a 80% decrease, at least or about a 90% decrease, at least or about a 95% decrease), as compared to a control level.
  • a 10% decrease e.g., at least or about a 20% decrease, at least or about a 30% decrease, at least or about a 40% decrease, at least or about a 50% decrease, at least or about a 60% decrease, at least or about a 70% decrease, at least or about a 80% decrease, at least or about a 90% decrease, at least or about a 95% decrease
  • control level in exemplary aspects is the level of the intraocular pressure in subjects to which cells were (or the composition was) not administered or the level of the intraocular pressure exhibited by the subject before administration of the cells or composition.
  • the method of decreasing intraocular pressure achieves a decrease, such that intraocular pressure is substantially restored to normal levels.
  • the method of increasing aqueous humor outflow in some aspects achieves at least or about a 10% increase (e.g., at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase, at least or about a 50% increase, at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or about a 90% increase, at least or about a 95% increase), as compared to a control level.
  • the control level in exemplary aspects is the level of the aqueous humor outflow in subjects to which cells were (or the composition was) not administered or the level of the aqueous humor outflow exhibited by the subject before administration of the cells or composition.
  • the method of increasing aqueous humor outflow achieves an increase, such that aqueous humor outflow is substantially restored to art-recognized normal levels.
  • the method of increasing cellularity or cell density of a TM in some aspects achieves at least or about a 10% increase (e.g., at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase) or at least or about a 50% increase (e.g., at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or about a 90% increase, at least or about a 95% increase), as compared to a control level.
  • a 10% increase e.g., at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase
  • a 50% increase e.g., at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or
  • the control level in exemplary aspects is the level of TM cellularity or cell density in subjects to which cells were (or the composition was) not administered or the level of TM cellularity of cell density exhibited by the subject before administration of the cells or composition.
  • the method of increasing TM cellularity or cell density achieves an increase, such that the cellularity or cell density is substantially restored to normal levels.
  • “normal levels” refers to a level within a range of intraocular pressure, range of aqueous humor outflow, or range of TM cellularity or cell density, which range is considered by a physician, e.g., an ophthalmologist, as representative of a healthy subject or an undiseased subject.
  • a normal level of intraocular pressure as measured by a Goldmann tonometer is a measure within the range of 10 to 22.
  • the present disclosures furthermore provide a method of treating or preventing a medical condition in a subject in need thereof.
  • the medical condition in some embodiments is a medical condition that is caused by or associated with decreased cell density in the trabecular meshwork, increased intraocular pressure in an eye, decreased outflow of aqueous humor from the eye, or a combination thereof.
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are muitipotent stem cells or TM cells, in an amount effective to treat or prevent the medical condition.
  • the terms “treat,” and “prevent” as well as words stemming therefrom, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
  • the methods of treatment or prevention provided herein can provide any amount of any level of treatment or prevention of a medical condition in a subject.
  • the treatment or prevention provided by the methods of treatment or prevention provided herein in same aspects includes treatment or prevention of one or more conditions or symptoms of the medical condition being treated or prevented.
  • “prevention” in some aspects encompasses delaying the onset of the medical condition, or a symptom or condition thereof.
  • the medical condition is glaucoma.
  • the glaucoma is open-angle glaucoma, angle-closure glaucoma, congenital glaucoma, or secondary glaucoma.
  • Methods of diagnosing or monitoring glaucoma include but not limited to gonioscopy-mediated examination, tonometry, optic nerve imaging, papillary reflex response, retinal examination, slit lamp examination, visual acuity, visual field measurement.
  • the presently disclosed method treats or prevents a symptom of glaucoma.
  • the symptom of glaucoma is tunnel vision, severe eye pain, cloudy vision, decreased vision, nausea, vomiting, halos around lights, red eye, cloudiness of the front of the eye, enlargement of the eye, light sensitivity, tearing.
  • glaucoma is the second most common cause of blindness in the United States
  • treatment of glaucoma may be considered as a prevention or delay or slowing of blindness. Accordingly, the medical condition prevented by the method of the present disclosures in exemplary aspects is blindness.
  • the medical condition is one that is caused by a decrease in keratocytes in a subject or in a tissue thereof.
  • the decrease in keratocytes is due to an increase in keratocyte degeneration, keratocyte cell injury, or keratocyte cell death (e.g., apoptosis, necrosis).
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or corneal keratocytes, in an amount effective to treat or prevent the medical condition.
  • the medical condition is one that is caused by a decrease in neural cells in a subject or in a tissue thereof.
  • the decrease in neural cells is due to an increase in neural cell degeneration, neural cell cell injury, or neural cell cell death (e.g., apoptosis, necrosis).
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or neural cells, in an amount effective to treat or prevent the medical condition.
  • the medical condition is one that is caused by a decrease in adipocytes in a subject or in a tissue thereof.
  • the decrease in adipocytes is due to an increase in adipocyte degeneration, adipocyte cell injury, or adipocyte cell death (e.g., apoptosis, necrosis).
  • the method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or adipocytes, in an amount effective to treat or prevent the medical condition.
  • the administered cells may be obtained through any of the methods of obtaining multipotent stem cells or of obtaining differentiated cells described herein.
  • the source of the cells administered to the subject may be any source, as described herein.
  • the source of the cells is a mammal.
  • the source of the cells is a human.
  • the species of the source of cells is the same species as the subject to which the cells are administered.
  • the source of the cells is the subject to which the cells are administered such that the cells are “autologous” to the subject.
  • the source of the cells is different from the subject, but the source and patient are of the same species, such that the cells are considered as “allogeneic” cells with reference to the subject.
  • the subject may be any living organism, e.g., an organism comprising a TM.
  • the subject is a mammal.
  • the term “mammal” refers to any vertebrate animal of the mammalia class, including, but not limited to, any of the monotreme, marsupial, and placental taxis.
  • the mammal is one of the mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits.
  • the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs).
  • the mammals are from the order Artiodactyla, including Bovines (cows) and S wines (pigs) or of the order Perssodactyla, including Equines (horses).
  • the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes).
  • the mammal is a human.
  • kits comprising any of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, described herein, or any of the compositions comprising the cells or isolated populations described herein.
  • the cells of the kit are provided in a container, e.g., a vial, tube, plate, well, flask, and the like.
  • the cells of the kit are provided in a cryopreserved form.
  • the cells of the kit are provided in a ready to use form (e.g., are in solution) and are not cryopreserved.
  • the cells of the kit are provided in a device for administration of the cells to a subject.
  • the cells are provided in an intravenous bag, a syringe, a matrix, e.g., an implantable matrix, a capsule, e.g., an implantable capsule, ready for administration to a subject.
  • the kit comprises a device for administration.
  • the kit comprises a set of instructions for use in accordance with any of the methods described herein.
  • the set of instructions comprise instructions for using the cells in a method of obtaining an isolated population of TM cells, corneal keratocytes, neural cells or adipocytes.
  • the set of instructions in alternative embodiments, comprise instructions for using the cells in a method of decreasing intraocular pressure in an eye, increasing cell density in the TM of an eye, or increasing outflow of aqueous humor from an eye.
  • the set of instructions in other embodiments, comprise instructions for using the cells in a method of treating or preventing a medical condition, e.g., a medical condition described herein.
  • the kit comprises instructions for administration of the composition comprising the cells to a subject.
  • the present disclosures furthermore provides a device comprising any of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, described herein, or any of the compositions comprising the cells or isolated populations described herein.
  • the device is a device for administration to a subject. Accordingly, in some aspects, the device is an intravenous bag, a syringe, a matrix, e.g., an implantable matrix, or a capsule, e.g., an implantable capsule.
  • ABCG2 (Clone BXP-21; Chemicon International, Temecula, Calif.), Pax6 (Covance, Princeton, N.J.), mucin 1, ankyrin G, AQP1, MGP, TIMP-3, myocilin (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.), CHI3L1 (R&D Systems, Minneapolis, Minn.), beta-tubulin III, glial fibrillary acidic protein (GFAP) (Chemicon International), and NF200 against neurofilament protein (Sigma-Aldrich, St. Louis, Mo.).
  • Table 1 provides further details on the types of antibodies used.
  • Human corneas were obtained from the Center for Organ Recovery & Education Pittsburgh, Pa.). Donor human corneas including sclera rim and hence trabecular meshwork (TM) that were not usable for transplantation, or corneoscleral rims after surgery were used for experiments. After careful removal of the iris, a cut was made through the inner edge of Schwalbe's line and the pigmented TM tissue was peeled.
  • TM trabecular meshwork
  • the tissue was cut into pieces and put in either a 35 mm dish or a 25 cm 2 flask. Medium was added and was left undisturbed for 10-14 days to let the cells migrate out from the explants.
  • TM tissue was digested in 0.3 mg/ml collagenase type L in Dulbecco's modified Eagle's medium (DMEM) containing albumin and glutamine overnight at 37° C. incubator. After digestion, the cells were filtered through a 70 gm mesh to remove the tissue and were washed in the same medium twice. Cells were seeded at 2 ⁇ 10 4 cells/cm 2 in TM stem cell growth medium (SCUM), described below.
  • DMEM Dulbecco's modified Eagle's medium
  • SCUM TM stem cell growth medium
  • the cells were passaged when they reached about 80-90% confluence by trypsinization and seeding at 2 ⁇ 5 ⁇ 10 3 cells/cm2 in SCGM.
  • the primary TM cells were cultured in medium without fetal bovine serum and any growth factors to keep their TM cell characteristics as a control.
  • SCGM was made by supplementing OptiMEM-1 (Invitrogen Life Technologies, Carlsbad, Calif.) with 5% fetal bovine serum (Hyclone, Logan, Utah), 10 ug/mL epidermal growth factor (EGF; Upstate Biotechnologies, Lake Placid, N.Y.), 100 ⁇ g/mL bovine pituitary extract (Biomedical Technologies, Stoughton, Mass.), 20 ug/mL ascorbic acid (Sigma-Aldrich, St.
  • Clonogenic assays were performed by limiting dilution (0.3 cells/well in 96-well plate) followed by subcultivation. After obtaining a substantial number of cloned cells, a gene expression profile was obtained to determine which clones were undifferentiated cells. The clones with expression of stem cell markers were passaged for further experiments.
  • TM stem cells To analyze their ability to differentiate into different types of cells, the TM stem cells (TMSCs) were cultured under the following different conditions:
  • Corneal keratocytic differentiation Aliquots of TMSCs (2.5 ⁇ 10 5 ) were collected in a conical-bottom 15-mL tube, centrifuged at 1500 rpm (400 g) for 5 minutes to form a pellet. The pellets of each aliquot were cultured in SCGM for 3 days and then transferred into keratocyte differentiation medium (KDM: advanced MEMTM (Invitrogen) with 10 mg/mL fibroblast growth factor 2 [FGF2] and 0.5 mM ascorbic acid-2-phosphate), which was changed every 3 days for up to 3 weeks.
  • KDM advanced MEMTM (Invitrogen) with 10 mg/mL fibroblast growth factor 2 [FGF2] and 0.5 mM ascorbic acid-2-phosphate
  • TMSCs were seeded onto FNC Coating Mix® (AthenaES, Baltimore, Md.) coated 35 mm dishes at 10,000 cells/cm 2 in neural differentiation medium (NDM) containing Advanced D-MEM with 10 mg/ml epithelial growth factor, 10 mg/ml fibroblast growth factor and I ⁇ M all-trans retinoic acid, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin, and 50 ⁇ g/ml gentamicin. The medium was changed every 3 days and fresh all-trans retinoic acid was added each time. The cells were cultured for 3 weeks for induction.
  • NDM neural differentiation medium
  • Adipogenic differentiation TMSCs were seeded onto 1% gelatin (Sigma-Aldrich) coated 35 mm dishes at 20,000 cells/cm2 in adipogenic differentiation medium (ADM) consisting of DMEM-Low glucose with 10% FBS, 1 ⁇ mM dexamethasone, 0.5 ⁇ M methyl-isobutylxanthine, 10 ⁇ g/ml recombinant human insulin, 200 ⁇ M indomethacin, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin, and 50 ⁇ g/ml gentanxicin.
  • ADM adipogenic differentiation medium
  • the cells were cultured in ADM for 7 days, then changed to adipogenic maintenance medium (AMM) containing of DMEM with 15% FBS, 10 ⁇ g/ml recombinant human insulin, 100 IU/ml penicillin, 100 streptomycin, and 50 ⁇ g/ml gentamicin for 4 days.
  • ADM adipogenic maintenance medium
  • the medium was changed back to ADM for another 7 days, then changed to AMM for another 4 days and the cells were fixed for histology or lysed for RNA.
  • Bovine aqueous humor was collected from enucleated bovine eyes by inserting a 26-gauge needle through the cornea limbus and positioning its tip into the center of the anterior chamber. AH was pooled and centrifuged at 10,000 g for 1 hour at 4° C. to pellet any pigment or cellular debris followed by filtering through 0.22 ⁇ m to get rid of any potential contaminations. The AH was kept at ⁇ 80° C. for later use.
  • TM cell differentiation was induced by culturing the TMSC in 50% stem cell growth medium (SCGM) with 50% AH, 100% AH, or DMEM/F12 plus 10% FBS, The TMSC were cultured in those TM differentiation media and the media were changed every 3 days for up to 10 days.
  • SCGM stem cell growth medium
  • Phagocytosis assay This assay was performed following the procedures described by Zhang et al 14. In brief, Alexa 488 conjugated Straphylococcus aureus bioparticles (heat- or chemically killed) (Molecular Probes, Inc. Eugene, Oreg.) were incubated with S. aureus bioparticle opsonizing reagent (purified rabbit polyclonal IgG antibody; Molecular Probes) at 37 C for 1 hr for enhancing the uptake of these particles. The differentiated TM cells were incubated with rabbit IgG opsonized Alexa 488 conjugated S. aureus bioparticles at a ratio of 50 bioparticles per cell at 37 C for 1 hr.
  • the cells were fixed with 4% paraformaldehyde solution for 15 min at room temperature (RT) and incubated with Alexa Flour 546 goat anti-rabbit IgG secondary antibody at RT for 1 hr.
  • the secondary antibody was believed to bind to the extracellular bioparticles opsonized with rabbit IgG, so that the unphagocytosed bioparticles would be excluded when counting.
  • Cell nuclei were labeled with DAPI at 1 ⁇ g/ml for 10 min. Cellular phagocytosis of bioparticles, DAPI nuclei and cellular morphology were visualized and imaged with an Olympus FluoView FV 1000 confocal microscope.
  • TM cells DAPI stained nuclei
  • TM cells total bioparticles ingested by these TM cells. At least ten individual views per condition were counted and averaged. The data were analyzed statistically by otte-way ANOVA followed by the Tukey post-test to assess the significance of differences.
  • Quantitative Reverse Transcription-Polymerase Chain Reaction qPCR
  • RNALater The anterior part of human eye including the cornea, TM and part of the sclera, was stabilized in RNALater (Ambion, Austin, Tex.) overnight.
  • the tissues or cultured cells were lysed with RLT buffer in the RNeasy mini kit (Qiagen, Valencia, Calif.) and RNAs were isolated following the manufacturer's instructions treated with DNAse 1 (Ambion) and concentrated by alcohol precipitation.
  • eDNAs were transcribed from the RNAs using SuperScript ⁇ reverse transcriptase (Invitrogen).
  • qPCR of cDNAs was performed by direct dye binding (SYBR Green; Applied Biosystems) as previously described. 15 Primers for SYBR assays were designed using online software (Primer 3; http://frodo.wi.mit.edu/ with the sequences shown in Table 2.
  • Amplification of 18S rRNA was performed for each cDNA (in triplicate) for normalization of RNA content.
  • a negative control lacking cDNA was also included in each assay.
  • Relative mRNA abundance was calculated as the Ct for amplification of a gene-specific cDNA minus the average Ct for 18S expressed as a power of 2(2 ⁇ Ct). Three individual gene-specific values thus calculated were averaged to obtain mean ⁇ SD.
  • mice Female C57BL/6 mice (Charles River Laboratories International, Inc., Wilmington, Mass.), 9 weeks of age, were used in the experiments described below. AH experimental procedures were reviewed and approved by Institutional Animal Care and Use Committees and handled according to guidelines provided in the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Ophthalmic and Vision Research.
  • the cloned TMSC cultured in SCUM were prelabeled with membrane dye Vybrant Di0 (Invitrogen) as described previously 16.
  • the cells were suspended in DMEM/F12 at 1 ⁇ 10 6 cells/ml and incubated with Di0 at 50 ug/ml for 20 minutes at 37° C.
  • the cells were washed twice with DMEM/F-12 and resuspended in serum-free DMEM/F12 at 2.5 ⁇ 10 4 cells/ ⁇ l for injection.
  • Corneal fibroblasts (at passage 8) cultured in DMEM.F12 with 10% FBS served as controls.
  • TMSCs were transplanted into the anterior chamber of mice following the procedures of McKenna et al., J Immunol 169: 2630-5637 (2002) with subtle modifications. Briefly, all mice were anesthetized by i.p. injection of 2 mg of ketamine hydrochloride and 0.04 mg of xylazine (IVX Animal Health, Inc., St. Joseph, Mo.) in. 0.2 ml of Dulbecco's phosphate buffered salt solution (PBS). The eyes were washed with PBS with antibiotics. The eyes were also anesthetized by topical drops of proparacaine HC 1 (Alcon Laboratories).
  • PBS Dulbecco's phosphate buffered salt solution
  • the right eye of each mouse was used for stem cell or fibroblast injection and the left eye was used as control.
  • the cornea was punctured by inserting a 30-gauge needle outside of the pupil area and parallel to the iris.
  • Aqueous humor was allowed to flow out and was removed by an ophthalmic sponge (Microsponge; Alcon Laboratories).
  • An air bubble was then introduced into the anterior chamber by injecting a 1.5 ⁇ l volume of air with a Hamilton micro syringe (Hamilton, Reno, Nev.) fitted with a 33-gauge beveled needle.
  • TMSCs or fibroblasts in 2 ⁇ l of DMEM/F-12 was injected with a micro syringe fitted with a 33-gauge blunt needle (Hamilton). The air bubble seals the corneal puncture and prevents leakage.
  • the eyes were treated once with gentamicin sulfate ophthalmic drops. The mice were sacrificed at 1 wk and 4 wks after transplantation. The mouse eyes were enucleated and fixed in 2% PFA at 4° C.
  • Sections were incubated overnight at 4° C. with primary antibodies. After three washes, secondary antibodies were added followed by incubation for 2 hrs at room temperature. Samples were photographed using a confocal microscope (Olympus) with a 40 ⁇ oil objective.
  • Oil Red O stain for adipogenic differentiation Oil red O(Sigma-Aldrich) was prepared at 0.5% in isopropanol, diluted to 0.3% in water and filtered before use. Cells were stained with oil red O for 20 min and rinsed with 60% isopropanol followed by hematoxylin stain for nuclei. Bright-field micrography was performed with a 40 ⁇ oil objective.
  • the ATP-binding cassette transporter family 62 (ABCG2) is present at relatively high levels in undifferentiated human embryonic stem cells, and plays a protective role against toxins, drugs, or hypoxia (18). ABCG2 has also been identified as a specific marker for adult stem cells (15, 19-22). PAX6 is a homeobox transcription factor expressed in embryonic ocular precursor cells and epithelial cells (23) and this molecule may contribute to the stem cell phenotype as a proliferation moderator (24) Ankyrin G and Mucin1 are considered as markers for the stem cells of TM since they have been observed with high expression in Schlemm's canal cells (25) which are also called TM insert cells (26).
  • Mucin 1 is a cell surface protein which functions as an interfacing protein to the aqueous fluid.
  • the water channels aquaporin 1 (AQP1) has been detected to be present in the eye tissues of the corneal epithelium, the ciliary epithelium, the posterior iris epithelium and the trabecular meshwork endothelium (27) as well as in cultured human trabecular meshwork cells (1).
  • the exact role of aquaporin 1 (AQP1) expression in TM and Schlemm's canal cell function has not yet been demonstrated, although it was hypothesized to influence osmotic permeability of the TM plasma membrane as well as the resting intracellular volume and, thus possibly paracellular permeability (28).
  • Matrix Gla protein encodes a protein involved in inhibition of calcification in cartilage and blood vessels; MGP has conserved the cation sensing mechanism present in vascular smooth muscle that responded to extracellular ionic calcium by upregulating its mRNA. So MGP plays a protective role in the TM and stress its position as an essential player at times of elevated pressure (29).
  • Aqueous humor contains CHI3L1 which has a protective role against inflammation, extracellular matrix (ECM) remodeling and cell death in the outflow pathway (30).
  • ECM extracellular matrix
  • the matrix metalloproteinase (MMP) family and their tissue inhibitors, the TI.M1's, are integrally involved in regulating the turnover of TM extracellular matrix (31).
  • AQP1, MGP, CHI3L1 and TIMP 3 are considered as TM markers.
  • Immunofluorescent staining was observed in the TM tissue where the TM markers are expressed ( FIG. 1A , right column) and some cells positive to the stem cell markers ( FIG. 1A , left column) also were observed.
  • the cells positive to stem cell markers were distributed throughout the TM tissue and not limited to any particular region of the TM.
  • Quantitative RT-PCR was performed to compare gene expression of the cells from TM and insert region and the results demonstrated that there were no obvious differences in the gene expression pattern between the two regions of TM ( FIG. 1B ); no expression of the cornea! stromal specific gene, keratocan, in TM and insert region indicates that the tissues do not contain keratocytes.
  • ABCG2 acts to remove Hoechst dye from cells, thus allowing isolation of cells as a “side population” (SP), in which ABCG2 is active, by use of flow cytometry (33, 34).
  • SP side population
  • DCV DyeCycle Violet
  • DCV is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux. DCV therefore is used to isolate SP cells on flow cytometry using violet lasers (35, 36) without the requirement for an ultraviolet laser for Hoechst 33342 emission.
  • FIG. 2A shows that the cultured TM cells contained a side population (the tail formed within the frame) which were collected by fluorescence activated cell sorting (FACS).
  • FACS fluorescence activated cell sorting
  • the labeled cells were then analyzed via flow cytometry to determine the % labeled cells.
  • the collected cells were 99.9% positive for expression of the stem cells marker CD73, 97.7% positive for expression of the stem cell marker CD9Q, 96.4% positive for expression of the stem cells marker CD 166 and 97.8% positive for expression of the stem cell marker Bzni1.
  • the collected cells were only 10.9% positive for expression of the TM cell marker CHI3L1 and 2.63% positive for expression of the TM cell marker AQP 1.
  • the isolated SP and non-SP cells were cultured in SCGM and at passage 8, the cells were lysed for extracting ruRNA. qPCR was done to compare the gene expression of SP and non-SP cells ( FIG. 2B ).
  • the stem cell genes ABCG2 and mucin 1 (Muc1) of the SP cells was approximately 2-fold higher than that of the non-SP cells; the TM genes AQP1, MOP and CHI3L1 of the SP cells were approximately 4-fold lower as compared to that of the non-SP cells.
  • SP cells demonstrated virtually no expression of the glaucomatous genes myocilin and ELAM-1. The differences are statistically significant (p ⁇ 0.05) analyzed by one-tailed t-test. However, ankyrin G(AnkG) expression of SP was the same as that of non-SP cells.
  • FIG. 3A-J show the immunofluorescent double staining on TMSC and primary TM cells with stem cell markers ABCG2, Pax6, ankyrin G, Mucin 1; TM cell markers AQP1, MOP, CHI3L1, TIMP3 and glaucomatous marker myocilin.
  • FIG. 3A-J show the immunofluorescent double staining on TMSC and primary TM cells with stem cell markers ABCG2, Pax6, ankyrin G, Mucin 1; TM cell markers AQP1, MOP, CHI3L1, TIMP3 and glaucomatous marker myocilin.
  • 3A-E on the upper column show the TMSC were positive to stem cell marker proteins ABCG2, Pax6 (A), ankyrin G (B), mucin 1(C); but not TM cell markers CHI3L1 (B), AQP 1 (C), MGP (D), TIMP3 (E) and not glaucomatous marker myocilin (D).
  • the primary TM cells of the lower column did not express stem cell markers, but instead expressed TM cell markers. Few cells were positive to myocilin.
  • Results obtained from qPCR FIG. 3K ) demonstrated the differential gene expression pattern between the primary TM cells and the TMSC.
  • TMSC demonstrated increased expression of stem cell genes ABCG2 and ankyrin G, decreased TM cell genes AQP1, MGP, CHI3LI, and decreased glaucomatous genes myocilin and ELAM I, as compared to primary TM cells. The differences were statistically significant as determined by the one-tailed t-test. qPCR and Western Blotting (WB) confirmed similar expression levels. The expression of mucin I differed by very little among primary TM cells and TMSC.
  • FIG. 3L shows the results of Western blotting that compare the different protein expression between corneal stromal fibroblasts and passage-4 TMSC. As evident in this figure, TMSC strongly expressed the stem cell markers ABCG2, Pax6, Mud and weakly expressed the TM cell markers AQP1, MGP and TIMP3.
  • TMSC can be Induced to Differentiate into Trabecular Meshwork Cells.
  • the TMSC were cultured in SCGM, and at passage-4, the TMSC were switched into different media for induction of differentiation into TM cells.
  • the cells were induced in medium containing 50% SCGM with 50% aqueous humor, 100% aqueous humor, or with medium containing 10% FBS.
  • the expression levels of stem cell markers and TM cell markers were analyzed among the induced cells and the TMSC in SCGM by immunofluorescent staining and qPCR.
  • A, B, C, D represents a double-stain of ABCG2 (green) and Pax6 (red); the second row represents a double-stain of ankyrin G (green) and CHI3L1 (red); the third row represents a double-stain of mucin 1 (green) and AQP1 (red); the fourth row represents a double-stain of MGP (green) and myocilin (red); the bottom row represents a stain of TIMP3 (green).
  • TMSC can be induced to differentiate into TM cells expressing TM markers and exhibiting lost or reduced expression of stem cell markers ABCG2, Pax6, AnkyrinG and mucin1.
  • the TMSC cultured in SCGM remained the stem cell markers ABCG2 (FIG. 4 A—green)), Pax6 (FIG. 4 A—red)), Ankyrin G (FIG. 4 E—green), Mucin1 (FIG. 4 I—green), but not the TM differentiation markers CHI3L1 (FIG. 4 E—red), AQP1 (FIG. 41 —red), MGP (FIG. 4 M—green), TIMP3 (FIG. 4 Q—green) and not the glaucomatous marker myocilin (FIG.
  • FIGS. 4B , F, J, N, R When the stem cells were induced in SCGMIAH for one week ( FIGS. 4B , F, J, N, R), some of the cells lost the stem cell markers but gained the express of the TM markers.
  • FIGS. 4C , G, K, O, S When the cells were induced in AH ( FIGS. 4C , G, K, O, S) or in 10% FBS ( FIGS. 4D , H, L, P, T), most of the cells lost the ability to express the stem cell markers but expressed the TM cell markers.
  • Some of the induced cells were positive to the glaucomatous specific marker myocilin ( FIG. 4N , 0 , P—red).
  • qPCR demonstrated that the transcript level of stem cell genes ABCG2 and Pax6 of the TMSC in SCUM increased at least 2-fold compared to that of the induced cells in SCGM/AH, in AH or in 10% FBS ( FIG. 4U ), qPCR also demonstrated that the relative gene expression of stem cell markers ABCG2, Pax6, CD73, CD90, CD166, CD117, Bmi1, Oct4, Notch 1, and KLF4 in induced TM cells was 50% or less that in passaged TM cells ( FIG. 4V ).
  • the transcript level of TM genes AQP1, MGP, and CHI3L1 of the induced TM cells were increased at least 2-fold as compared to that passaged TMSCs ( FIG. 4W ).
  • the expression of glaucomatous gene myocilin in the TMSC in SCGM was also decreased compared to that of the induced cells.
  • the difference between the TMSC and the induced TM cells was statistically significant by t-test (p ⁇ 0.05). There was no significant difference in the expression of mucin 1 and ankyrin G between the TMSC and the induced cells. The differences among the induced cells also were not significant.
  • MMPI interstitial collagenase
  • Trabecular meshwork cells have phagocytic activity which eliminates debris, pigment and other materials from the aqueous outflow drainage pathway and maintains the aqueous humor outflow pathway (14, 37, 38).
  • a phagocytosis assay was performed with TMSC cultured in SCGM ( FIG. 5A ), with induced cells cultured in SCGM/AH ( FIG. 5B ), in AH ( FIG. 5C ), or in 10% FBS ( FIG. 5D ) and with primary TM cells ( FIG. 5E ) cultured in medium without fetal bovine serum and growth factors.
  • FIG. 5E provides the statistical result of the phagocytic assay.
  • the Y-axis shows the number of the bioparticles ingested per cell.
  • the difference between the TMSC cultured in SCGM and the induced cells as well as the primary TM cells is statistically significant (p ⁇ 0.0001) analyzed by ANOVA followed by Bartlett's test with Prism Graph Pad software (Prism; Graph Pad Software, San Diego, www.graphpad.com). There is no significant difference among the induced cells and the primary TM cells.
  • TM stem cells One well-documented aspect of adult stem cells is the ability to differentiate into a number of different cell types. This property was examined in the cloned TM stem cells by culturing them in different conditions.
  • the TMSC was cultured in neural differentiation medium (NDM) containing EGF, FGF and retinoic acid for neural induction.
  • NDM neural differentiation medium
  • FIG. 6A the cells positive for neurofilament
  • FIG. 6B beta-tubulin III
  • GFAP FIG. 6C
  • the cells cultured in NDM lost the expression of mucin 1.
  • the TMSC cultured in SCGM without induction were positive to mucin 1 ( FIG. 6H ) but negative to neurofilament ( FIG. 6E ), beta-tubulin III ( FIG. 6F ) and GFAP ( FIG. 6G ).
  • the TMSC was cultured in adipogenic differentiation medium (ADM) and adipogenc maintenance medium (AMM) for adipocytic induction.
  • ADM adipogenic differentiation medium
  • AMM adipogenc maintenance medium
  • Oil red O stain was perform to identify lipoid deposits which are special to adipocytes.
  • FIG. 6J shows the TM stem cells in SCGM had no lipoid materials with oil red O negative. After induction in ADM and maintaining in AMM, the TM stem cells changed to be positive to oil red O stain with lipoid deposits within the cells.
  • Real-time qPCR was carried out to compare the expression of adipocytic genes ap2 (which encodes ALBP) and leptin among stem cells maintained in SCGM or induced adipocytes in ADM.
  • the expression of ap2 and leptin were increased in adipocytes, as compared to the expression of these genes in the stem cells. The increase was statistically significant as determined by t-test.
  • corneal stromal stem cells were able to differentiate into keratocytes by culturing the stem cells as pellets in a medium containing FGF and ascorbic-2-phosphate39. We adopted this method to induce the keratocyte differentiation from TMSC. After culturing over 3 weeks as pellets, the TM stem cells secreted corneal stromal specific extracellular matrices keratan sulfate ( FIG. 6K ) and keratocan ( FIG. 6L ).
  • FIGS. 7A and 7B show the immunofluorescent staining on the mouse TM cryosections 2 weeks after hTMSC injection.
  • the injected green cells homed to the TM tissue pointed by white solid arrows ( FIGS. 7A , 7 B).
  • Some of the green cells were positive to the TM differentiation marker AQP1 (FIG. 7 A—red) and some were positive to the stem cell marker ankyrin G (FIG. 7 B—red).
  • FIG. 7C-7Q are the wholemount staining on mouse TM tissue with TMSC injection for 1 week ( FIGS. 7D , 71 , 7 N), 4 weeks ( FIGS. 7F , 7 K, 7 P); with fibroblast injection for 1 week ( FIGS. 7E , 73 , 70 ), 4 weeks ( FIGS. 7C , 7 L, 7 Q); and normal tissue without any injection as controls ( FIGS. 7C , H, M).
  • TM cell antibody AQPI reacts to both mouse and human antigens
  • TM cell antibody CHZ3L1 is specific to human antigen
  • stem cell antibody mucin 1 reacts to both mouse and human antigens. Mucin 1 has been identified for the expression on corneal endothelium 40.
  • FIG. 7C , H, M on the control tissue show that AQPI presented in the mouse TM cells as well as in the corneal endothelial cells ( FIG. 7C ) but human specific CHI3L1 antibody didn't stain any mouse cells ( FIG. 7H ); there were some cells positive to mucin 1 in both the TM and the endothelium ( FIG. 7M ).
  • FIG. 7D , 1 , N are stains on the tissue with TMSC injection for 1 week.
  • 1 week after injection there were some injected green human TMSC positive to AQP1 ( FIG. 7D ), some positive to human specific antibody CHI3L1 ( FIG. 71 ); the number of cells positive to stem cell marker mucin 1 increased ( FIG. 7N ) compared to the control without cell injection ( FIG. 7M ).
  • FIGS. 7E , J, O There were very few injected green cells in the TM region 1 week after injection with human fibroblasts and no increase of AQPI expression ( FIG. 7E ), no human CHI3L1 expression ( FIG. 7J ), no increased mucin 1 expression ( FIG. 7O ).
  • the number of injected green cells in the TM region was significant increased compared to that at 1 week after injection. Although more green cells were in the TM region, more injected TMSC were positive to mucin 1 ( FIG. 7P ) and less cells were positive to the differentiation markers CH13L1 ( FIG. 7K ) and AQP1 ( FIG. 7F ). Interestingly, although there were almost no injected fibroblasts in the TM region 1 week after injection, 4 weeks after fibroblast injection, there were more green cells in the TM region that that at 1 week ( FIGS. 7G , L, Q). There was no expression of human specific CHI3L1 among the injected green fibroblasts ( FIG. 7L ), although the green cells were in the TM region where AQP1 ( FIG. 7E ) and mucin I ( FIG. 70 ) were positive to the original mouse cells.
  • MMP-3 matrix metalloproteinase-3, stromelysin-1, STMY1, STR1, SL- (Luna et al, 2009; 1, transin, transin-1, collagenase activating protein, Kelley et al, 2007; procollagenase activator, proteoglycanase) Fleenor et al, 2003; Oh et al, 2006; Pang et al, 2003; Alexander et al, 1998; WuDunn, 2001) MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kD
  • Example 2 The following represents a listing of the references cited in Example 2:
  • TM trabecular meshwork
  • SCGM Stem cell growth medium
  • TM tissue was digested in 0.3 mg/ml collagenase type-L (Sigma-Aldrich, St. Louis, Mo.) in Dulbecco's modified Eagle's medium (DMEM) at 37° C. for 20-22 hours. After digestion, the cells were filtered through a 70 ⁇ m mesh and washed twice with DMEM. Cells were seeded at 2 ⁇ 10 4 cells/cm 2 in SCGM.
  • DMEM Dulbecco's modified Eagle's medium
  • cells were passaged at 80-90% confluency by trypsinization and seeded at 2-5 ⁇ 10 3 cells/cm 2 in SCGM or seeded for clonal expansion by limiting dilution at 30 cells in a 96-well plate (0.3 cells/well).
  • a 96-well plate 0.3 cells/well.
  • about 1-10 percent of the 96 wells had clones with small cells which were picked up for subcultivation at 2-3 weeks after seeding.
  • about 1/3-1/2 could be continuously passaged up to 30-50 population doublings.
  • At least 6 clones from 3 donors were used and repeated in this study.
  • SCGM was modified from a corneal endothelial cell culture medium 16 containing OptiMEM-1 (Invitrogen) supplemented with 5% fetal bovine serum (FBS) (Hyclone), 10 mg/ml EGF (Upstate Biotechnologies), 100 ⁇ g/ml bovine pituitary extract (Biomedical Technologies), 20 ⁇ g/ml ascorbic acid, 200 ⁇ g/ml calcium chloride, 0.08% chondroitin sulfate (Sigma-Aldrich), 100 IU/ml penicillin, 100 pg/ml streptomycin and 50 ⁇ g/ml (Sigma-Aldrich).
  • Primary TM cells were cultured in DMEM without FBS or any growth factors.
  • SP Side Population
  • SP cell sorting was carried out as previously described (17-19) using DyeCycle Violet (DCV) dye (Invitrogen) with minor modifications.
  • DCV DyeCycle Violet
  • To inhibit DCV efflux 1 ⁇ 10 5 to 5 ⁇ 10 5 cells were preincubated for 20 minutes with 25 ⁇ g/ml fumitremorgin C before DCV incubation. After staining, the cells were washed twice in Hanks' balanced salt solution (HESS) with 2% FBS and stored on ice.
  • HESS Hanks' balanced salt solution
  • TMSC TMSC
  • Antibodies used are listed in Table 3.
  • fluorescent conjugated antibodies CD73-PE, CD90-Alexa 647, CD166-FITC
  • appropriate isotype controls were incubated with cells on ice for 30 minutes followed by washed in 1% bovine serum albumin (BSA) in PBS once and resuspended in the same buffer for flow analysis using FACSAria flow cytometer (BD Biosciences). 2 ⁇ g/ml propidium iodide was added to identify nonviable cells.
  • BSA bovine serum albumin
  • Neural differentiation Clonal TMSC were seeded onto 35 mm dishes coated with FNC 7 Coating Mix (AthenaES, Baltimore, Md.) at 1 ⁇ 10 4 cells/cm 2 in neural differentiation medium (NDM) containing Advanced D-MEM with 10 mg/ml EGF, 10 mg/ml FGF2, 1 ⁇ M all-trans retinoic acid (17). The medium was changed every 3 days and fresh 1 ⁇ M all-trans retinoic acid was added each time. The cells were cultured for 1-2 weeks for neural induction.
  • NDM neural differentiation medium
  • Adipocytes were induced as previously described (20) with minor modifications.
  • TMSC were seeded onto 1% gelatin (Sigma-Aldrich) coated 35-mm dishes at 2 ⁇ 10 4 cells/cm 2 and cultured in adipogenic differentiation medium (ADM) for 7 days, switched to adipogenic maintenance medium (AMM) for 4 days, then cycled again through ADM (7 days) and AMM (4 days) before fixation for histology or lysis for RNA.
  • ADM consists of DMEM with 10% FBS, 1 ⁇ M dexamethasone, 0.5 mM methylisobutylxanthine, 10 ⁇ g/ml recombinant human insulin, 200 ⁇ M indomethacin.
  • AMM contains DMEM with 15% FBS, 10 ⁇ g/ml insulin for 4 days.
  • Keratocyte differentiation was carried out as previously described (19). In brief, 3 ⁇ 10 5 TMSC were collected in a conical-bottom 15-mL tube, centrifuged at 1500 rpm (400 g) for 5 minutes to form a pellet. The pellets were cultured in SCGM for 3 days and then changed into keratocyte differentiation medium (KDM) (Advanced D-MEM (Invitrogen) with 10 mg/mL fibroblast growth factor 2 and 0.5 mM ascorbic acid) which was changed every 3 days for up to 3 weeks. Pellets cultured in SCGM served as control.
  • KDM keratocyte differentiation medium
  • Bovine aqueous humor was collected from enucleated bovine eyes by inserting a 27-gauge needle through the corneal limbus. AH was pooled and centrifuged at 10,000 g for 1 hour at 4° C. followed by filtering through 0.22 um (8) Steriflip Filter Units (50 ml) (Millipore, Billerica, Mass.). The AH was aliquoted and stored at ⁇ 80° C. for later use. TM cell differentiation was induced by culturing TMSC 35-mm dishes in three different conditions: 50% AH in SCGM, 100% AH, or DMEM/F12 plus 10% FBS. The media were changed every 3 days for up to 10 days.
  • AH Bovine aqueous humor
  • Alexa-488 conjugated Staphylococcus aureus bioparticles from heat- or chemically killed S. aureus ) were incubated with opsonizing reagent (purified rabbit IgG antibody) (Invitrogen) at 37° C. for 1 hour to enhance particle uptake.
  • opsonizing reagent purified rabbit IgG antibody
  • the cells were incubated with opsonized Alexa-488 conjugated S. aureus bioparticles at a ratio of 20 bioparticles per cell at 37° C. for 1 hour.
  • the cells were fixed with 4% paraformaldehyde solution for 15 minutes at room temperature (RT) and incubated with Alexa-546 goat-anti-rabbit IgG secondary antibody for 1 hour.
  • the secondary antibody binds to the extracellular bioparticles opsonized with rabbit IgG, so the unphagocytosed bioparticles can be excluded when counting.
  • Cell nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) at 1 ⁇ g/ml for 10 minutes. Cellular phagocytosis of bioparticles was visualized and imaged with an Olympus FluoView FV 1000 confocal microscope.
  • the number of phagocytosed bioparticles was quantified by counting the cells and total bioparticles ingested by these cells. At least ten individual views per condition were counted and averaged. The data were analyzed statistically by one-way ANOVA followed by the Tukey post-test to assess the significance of differences between all groups.
  • RNAs were transcribed from the RNAs using SuperScript II reverse transcriptase (Invitrogen).
  • qRTPCR of cDNAs was performed by direct dye binding (SYBR Green; Applied Biosystems) as previously described (17). Primers for SYBR assays were designed using online software (Primer 3; http://frodo.wi.mit.edu/) with the sequences shown in Table 4. Amplification of 18S rRNA was performed for each cDNA (in triplicate) for normalization of RNA content.
  • a negative control lacking cDNA was also included in each assay. Relative mRNA abundance was calculated as the Ct for amplification of a gene-specific cDNA minus the average Ct for 18S expressed as a power of 2 (2 ⁇ Ct). Three individual gene-specific values thus calculated were averaged to obtain mean ⁇ SD.
  • Oil red O (Sigma-Aldrich) was prepared at 0.5% in isopropanol, diluted to 0.3% in water and filtered before use. Cells were stained with oil red O for 20 minutes and rinsed with 60% isopropanol followed by hematoxylin stain for nuclei. Bright-field micrography was performed with a 40 ⁇ objective.
  • Membranes were incubated with primary antibodies diluted in blocking buffer with 0.1% Tween-20 followed by incubation with IRDye 680LT goat-anti-mouse, IRDye 800CW goat-anti-rabbit or IRDye donkey-anti-goat secondary antibodies for Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebr.). Fluorescent signal was visualized with LI-COR substrate followed by detection and capture of 16-bit images with an Odyssey Infrared Imager (LI-COR Biosciences).
  • SP Side Population
  • FIG. 8A shows unfractionated cells from TM contain a small but significant side population which was collected by fluorescence-activated cell sorting (FACS). The percentage of SP cells ranged from 0.1-1.5% of the total population across multiple sorts.
  • FIG. 8B The isolated SP and non-SP cells were further expanded in SCGM and at passage-eight, gene expression was analyzed by qRT-PCR ( FIG. 8B ).
  • the expression of stem cell genes ABCG2, Notch1, MUC1 and AnkG of SP cells was approximately 1.5 to 2-fold higher than that of non-SP cells.
  • the expression of TM genes AQP1, MGP and CHI3L1 was approximately 4-fold lower in SP cells compared to non-SP cells. SP cells had almost no MYOC or ELAM-1 expression. The differences between SP and non-SP cells are statistically significant (p ⁇ 0.05).
  • FIG. 8C confirms that the isolated TM tissue which generated the SP cells was TM and not cornea.
  • corneal stroma expressed AQP1 and KERA but not AnkG nor CHI3L1.
  • TMSC isolated by clonal growth and expanded in SCGM were initially compared with unfractionated primary TM cells cultured in medium without FBS or any growth factors. Immunofluorescent staining shows clonal TMSC were positive for stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; but not TM cell markers TIMP3, CHI3L1, AQP1, MGP or MYOC ( FIGS. 9A-9E ). In contrast, primary TM cells expressed these TM cell markers but not stem cell markers ( FIGS. 9F-9J ). qRT-PCR result ( FIG.
  • FIG. 10 revealed passage-four TMSC enriched with stem cell markers CD73, CD90, CD166 and Bmi1 (>95%) and lowered in TM markers AQP1 and CHI3L1 ( ⁇ 10%). This experiment was repeated on passage-two and passage-six TMSC with similar results.
  • TMSC neurofilament protein
  • FIGS. 11A-11C neural differentiation (13) medium containing EGF, FGF, and retinoic acid
  • FIGS. 11A-11C When TMSC were cultured in neural differentiation (13) medium containing EGF, FGF, and retinoic acid, expression of neurofilament protein, ⁇ -tubulin III and GFAP was observed ( FIGS. 11A-11C ), whereas MUC1 expression disappeared ( FIG. 11D ).
  • TMSC cultured in SCGM were MUC1 positive ( FIG. 11H ) without neural marker expression ( FIGS. 11E-11G ).
  • Analysis of mRNA levels FIG. 11I ) confirmed significantly upregulated transcript of both neurofilament and GFAP after induction (p ⁇ 0.05).
  • FIG. 13A shows increased mRNA expression of keratan sulfate (KERA) and ALDH after keratocyte induction. The upregulation is significant (p ⁇ 0.05).
  • TMSC Differentiate into TM Cells with Phagocytic Function
  • TM cells function to maintain aqueous humor outflow and proper intraocular pressure with phagocytic activity and secretion of specific enzymes and extracellular matrix (4). TM cell number decreases with age and affects intraocular pressure (6-9).
  • SCGM/AH bovine aqueous humor
  • AH bovine aqueous humor
  • DMEM/F12 DMEM/F12 containing 10% FBS.
  • FIGS. 14A-14E show TMSC cultured in SCGM retained expression of stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; but not TM differentiation markers TIMP3, CHI3L1, AQP1, MGP, and not MYOC.
  • FIGS. 14F-14J show TMSC cultured in SCGM retained expression of stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; but not TM differentiation markers TIMP3, CHI3L1, AQP1, MGP, and not MYOC.
  • qRT-PCR revealed expression of ABCG2, Pax6, Notch1, MUC1, and AnkG to be decreased while expression of AQP1 and MGP increased upon TMSC differentiation in SCGM/AH, AH or 10% FBS.
  • the expression of MYOC and ELAM-1 also increased after induction. Expression differences of all genes between TMSC in SCGM and induced cells in AH or in 10% FBS were statistically significant (p ⁇ 0.05, oneway ANOVA followed by Dunnett's post-test). The differences between cells in SCGM and SCGM/AH were not consistently statistically significant. There were no statistical differences between cells in AH and 10% FBS.
  • FIG. 15B Western blotting ( FIG. 15B ) identified ABCG2 and OCT4 expression in clonal TMSC but not in primary TM cells.
  • a low level of ABCG2 was detected in cells cultured in SCGM/AH but not in cells in AH or 10% FBS.
  • AQP1 and MGP were expressed in primary TM cells and induced cells but not in TMSC.
  • CHI3L1 appeared as a doublet migrating at ⁇ 39 kDa in primary and induced TM cells and weakly in TMSC.
  • the lower molecular weight band may represent a glycosylation variant of the protein (28).
  • TM cells have phagocytic activity which eliminates debris, pigment, and other materials from the aqueous to maintain the outflow pathway (21, 29, 30). Phagocytic ability of the TMSC was assessed using fluorescently tagged S. aureus bioparticles comparing clonal TMSC, induced and primary TM cells ( FIGS. 16A-16E ). Ingested S. aureus bioparticles appear green. On average, 0.18 green particles per cell were ingested by TMSC in SCGM ( FIG. 16F ). In contrast, TMSC induced in SCGM/AH ingested 1.12 particles per cell; AH, 1.61; 10% FBS, 1.83, and primary TM cells had 2.11 particles per cell. ANOVA followed by Dunnett's test shows the increase in phagocytic activity by TSMC to be significant (p ⁇ 0.0001) under all conditions; but none of the induced TSMC differed significantly from the activity of primary TM cells.
  • stem cells from human TM. These cells can be isolated as a side population by FACS or by clonal growth. In culture they present a homogeneous population displaying antigenic markers previously characterized for mesenchymal stem cells (ABCG2, CD73, CD90, CD166 and Bmi1) as well as expressing gene products associated with pluripotent stem cells (Notch1, OCT4). Their stem cell character was confirmed by the ability of these cells to display phenotypic properties of cells from several different developmental lineages (neural, adipose, cornea) under culture conditions known to induce differentiation of multipotent stem cells.
  • ABCG2, CD73, CD90, CD166 and Bmi1 antigenic markers previously characterized for mesenchymal stem cells
  • Notch1, OCT4 pluripotent stem cells
  • TM cells are capable of differentiating into TM cells with phagocytic function and expressing TM markers AQP1, MGP, CHI3L1 and TIMP3 in the presence of aqueous humor or 10% serum. All of these indicate that these cells represent a resident population of adult stem cells in the human TM.
  • TMSC stem cell population in TM which expressed MUC1, AnkG, PAX6, and Oct4. Expression of these markers clearly distinguish TMSC from typical mesenchymal stem cells.
  • PAX6 is a homeobox gene essential to ocular development and is present in some adult ocular tissues but not generally present in TM31. PAX6 is present in corneal stromal stem cells (17, 32) but is not expressed by mesenchymal stem cells (33).
  • MUC1 is a cell surface mucin associated with breast and other epithelial cancers (34).
  • AnkG was recently described as essential for production of new neurons in the brain (35) and was described with higher expression in Schwalbe's cells that have been postulated to be responsible for cell regeneration in the TM (15). The expression of these three genes in the TMSC, therefore, defines markers distinguishing these cells from bone marrow-derived mesenchymal stem cells.
  • TMSC differentiate to TM cells is a novel and, at current time, unique property of this cell population.
  • TMSC differentiate to TM cells in the presence of fetal bovine serum suggests that differentiation to TM is the default lineage for these cells, implying that they are indeed a specialized population of stem cells, not mesenchymal stem cells from the vasculature or other tissues.
  • the identification of cells that naturally differentiate to TM in vitro can be useful as a research tool to better understand steps in the developmental lineage of these rare cells.
  • the ability to expand the numbers of TMSC provides access to large number of homogeneous TM cells for study in vitro, a facility not previously available from such a small tissue.
  • TMSC express characteristic TM proteins after induction. These markers have essential roles in TM function and help to establish that TMSC can reestablish primary TM functions maintaining aqueous outflow.
  • the water channel aquaporin 1 (AQP1) has been detected in the TM in vivo (27) as well as in cultured human TM cells and plays an important role in modulation of aqueous outflow (5).
  • Matrix Glaprotein (MGP) has the ability to function in the TM as a calcification inhibitor 36 and may be a key contributor to intraocular pressure homeostasis by regulating calcification and hardening of the TM (37).
  • Aqueous humor contains chitinase 3-like 1 (CHI3L1) which has a protective role against inflammation, ECM remodeling and cell death in the outflow pathway (24).
  • Myocilin expression in TM cells is induced upon treatment with dexamethasone, TGF- ⁇ or mechanical stretch and may lead to impaired outflow resistance (38).
  • TM cells induced from TMSC with 10% serum also showed increased myoeilin expression ( FIG. 15 ). This may be a result of the steroid content of fetal bovine serum or simply reflect the difference in myocilin expression between TMSC and TM cells (as observed in FIG. 9 ).
  • TM cells have phagocytic activity that is essential in maintaining normal aqueous outflow.
  • TMSC after induction demonstrated phagocytic function almost as strong as primary TM cells.
  • Example 3 The following is a list of references cited in Example 3.
  • compositions or methods of treatment also should be construed to define “uses” of the invention.
  • the invention includes use of a source of salicylic acid for the treatment of conditions identified herein or achieving a therapeutic goal identified herein (e.g., lowing blood glucose in a human in need thereof).
  • a source of salicylic acid for manufacture of a medicament for such treatments/purposes.
  • the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above.
  • aspects of the invention described as a genus all individual species are individually considered separate aspects of the invention.
  • aspects described as a range all subranges and individual values are specifically contemplated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject.

Description

    PRIORITY CLAIM
  • This application claims priority to provisional application U.S. Ser. No. 61/462,255, filed Jan. 31, 2011 and provisional application U.S. Ser. No. 61/438,163, filed Jan. 31, 2011, both of which are hereby incorporated by reference herein in their entireties.
    • GRANT FUNDING
  • This invention was made with government support under Grant Nos. EY016415 and EY008098, awarded by the National Institutes of Health. The government has certain rights in the invention.
    • BACKGROUND
  • The trabecular meshwork (TM) is a region of spongy tissue in the eye located around the base of the cornea and near the ciliary body. The TM functions to drain the aqueous humor from the eye into the circulatory system via the anterior chamber and a series of tubes called Schlemm's canal. In addition to producing and secreting extracellular matrix proteins and proteolytic enzymes, cells of the TM (i.e., TM cells) phagocytose extracellular debris to prevent blockage of Schlemm's canal. Decreased TM cellularity and impaired TM function lead to the pathogenesis of glaucoma, a medical condition of the eye in which aqueous humor outflow is decreased and/or levels of aqueous are increased, either or both of which ultimately lead to an elevation in intraocular pressure.
  • Current treatments for glaucoma include medications, laser treatment, or surgical treatment. Laser trabeculoplasty is a surgery in which a laser makes tiny, evenly spaced burns in the TM to re-stimulate its drainage function. Laser trabeculoplasty surgery increases cell division in the TM, thereby increasing TM cellularity. Within days of the procedure, cells found in the anterior, non-filtering region of the TM, called the insert area, migrate out of this region and repopulate the laser-burned sites. While laser trabeculoplasty is a quick, easy, convenient, and relatively low-risk procedure, there are drawbacks to this technique. For example, about half of the patients require further medical or surgical treatment within two to five years. Also, for example, the procedure has a relatively small effect on lowering the eye pressure and repeat treatments are usually not very effective. In some people, such as individuals with glaucoma from eye inflammation or eye trauma, the procedure has no benefit and can even worsen the glaucoma.
  • Surgical treatment options for glaucoma, such as trabeculectomy, also have risks. In some cases, the glaucoma operation fails and requires glaucoma medication or another glaucoma operation. Frequently, the eye pressure becomes severely reduced immediately after surgery. While this is harmless over a short period of time, this can lead to vision changes if the reduced eye pressure continues over a long period of time. Also, surgery treatment most often requires general anesthesia. Further, a leak from the surgery, bleeding in the eye, or infection of the eye can occur post-surgery.
  • Alternatively, the application or administration of stem cells that have the potential to differentiate into TM cells is an attractive means of treating or preventing glaucoma. It has been postulated that the insert area contains stem-like cells that serve as a source of TM cell renewal, and some groups report attempts to isolate such cells through surgical dissection of the TM insert area. However, Kelley et al., Exp Eye Res 88(4); 747-751 (2009) concede that this method represents a difficult technique. Other groups have cultured TM cells or have produced neurospheres from human TM cultures with an aim to isolate multipotent progenitor cells from the TM. While these groups report the expression profiles of the isolated cells, none have demonstrated that the isolated cells are capable of differentiating into TM cells.
  • In view of the foregoing, there exists a need in the art for isolated populations of multipotent stem cells that are capable of differentiating into TM cells and non-invasive, efficient methods of obtaining such populations.
    • SUMMARY
  • Presented herein for the first time are data which demonstrate that multipotent stem cells exist throughout the TM and are not limited to the insert area (also known as “insert region”) of the TM. Once isolated, the multipotent stem cells can be cultivated and passaged in vitro, undergoing multiple cellular divisions without losing their likeness to stem cells, are capable of differentiating into functional trabecular meshwork (TM) cells, and are capable of localizing to the TM after injection into the eye.
  • Accordingly, the present disclosures provide isolated populations of multipotent stem cells which are capable of differentiating into TM cells. In some embodiments, the isolated population comprises multipotent stem cells isolated from a TM, e.g., a TM obtained from a tissue bank. In exemplary aspects, the TM is a TM of a mammal, e.g., a human, pig, horse, cow, dog, monkey, and the like. In exemplary aspects, the isolated population comprises multipotent stem cells isolated from a filtering region of a TM, and in some embodiments, the isolated population comprises multipotent stem cells isolated from both a filtering region and non-filtering region of the TM. In exemplary embodiments, the isolated population comprises multipotent stem cells isolated from a region other than the insert area of the TM, and in other embodiments, the isolated population comprises multipotent stem cells isolated from the insert area of the TM and from a region other than the insert area.
  • In exemplary embodiments, the isolated population represents a highly purified population of multipotent stem cells, wherein, for example, at least 90% of the cells of the population are multipotent stem cells. In exemplary aspects, at least 90% of the cells of the population express a stem cell marker selected from the group consisting of ABCG2, Pax6, Nestin, Ankyrin G, Mucin 1, CD73, CD90, CD 166, Bmi-1, CD 117, Notch 1, Oct4, KLF4, and a combination thereof. In exemplary aspects, at least 90% of the cells of the population express Ankyrin G and Mucin 1.
  • In exemplary embodiments, the stem cells are multipotent insofar as the multipotent stem cells are capable of differentiating into TM cells (e.g., phagocytic TM cells), corneal keratocytes, neural cells, and adipocytes. In exemplary embodiments, the multipotent stem cells represent a single type of precursor cells or progenitor cells that has the capacity to become TM cells (e.g., phagocytic TM cells), the capacity to become corneal ketocytes, the capacity to become neural cells, and the capacity to become adipocytes.
  • Also provided herein are methods of obtaining an isolated population of TM cells. An exemplary method comprises obtaining an isolated population of multipotent stem cells and culturing the isolated population of multipotent stem cells in a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor, to induce differentiation of the multipotent stem cells into TM cells. In exemplary aspects, the isolated population of multipotent stem cells is any one of the presently disclosed isolated populations of multipotent stem cells, e.g., those isolated from a trabecular meshwork. In exemplary aspects, the isolated population of multipotent stem cells is obtained by side population cell sorting of cells of a trabecular meshwork. In exemplary aspects, the isolated population of multipotent stern cells is obtained by clonal expansion of cells of a trabecular meshwork. In exemplary aspects, the isolated population of multipotent stem cells is obtained by selective expansion of stem cells of a trabecular meshwork. The isolated populations of TM cells obtained therefrom are moreover provided.
  • Further provided herein are compositions comprising the presently disclosed isolated population of multipotent stem cells or the presently disclosed isolated population of TM cells. In exemplary aspects, the composition comprises a pharmaceutically acceptable carrier, diluents, or excipient, such that the composition may be considered as a pharmaceutical composition. In exemplary aspects, the composition comprises a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor. In exemplary aspects, the cells are from a human and the aqueous humor is from a non-human. In exemplary aspects, the cells are in solution. In exemplary aspects, the cells are cryopreserved. In exemplary aspects, the compositions are formulated for administration to a subject by implantation or injection. In exemplary aspects, the compositions are formulated for sustained, continuous release. In exemplary aspects, the cells are in a matrix, capsule, or gel.
  • Furthermore provided are kits and devices comprising the compositions of the present disclosures. In exemplary aspects, the kits comprise instructions for use, e.g., instructions for administration of the composition to a subject, and/or comprise a device for administration of the composition to a subject. In exemplary aspects, the device is a syringe, a matrix, a capsule, or an intravenous bag.
  • The present disclosures additionally provide multiple different uses of the presently disclosed compositions. In exemplary embodiments, the composition is used in a method of decreasing intraocular pressure in an eye. The method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to decrease the intraocular pressure in the eye.
  • In additional exemplary embodiments, the composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures is used in a method of increasing cell density in a trabecular meshwork of an eye. The method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to increase cell density in the trabecular meshwork of an eye.
  • In yet other exemplary embodiments, the composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, is used in a method of increasing outflow of aqueous humor from an eye. The method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to increase outflow of aqueous humor from the eye.
  • The present disclosures furthermore provide a method of treating or preventing a medical condition. In exemplary aspects, the medical condition is caused by or associated with decreased cell density in a trabecular meshwork, increased intraocular pressure in an eye, decreased outflow of aqueous humor from an eye, or a combination thereof. The method comprises administering to a subject in need thereof a composition comprising an isolated population of multipotent stem cells or TM cells of the present disclosures, in an amount effective to treat or prevent the medical condition. In exemplary aspects, the medical condition is glaucoma.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 demonstrates an exemplary distribution of stem cells in trabeculate meshwork. (A): Immunofluorescent staining on cryosections of human anterior segment shows the distribution of cells positive to stem cell markers ABCG2, Pax6, Muc1 or AnkG (Red) in human TM tissue which is outlined by the TM cell markers AQPI, MGP, CHI3L1, TIMP3 (Green). The cells positive to stem cell markers spread through the TM tissue and are not limited to a specific region. DAPI stains nuclei as blue. Schlemm's canal, TM and cornea are pointed out by arrows. Bars=50 um. (B): Expression of stem cell genes (ABCG2, Pax6, Mud, AnkG) and TM cell genes (AQPI, MGP, CHI3L1) was detected by qPCR to compare the differences between the tissue of TM and of insert region. Corneal keratocyte specific marker keratocan was also compared to exclude the contamination with corneal cells. Both TM and insert express stem cell markers as well as TM markers but not keratocan. Error bars show SD of triplicate analyses. Abbreviations: TM, trabecular meshwork; ABCG2, ATP-binding cassette sub-family G member 2; Mud, mucin 1; AnkG, ankyrin G; MGP, matrix gla protein; AQPI, aquaporin 1; CH13L1, chitinase 3-like 1; TIMP3, tissue inhibitor of metalloproteinases-3; qPCR, quantitative reverse transcription-polymerase chain reaction, Kera, keratocan.
  • FIG. 2 demonstrates an exemplary isolation and characteristics of Side Population cells. (A): The SP cells were isolated by fluorescence activated cell sorting (FACS) from cultured human TM cells. Passage-three TM cells stained with DyeCycle Violet Dye (DCV) were analyzed using violet 405-nm excitation with blue (450/40) and red (620 LP) emission. Cells showing reduction of both blue and red fluorescence (SP cells) were collected as defined by the box outlined on the left (arrow) which can be eliminated by preincubation with ABCG2 inhibitor fumitremorgin C (FTC). (B): The sorted SP and non-SP cells were passaged in vitro and mRNA pools for stem cell makers ABCG2, Muc1 AnkG; TM markers AQP 1, MGP, CHI3L1; and glaucoma markers myocilin and ELAM 1 were quantified by qPCR to compare the differences between the passaged non-SP and SP cells at passage-eight. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between non-SP and SP. Abbreviations: SP, side population; TM, trabecular meshwork. Myoc, myocilin, ELAM1, endothelial-leukocyte adhesion molecule 1.
  • FIG. 3 demonstrates exemplary expression of stem cell markers in passaged TM stem cells. Different expression of stem cell markers ABCG2, Pax6, Ankyrin G, Mucin1 and TM differentiation markers CHI3L1, AQPI, MGP, TTMP3 as well as glaucoma related marker myocilin was detected by immunofluorescent staining on TMSC (A-E) and primary TM cells (F-J). A and F show double-stain of ABCG2 and Pax6, B and E are stains of Ankyrin G and CHI3L1, C and H are Mucin 1 and AQPI, D and I are MGP and Myocilin, E and J are T1MP3 stain. DAPI stains nuclei as blue. Bars=50 um. (K): mRNA pools for stem cell makers ABCG2, Mud, AnkG; TM markers AQP1, MGP, CHI3L1; and glaucoma markers myocilin and ELAM1 were quantified by qPCR to compare the differences between the primary cultured TM cell culture and TM stem cells at passage-four. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between the primary TM cells and TMSC. (L): Western blotting shows the passage-four TMSC retained the expression of stem cell markers ABCG2, Pax6, Mud but with little expression of TM markers AQP 1, MGP and TIMP3. Line 1, human corneal fibroblasts as control; Line2, passage-4 TMSC. Abbreviations: TMSC, trabecular meshwork stem cells; 1° TM, primary trabecular meshwork cells.
  • FIG. 4 demonstrates an exemplary induction of TMSC differentiation into TM cells. (A): Double fluorescent staining compares the different expression of the TMSC cultured in SCGM (the first column: A, E, I, M, Q) and the induced TM cells in SCGM and AH (the second column: B, F, 3, N, R), in AH only (the third column: C, O, K, 4, 5), or in 10% FBS (the fourth column: D, H, L, P, T). A-D show double-stain of ABCG2 and Pax6, E-H are stains of Ankyrin G and CHI3L1, I-L are Mucin 1 and AQP1, M-P are MGP and Myocilin, Q-T are TIMP3 stain. DAPI stains nuclei as blue. Bars=50 um. (U): mRNA pools for stem cell makers ABCG2, Pax6, Muc1, AnkG; TM markers AQP1, MGP; and glaucoma markers myocilin were quantified by qPCR to compare the differences between the passaged TMSC and the induced TM cells in different media. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between the TMSC and the induced TM cells in all three different media. Abbreviations: SCGM, stem cell growth medium; 5CGM/AH, 50% stem cell growth medium+50% aqueous humor; AH, aqueous humor; FBS, fetal bovine serum.
  • FIGS. 4V-4X demonstrate differential gene expression among passaged TMSC and differentiated TM cells. (V): mRNA pools for stem cell makers ABCG2, Pax6, CD73, CD90, CD 166, CD 117, Bmi 1, OCT4, Notch 1, KLF4, Muc1 and AnkG were quantified by qPCR to compare the differences between passaged TM stem cells and induced TM cells with aqueous humor at passage-two as well as passage-five. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between passaged TMSC and induced TM cells. (W): mRNA pools for TM cell makers AQP1, MGP and CHI3L1 were quantified by qPCR to compare the differences between passaged TM stem cells and induced TM cells with aqueous humor at passage-two as well as passage-five. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between passaged TMSC and induced TM cells. (X): Different expression levels of MMPI (interstitial collagenase) were compared by qPCR on passaged TMSC, induced TM cells and fibroblasts. Error bars show SD of triplicate analyses. Asterisks indicate significant (p<0.05) difference between the cells and other groups.
  • FIG. 5 demonstrates an exemplary phagocytosis of TM cells induced from TMSC. Passaged TMSC were induced to differentiate into TM cells by culturing in STCMIAH, in AH or in 10% FBS for one week. Phagocytic function was detected by incubating the cells with Staphylacoccus aureus bioparticles (Green) as described in Materials and Methods. Green particles in A-E are the ingested bioparticles by the cells and the yellow dots are not washed out free particles with conjugating with the red secondary antibody. DAPI stains nuclei as blue. Bars=50 um. (F) The number of ingested bioparticles per cell was counted and compared in TMSC, in the induced TM cells in different induction media and the primary TM cells. Asterisks indicate significant (p<0.0001) difference between TMSC and the induced TM cells. There is no significant difference among the different induction conditions and the primary TM cells. Abbreviations: SCGM, stem cell culture medium; SCGM/AH, 50% stem cell culture medium+50% aqueous humor; AH, aqueous humor; FBS, fetal bovine serum; 1° TM, primary TM cells.
  • FIG. 6 demonstrates an exemplary induction of TMSC into neural cells, adipocytes and keratocytes. The TMSC were cultured in NDM for neural induction and in ADM and AMM for adipogenic induction as described in the Materials and Methods. The keratocyte differentiation was induced as three dimensional culture in KDM. Immunofluorescent stain compares the cells in NDM (A-D) and in. SCGM (E-F). (A) and (E) are the stain of NF200; (B) and (F) are that of—tubulin HI; (C) and (G) are GFAP; D and H are Mucin 1. (I) and (7) show oil red O stain on cells induced in ADM and AMM (I) and cells in SCGM (J) as control. (K) and (L) show the stains on the cryosections of cells cultured as pellets in KDM. Expression of corneal stromal extracellular matrix keratocan sulfate (Green) and keratocan (Red) was shown in (K) and (L), respectively. DAPI stains for nuclei as blue. Bars=50 um. Abbreviations: TMSC, trabecular meshwork stem cells; NDM, neural differentiation medium; ADM, adipogenic differentiation medium; AMM, adipogenic maintenance medium; KDM, keratocyte differentiation medium; NF200, neurofilament 200; GFAP, glial fibrillary acidic protein.
  • FIG. 7 demonstrates an exemplary injection of human TMSCs into mouse anterior chamber (AC). Human TMSC were injected into normal mouse AC for 1 week, 2 weeks and 4 weeks. At 2 weeks, the cryosections of the eyeballs were stained with TM marker AQPI (A) and TMSC marker AnkG (B), Schlemm's canal is labeled by the dashed arrows; the white solid arrows point to the injected green cells in the TM region; yellow arrows point out that the sclera is on the left and the cornea is on the right of the TM. TM tissue whole mount stain was performed an TMSC injection at 1 week (D, I, N) and 4 weeks (F, K, P), on fibroblast injection at 1 week (E, 7, 0) and 4 weeks (G, L, Q) and on normal wild mouse tissue (C, H, M) as controls. C-G are stains with anti-AQP1 antibody which reacts with both human and mouse antigen; H-L are stains with anti-human specific CHI3L1 antibody; M-Q are stains for Mud antibody which is not specific as AQP1. FIG. 7M shows the sclera is over the left; cornea is over the right while the TM is in the middle which applies to all the whole mount stain in FIG. 7. The injected human TMSC or fibroblasts were prelabeled with Di0 as green. DAPI stains for nuclei as blue. Bars=50 um. Abbreviations: hTMSC, human trabecular meshwork stem cells; AC. Anterior chamber; TMSC-1w, 1 week after trabecular meshwork stem cell injection; Fibro-1w, 1 week after fibroblast injection.
  • FIG. 8A-C demonstrate isolation of TMSC as side population (SP) cells. (A) SP cells were isolated by FACS from passage-three human TM cells using DyeCycle Violet Dye. Cells showing reduction of both blue and red fluorescence (SP cells) were collected as defined by the box outlined on the left (arrow). (B) The sorted SP and non-SP cells were passaged and assessed for differential gene expression by qRT-PCR. Error bars show SD of triplicate analyses. * p<0.05 (n=3, Student's t test). (C) RNAs extracted from dissected TM tissue and the adjacent corneal stroma tissue were compared on the expression of TM markers AnkG, CHI3L1; stromal marker KERA and the common marker for both TM and stroma AQP1 to assess if the dissected TM tissue contains corneal tissue. SP, side population; FACS: fluorescence-activated cell sorting.
  • FIG. 9A-K demonstrate differential expression of stem cell- and TM-markers between TMSC and primary TM cells. Clonal passaged TMSC (A-E) and primary TM cells (F-J) were double-stained with stem cell markers ABCG2 (green), Notch1 (red), OCT4 (red), AnkG (green), MUC1 (green); TM markers TIMP3 (green), CHI3L1 (red), AQP1 (red), MGP (green); and MYOC (red). Arrows in A point to the ABCG2 and Notch1 double-positive cells. Arrow in J points the MGP and MYOC double-positive cell. DAPI stains nuclei blue. Bars=50 μm. (K) Expression of stem cell- and TM-markers from primary TM cells and clonal TMSC at passage-four was quantified by qRT-PCR. Error bars show SD of triplicate analyses. * p<0.05 (n=3, Student's t test). TMSC, trabecular meshwork stem cells; 1° TM, primary trabecular meshwork cells.
  • FIG. 10A-F demonstrates flow analysis of passage-four TMSC to assess the cell purity. Stem cell markers (A) CD73, (B) CD90, (C) CD166, Bmi1 and TM cell markers (E) CHI3L1, AQP1 were analyzed by flow cytometry. The peak on the left in each histogram represents the isotype control for comparison with the cells labeled for each marker (on the right).
  • FIG. 11A-I demonstrate induction of neural cell differentiation from TMSC. Immunofluorescent staining on neural markers neurofilament, β-tubulin III, GFAP and TMSC marker MUC1 shows different expression between TMSC in NDM (A-D) for neural induction and in SCUM (EH) to stem cell maintenance. DAPI stains nuclei blue. Bars=50 μm. (I) Neural markers NF and GFAP from TMSC in SCGM and in NDM for neural induction were quantified by qRT-PCR. Error bars show SD of triplicate analyses. * p<0.05 (n=3, Student's t test). TMSC, trabecular meshwork stem cells; NDM, neural differentiation medium; SCUM, stem cell growth medium; GFAP, glial fibrillary acidic protein. NF, neurofilament.
  • FIG. 12A-C demonstrate induction of adipocyte differentiation from TMSC. TMSC were cultured in ADM and AMM alternately for adipogenic induction. Oil red O (red) staining was compared on TMSC in SCGM (A) and in ADM/AMM (13). Hematoxylin stains nuclei blue. Bars=50 μm. (C) Adipocytic markers ap2 and Leptin from TMSC in SCGM and induced cells in ADM/AMM were quantified by qRT-PCR. Error bars show SD of triplicate analyses. * p<0.05 (n=3, Student's t test). ADM, adipogenic differentiation medium; AMM, adipogenic maintenance medium; ap2, adipocyte protein 2.
  • FIG. 13A-G demonstrate induction of corneal keratocyte differentiation from TMSC. Cryosections of TMSC cultured as pellets in KDM (A-B) or in SCGM (C-D) were stained with keratan sulfate (A, C) and keratocan (B, D). Human corneal stromal stem cells cultured as pellets in KDM served as positive control were also stained with keratan sulfate (E) and keratocan (F). DAPI stains nuclei blue. Bars=50 μm. (G) Keratocytic markers KERA and ALDH from TMSC in SCGM and TMSC cultured as pellets in KDM were quantified by qRT-PCR. Error bars show SD of triplicate analyses. * p<0.05 (n=3, Student's t test). KDM, keratocyte differentiation medium; KERA, keratocan; ALDH, aldehyde dehydrogenase.
  • FIG. 14A-T demonstrate different protein expression of TMSC and induced TM cells. Immunofluorescence compares different expression of stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; TM markers TIMP3, CHI3L1, AQP1, MGP and MYOC of TMSC cultured in SCGM (A-E), in 50% AH in SCUM (SCGM/AH) (F-J), in AH (K-O), or in 10% FBS (P-T). Double-stain model is the same as FIG. 2 and the markers are labeled as green/red on top. DAPI stains nuclei blue. Bars=50 SCGM, stem cell growth medium; AH, aqueous humor; FBS, fetal bovine serum.
  • FIG. 15A-B demonstrate different gene expression of TMSC and induced TM cells by qRT-PCR and Western blotting. (A) mRNA pools for stem cell makers ABCG2, Pax6, Notch1, MUC1, AnkG; TM markers AQP1, MGP; and MYOC and ELAM1 were quantified by qRT-PCR to compare the differences between TMSC and TM cells induced in different media. Error bars show SD of triplicate analyses. (B) Western blotting compares expression of stem cell markers ABCG2, OCT4 and TM cell markers AQP1, MGP and CHI3L1 on passage-four TMSC in SCGM, 1° TM cells, induced TM cells in SCGM/AH, AH or 10% FBS. α-tubulin serves as loading control. 1° TM, primary trabecular meshwork cells.
  • FIG. 16A-F demonstrate phagocytosis. Figures A-E show phagocytosis assay to compare TMSC, induced and primary TM cells. Green dots are phagocytosed fluorescently-conjugated S. aureus bioparticles. Yellow dots are unphagocytosed free bioparticles labeled with red secondary antibody. DAPI stains nuclei blue. Bars=50 (F) The number of phagocytosed bioparticles per cell shows on the y-axis. The green particles and the nuclei in each view were counted and at least ten different views were counted in each condition. * p<0.0001 between TMSC in SCUM and induced TM cells in different media and 1° TM (n=10, one-way ANOVA followed by the Tukey post-test).
    •  DETAILED DESCRIPTION Isolated Populations of Multipotent Stem Cells
  • The present disclosures provide isolated populations of multipotent stem cells which are capable of differentiating into TM cells (e.g., phagocytic TM cells). As used herein, the term “multipotent” refers to adult stem cells or somatic stem cells that can develop into two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) different differentiated cell types. The multipotent stem cells of the isolated populations provided herein are not embryonic stem cells, and, therefore, are neither totipotent stem cells nor pluripotent stem cells, which stem cells are described in Kefley et al., Exp Eye Res. 88 (4): 747-751 (2009). In some embodiments, the stem cells are multipotent due to their potential for differentiating into any of TM cells, corneal ketocytes, neural cells, or adipocytes. In exemplary embodiments, the multipotent stem cells represent a single type of precursor cell or progenitor cell that has the capacity to become TM cells, the capacity to become corneal ketocytes, the capacity to become neural cells, and the capacity to become adipocytes. In some aspects, the multipotent stem cells of the isolated populations provided herein have only these four capacities (e.g., can only differentiate into one of TM cells, corneal ketocytes, neural cells, and adipocytes). In alternative aspects, the multipotent stem cells of the isolated populations provided herein have the capacity to differentiate into additional cell types other than TM cells, corneal ketocytes, neural cells, and adipocytes. In some aspects, the multipotent stem cells which are capable of differentiating into TM cells have the capacity to differentiate into phagocytic TM cells. Additional features and descriptions of the differentiated cells derived from the multipotent stem cells are provided below in the section entitled “Differentiated Cell Types.”
  • In some aspects, the multipotent stems cells of the isolated populations provided herein express one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more) stem cell markers. In the context of the cells of the present disclosures, a cell marker refers to a molecule, such as a polypeptide, protein, mRNA, that is expressed by the cells and assists scientists in the identification of that cell type (either alone, in the case of certain cell type-specific markers, or in combination with other markers or cellular characteristics. For example a stem cell marker is a marker that is expressed by stem cells and is useful for distinguishing a stem cell from other types of cells, such as differentiated cells, e.g., a TM cell, a neural cell, a corneal keratocyte, corneal fibroblasts, a stromal cell, an adipocyte. In exemplary embodiments, the stem cells marker is CD34, CD38, CD90, CD 133, CD105, c-kit, CD73, CD90, CD166, ABCG2, Pax6, Nestin, Ankyrin G, Mucin 1, bone morphogenetic protein receptor, Lineage surface antigen (lin), Stro-1 antigen, Oct4, or KLF4. In some aspects, the multipotent stem cells express one or more stem cell markers selected from the group consisting of CD73, CD90, CD 166, Bmi-1, Oct4, KLF4, ABCG2, Pax6, Nestin, Ankyrin G, and Mucin 1. In some aspects, the multipotent stem cells express two, three, four, five, six, seven, eight, nine, ten, or all of the stem cell markers CD73, CD90, CD166, Bmi-1, Oct4, KLF4, ABCG2, Pax6, Nestin, Ankyrin G, and Mucin 1. In exemplary aspects, the multipotent stem cells express Mucin 1 and Ankyrin G. In some aspects, the multipotent stem cells express the stem cell marker at a level which is detectable by standard immunohistochemistry techniques, including but not limited to immunofluorescence, fluorescent activated cell sorting (FACS) analysis, and the like, or by polymerase chain reaction (PCR) based techniques, e.g., quantitative PCR. In some aspects, the multipotent stem cells express the stem cell marker at an increased level, as compared to the expression level of the stem cell marker in a differentiated cell, e.g., a TM cell, a neural cell, a corneal keratocyte, corneal fibroblasts, a stromal cell, an adipocyte, and the like.
  • In some aspects, the multipotent stem cells of the isolated populations provided herein express one or more (e.g., one, two, three, four, five, or more) non-stem cell markers at reduced or undetectable levels. In exemplary instances, the multipotent stem cells express at a reduced or undetectable level a marker that is characteristic of a differentiated cell which is derived from the stem cell. In some instances, the multipotent stem cells express one or more (e.g., one, two, three, four, five, or more) of TM cell markers at reduced levels or at undetectable levels as compared to that expressed by a TM cell (e.g., a differentiated TM cell, a mature TM cell). In some aspects, the TM cell marker is selected from a group consisting of: AQP1, MGP, and CH13L1, NCAM, and TIMP3, or lack of detectable expression of MYOC, or a combination of these TM cell markers. In some aspects, the multipotent stem cells express one or more keratocyte markers at reduced levels or at undetectable levels, as compared to that expressed by keratocytes. In some aspects, the keratocyte marker is keratocan. In some aspects, the multipotent stem cells express one or more neural cell markers at reduced levels or at undetectable levels, as compared to that expressed by neural cells. In some aspects, the neural cell marker is GFAP, neurofilament, (3-tubulin III, or a combination thereof. In some aspects, the multipotent stem cells express one or more adipocyte markers at reduced levels or at undetectable levels, as compared to that expressed by adipocytes. In some aspects, the adipocyte marker is selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, and adipocyte lipid-binding protein (ALBP/ap2). In some aspects, the adipocyte marker is formation of lipoid deposits, e.g., as detected by Oil Red O staining.
  • In some embodiments, the multipotent stem cells of the isolated populations provided herein may be considered as tissue-specific stem cells that differentiate into the cells of the tissue from which the multipotent stem cells are isolated or obtained. Tissue-specific stem cells are further described in Kelley et al., supra. Accordingly, in some embodiments, the isolated population provided herein comprises multipotent stem cells isolated from the trabecular meshwork, e.g., TM of a mammal (e.g., rat, mouse, pig, cow, dog, chimpanzee, primate, human, and the like). In exemplary aspects, the isolated population comprises multipotent stem cells isolated from a filtering region of the TM, and in same embodiments, the isolated population comprises multipotent stem cells isolated from both a filtering region and non-filtering region of the TM. In some aspects, the isolated population comprises multipotent stem cells that are isolated only from a filtering region of the TM and not from a non-filtering region of the TM. In some aspects, the multipotent stem cells are cells isolated from a region of the TM other than the insert area. In some aspects, the multipotent stem cells are cells isolated from the insert area of the TM and from a region of the TM other than the insert area.
  • In some aspects, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the multipotent stem cells of the isolated population are from a filtering region of the TM. In some aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5% less than or about 2%, or almost 0%) of the multipotent stem cells of the isolated population are from a non-filtering region of the TM. In some aspects, the isolated population lacks multipotent stem cells isolated from the insert area of the TM. In some aspects, the isolated population of multipotent stem cells comprise the multipotent stem cells obtained in accordance with one of the methods of obtaining an isolated population of multipotent stem cells provided herein.
  • In alternative embodiments, the multipotent stem cells of the isolated populations provided herein are not tissue-specific stem cells. Accordingly, in some aspects, the multipotent stem cells are isolated from a tissue other than the TM. In some aspects, the multipotent stem cells are isolated from a tissue other than a neural tissue. In some aspect, the multipotent stem cells are isolated from a tissue other than adipose. In some aspects, the multipotent stem cells are isolated from bone marrow, adipose tissue, skin, umbilical cord, amniotic fluid.
  • As used herein, the term “isolated” means having been removed from its natural environment and separated from some or all of the coexisting materials in the natural environment. Accordingly, the isolated populations of multipotent stem cells are stern cells that have been removed from their natural environment and separated from some or all of the other cells and/or tissue of the origin of the multipotent stem cells. For example, an isolated population of multipotent stem cells from a TM represents multipotent stem cells removed from the TM and separated from some or all of the co-existing TM cells and fibroblasts (and connective tissue) found in a TM. In a further example, an isolated population of multipotent stem cells isolated from the filtering region of the TM represents multipotent stem cells removed from the filtering region of the TM and separated from other cells of the filtering region of the TM. In yet another example, an isolated population of multipotent stem cells isolated from the filtering region and non-filtering region of the TM, e.g., the insert area, represent cells removed from the filtering region and non-filtering region, e.g., the insert area, of the TM and separated from other cells of the filtering region and non-filtering region of the TM.
  • In exemplary aspects, the isolated populations provided herein are purified, e.g., purified from other components (e.g., cells) of the natural environment from which the cells were isolated. The term “purified” as used herein means having been increased in purity, wherein “purity” is a relative term, and not to be necessarily construed as absolute purity. For example, the purity can be greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) The isolated populations in some aspects may be purified of cells of the TM which are not stem cells, e.g., the isolated populations are purified from T1v1 cells.
  • In some embodiments, the isolated population represents a substantially purified population of multipotent stem cells, wherein, for example, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the population are multipotent stem cells. In some aspects, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the population express at least one stem cell marker selected from the group consisting of ABCG2, Ankyrin 5 Pax6, Nestin, Mucin 1, CD73, CD90, CD166, Bmi-1, Oct4, CD117, Notch1, and KLF4. In some embodiments, the stem cell marker is expressed by greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the population at an increased level, as compared to cells which are known not to be stem cells, e.g., non-stem cells (e.g., TM cells, fibroblasts, keratocytes, neural cells, adipocytes, and the like).
  • In some aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of cells of the isolated population are cells other than multipotent stem cells. In some aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are non-stem cells (e.g., TM cells, fibroblasts, keratocytes, neural cells, adipocytes, and the like).
  • In some aspects, the isolated populations are homogeneous populations consisting of only one type of cell, the multipotent stem cells. In some aspects, the isolated populations are substantially homogenous populations consisting essentially of multipotent stem cells. In exemplary embodiments, greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated populations provided herein are multipotent stem cells, e.g., multipotent stem cells that express one or more stem cell markers, as described herein. In some aspects, the isolated population is a clonal population of multipotent stem cells in which each cell of the population is genetically indistinct from another cell of the population. In alternative aspects, the isolated population consists of only or consists essentially of multipotent stem cells, but the isolated population is not a clonal population of genetically indistinct multipotent stem cells.
    • Methods of Obtaining Isolated Populations of Multipotent Stein Cells
  • The presently disclosed isolated populations of multipotent stem cells may be obtained through one of a variety of methods. In exemplary embodiments, the multipotent stem cells are from a TM. In exemplary aspects, the TM is a TM of a mammal, such as any mammal described herein, e.g., mouse, rat, pig, human, dog, cat, horse, cow, chimpanzee, primate. In exemplary aspects, the human is an adult (e.g., aged 18 years or more). In exemplary aspects, the human is a child or a fetus. In exemplary aspects, the human is living. In exemplary aspects, the human is deceased, e.g., recently deceased (e.g., deceased within 1 month, 2 weeks, 1 week, 3 days, 2 days, 1 day, 12 hours, 6 hours, from time of TM collection). In exemplary embodiments, the cells of a trabecular meshwork are cells of an eye, or part thereof (e.g., cornea, sclera rim, TM) obtained from a tissue bank, e.g., a human tissue bank. Collection of TM tissue from a cornea obtained from a tissue bank and processing of the TM tissue to obtain cells are described herein (Example 1).
  • In exemplary embodiments, the multipotent stem cells are from a source other than a TM, e.g., bone marrow, adipose tissue, skin, umbilical cord, amniotic fluid.
  • In exemplary embodiments in which the multipotent stem cells are from a TM, the isolated population of multipotent stem cells are obtained by side population cell sorting of cells of a TM. Such cell sorting methods are described herein (e.g., Example 1) and, in the context of other cell types, in, e.g., Goodell, Curr Protocols in Cytometry 34: 9.18.1-9.18.11 (2005), Telford, “Stem Cell Side Population Analysis and Sorting Using DyeCycle Violet,” Current Protocols in Cytometry Unit 9.30 (2010), Telford et al., Stem Cells 25: 1029-1036 (2007), Telford, Applications of Flow Cytometry in Stem Cell Research and Tissue Regeneration, ed. Krishan et al., pages 25-44 (2010), and Camargo et al., Blood 107: 501-507 (2006).
  • In exemplary aspects, the isolated population of multipotent stem cells which are capable of differentiating into TM cells are obtained through a side population cell sorting method comprising (i) contacting cells isolated from a trabecular meshwork with a dye which (a) is effluxed by an, ABCG2 protein and (b) emits a detectable signal at a known wavelength, (ii) isolating cells exhibiting a reduced emission of the detectable signal at the known wavelength from cells exhibiting an increased emission of the detectable signal at the known wavelength.
  • In exemplary aspects, the cells isolated from a TM are propagated or cultured at a low cell density before being contacted with the dye. For example, in some aspects, the cells are propagated at a cell density of about 1000 cells/cm2 to about 20,000 cells/cm2. In exemplary aspects, the cells are propagated or cultured at the low cell density for about 14 to about 28 days or at least or about 2 (e.g., at least or about three, at least or about four, at least or about five, at least or about six, at least or about seven, at least or about eight, at least or about nine, at least or about ten) passages.
  • In exemplary aspects, the dye used in the side population cell sorting method is a dye that intercalates into DNA. In some aspects, the dye is a fluorescent dye. In some aspects, the dye is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux, e.g., DyeCycle Violet. Such dyes are commercially available through vendors, such as Invitrogen (Carlsbad, Calif.). In some aspects, the dye is Hoechst 33342, which is commercially available from Sigma-Aldrich, St. Louis, Mo.).
  • In alternative embodiments, the isolated population of multipotent stem cells are obtained by clonal expansion of cells of a trabecular meshwork, which cells express stem cell markers. Such methods are described herein (e.g., Example 1) and, in the context of other cell types, in, e.g., Halleux et al., J Musculoskele Neuron Interact 2(1): 71-76 (2001).
  • In yet other embodiments, the isolated population of multipotent stem cells is obtained by selective expansion of stem cells of a TM in a culture medium which promotes growth of stem cells while preventing or inhibiting growth of non-stem cells of the TM (e.g., mature TM cells, fibroblasts). In exemplary aspects, the culture medium is a culture medium comprising growth factors and cytokines (e.g., IL-6, stem cell factor) suitable for the growth of stem cells. In exemplary aspects, the culture medium substantially lacks growth factors or cytokines necessary for the growth of TM cells or fibroblasts.
  • Once obtained, the isolated populations of multipotent stem cells may be cultured under any suitable culturing conditions known in the art, e.g., conditions which promote cellular growth and expansion. Suitable culturing conditions include those described herein (e.g., Example 1) and in Adult Stem Cells, Turksen, ed., Humana Press, 2004, and Stem Cells Handbook, Sell, ed., Humana Press, 2003, or conditions varied therefrom which conditions may be empirically determined. In exemplary embodiments, the isolated populations of multipotent stem cells are cultured in a medium comprising serum, epidermal growth factor, pituitary extract, ascorbic acid, chondroitin sulfate, calcium chloride, or a combination thereof. In exemplary aspects, the medium comprises at least one antibiotic, e.g., penicillin, streptomycin, gentamicin, and the like.
    • Methods of Obtaining Isolated Populations of Differentiated Cells
  • Presented herein for the first time are data which demonstrate that multipotent stem cells can be induced to differentiate into functional trabecular meshwork cells, e.g., phagocytic TM cells. As demonstrated herein, the multipotent stem cells that have the capacity to differentiate into TM cells also are capable of differentiating into other cells types, including, but not limited to, keratocytes, neural cells, and adipocytes, thus, demonstrating the multipotent nature of the stem cells. Accordingly, the present disclosures also provide methods of obtaining an isolated population of differentiated TM cells, differentiated keratocytes, differentiated neural cells, or differentiated adipocytes from multipotent stem cells. In exemplary embodiments, the method comprises obtaining an isolated population of multipotent stem cells (e.g., from a TM) and culturing the isolated population of multipotent stem cells in a medium comprising factors sufficient and appropriate for induction of differentiation of the multipotent stem cell into the differentiated cell (e.g., TM cell, keratocyte, neural cell, adipocyte).
  • In exemplary embodiments, the step of obtaining the isolated population of multipotent stem cells is preformed as described herein (e.g., the section entitled “Methods of obtaining isolated populations of multipotent stem cells”). In exemplary aspects, the isolated population of multipotent stem cells is obtained via side population cell sorting of cells of a TM, clonal expansion of cells of a TM, or selective expansion of stem cells of a TM in a culture medium which promotes growth of stem cells while preventing of inhibiting growth of non-stem cells of the TM.
  • In exemplary embodiments, the method provided herein is a method of obtaining an isolated population of differentiated TM cells. In exemplary aspects, the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting, clonal expansion of cells of a TM, selective expansion of stem cells of a TM). In exemplary aspects, the isolated population of multipotent stem cells is in accordance with the descriptions of isolated populations of multipotent stem cells described herein (see, e.g., “Isolated populations of multipotent stem cells”). Once obtained, the isolated population of multipotent stem cells are cultured in a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor. In exemplary aspects, the medium comprises aqueous humor, fetal bovine serum, or both aqueous humor and fetal bovine serum. In exemplary aspects, the aqueous humor is obtained from a non-human mammal (e.g., cow, pig, horse, dog, cat, monkey) and the multipotent stem cells are human multipotent stem cells. In some aspects, the medium comprises at least or about 25% (v/v) aqueous humor. In exemplary aspects, the medium comprises at least or about 30% (e.g., 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%) (v/v) aqueous humor. In some aspects, the medium comprises X % (v/v) aqueous humor and Y % stern veil growth medium (e.g., as described herein), wherein Y %=(100%-X %) and X % is an integer between 0 and 100. In some aspects, the medium comprises at least or about 5% (v/v) fetal bovine serum. In exemplary aspects, the medium comprises at least or about 10% (e.g., 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%)) (v/v) fetal bovine serum. In exemplary aspects, the medium comprising fetal bovine serum comprises Dulbecco's Modified Eagle Medium (DMEM): Nutrient Mixture F-12 (DMEMIF'12)® (Invitrogen, Carlsbad, Calif.). In exemplary aspects, the multipotent stem cells used in the method of obtaining an isolated population of differentiated TM cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • In exemplary embodiments, the method provided herein is a method of obtaining an isolated population of differentiated keratocytes. In exemplary aspects, the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in a keratocyte differentiation medium (KDM). In some aspects, the KDM comprises fibroblast growth factor-2 and/or ascorbic acid-2-phosphate. In some aspects, the KDM comprises Advanced® MEM (Invitrogen) supplemented with fibroblast growth factor-2 and/or ascorbic acid-2-phosphate. In exemplary aspects, the multipotent stem cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • In exemplary embodiments, the method provided herein is a method of obtaining an isolated population of differentiated neural cells. In exemplary aspects, the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in a neural differentiation medium (NDM). In some aspects, the NDM comprises epithelial growth factor, fibroblast growth factor, all-trans retinoic acid, or a combination thereof. In some aspects, the NDM comprises penicillin, streptomycin, gentamicin, or a combination thereof. In some aspects, the NDM comprises Advanced® DMEM (Invitrogen) supplemented with epithelial growth factor, fibroblast growth factor, all-trans retinoic acid, penicillin, streptomycin, gentaraicin, or a combination thereof. In exemplary aspects, the multipotent stem cells in the NDM are plated onto a dish (e.g., a plastic dish) coated with a medium which promotes attachment of cell to the dish, e.g., FNC Coating Mix® (AthenaES). In exemplary aspects, the multipotent stem cells used in the method of obtaining an isolated population of differentiated neural cells are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
  • In exemplary embodiments, the method provided herein is a method of obtaining an isolated population of differentiated adipocytes. In exemplary aspects, the method comprises obtaining an isolated population of multipotent stem cells (e.g., via side population cell sorting or clonal expansion of cells of a TM) and culturing the isolated population in an adipogenic differentiation medium (ADM). In some aspects, the ADM comprises fetal bovine serum, dexamethasone, methyl-isobutylxanthine, insulin, or a combination thereof. In some aspects, the ADM comprises indomethacin, penicillin, streptomycin, gentamicin, or a combination thereof. In some aspects, the ADM comprises DMEM-Law glucose (Invitrogen) supplemented with fetal bovine serum, dexamethasone, methyl-isobutylxanthine, insulin, indomethacin, streptomycin, gentainicin, or a combination thereof. In exemplary aspects, the multipotent stem cells in the ADM are plated onto a dish (e.g., a plastic dish) coated with gelatin (e.g., 1% (v/v) gelatin). in exemplary aspects, the multipotent stem cells used in the method of obtaining an isolated population of differentiated adipocytes are the multipotent stem cells of the present disclosures. Such methods are further described herein (e.g., Example 1).
    • Differentiated Cell Types
  • In addition to providing methods of obtaining isolated populations of differentiated cells, the present disclosures further provide the isolated populations of the differentiated cells obtained through these methods. In exemplary aspects, the differentiated cells (e.g., the TM cells, corneal keratocytes, neural cells, or adipocytes) obtained through the above-described methods express a stem cell marker at a reduced level or an undetectable level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated. In exemplary aspects, the stem cell marker is selected from the group consisting of ABCG2, Pax6, Nestin, AnkyriuG, Mucin1, CD73, CD9Q, CD166, Bmi-1,
  • CD117, Notch1, Oct4, KLF4, and a combination thereof. Further descriptions of each type of differentiated cells are provided below.
  • A. TM cells
  • When the differentiated cells are TM cells, the TM cells in some aspects express a TM cell marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated. In exemplary aspects, the TM cell marker is selected from the group consisting of MGP, AQP1, CHI3L1, NCAM, TIMP3, and a combination thereof.
  • In exemplary aspects, the differentiated TM cells are phagocytic TM cells, For example, in certain aspects, the TM cells of the isolated populations provided herein are capable of phagocytosing extracellular debris, such that the TM cells function to prevent blockage of Schlemm's canal in an eye.
  • In accordance with the foregoing, the present disclosures further provide isolated populations of TM cells, e.g., phagocytic TM cells, which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells. In exemplary aspects, the isolated populations of TM cells are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells. For example, in some aspects, the isolated population of TM cells is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are TM cells. In further aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a TM cell, e.g., a multipotent stem cell, a keratocyte, a neural cell, adipocyte.
  • B. Corneal Keratocytes
  • When the differentiated cells are corneal keratocytes, the corneal keratocytes in some aspects express a keratocyte marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated. In exemplary aspects the keratocyte marker is keratocan.
  • In accordance with the foregoing, the present disclosures provides isolated populations of corneal keratocytes which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells. In exemplary aspects, the isolated populations of corneal keratocytes are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells. For example, in some aspects, the isolated population of corneal keratocytes is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g—greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are corneal keratocytes. In further aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a corneal keratocyte, e.g., a multipotent stem cell, a TM cell, a neural cell, an adipocyte.
  • C. Neural Cells
  • When the differentiated cells are neural cells, the neural cells in some aspects express a neural cell marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated. In exemplary aspects the neural cell marker is selected from the group consisting of GFAP, neurofilament, and J3-tubulin III, and a combination thereof.
  • In accordance with the foregoing, the present disclosures provides isolated populations of neural cells which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells. In exemplary aspects, the isolated populations of neural cells are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells. For example, in some aspects, the isolated population of neural cells is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are neural cells. In further aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than a neural cell, e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, an adipocyte.
  • D. Adipocytes
  • When the differentiated cells are adipocytes, the adipocytes in some aspects express an adipocyte marker at an increased level, as compared to multipotent stem cells, e.g., the multipotent stem cells from which the cells derived or originated. In exemplary aspects the adipocyte marker is selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, ALBP/ap2, and a combination thereof. In exemplary aspects, the adipocytes exhibit an increased level of lipoid deposits, as compared to the multipotent stem cells from which the adipocytes originated.
  • In accordance with the foregoing, the present disclosures provides isolated populations of adipocytes which are obtained through the presently disclosed methods, e.g., obtained through induced differentiation of multipotent stem cells. In exemplary aspects, the isolated populations of adipocytes are purified or homogenous or substantially homogenous as taught above, with respect to isolated populations of multipotent stem cells. For example, in same aspects, the isolated population of adipocytes is purified or homogenous or substantially homogenous such that greater than or about 50% (e.g., greater than or about 60%, greater than or about 70%, greater than or about 80%, greater than or about 90%, greater than or about 95%, greater than or about 98%, or almost 100%) of the cells of the isolated population are adipocytes. in further aspects, less than or about 50% (e.g., less than or about 40%, less than or about 30%, less than or about 20%, less than or about 10%, less than or about 5%, less than or about 2%, or almost 0%) of the cells of the isolated population are cells other than an adipocyte, e.g., a multipotent stem cell, a TM cell, a corneal keratocyte, a neural cell.
    • Single Cells
  • In addition to the isolated populations of multipotent stem cells and isolated populations of differentiated cells (e.g., TM cells, corneal keratocytes, neural cells, adipocytes), the present disclosures furthermore provides the cells in singular form. Accordingly, the present disclosures provides an isolated multipotent stem cell capable of differentiating into a TM cell, as well as an isolated differentiated cell e.g., an isolated TM cell, an isolated corneal keratocyte, an isolated neural cell, an isolated adipocyte. In exemplary embodiments, the isolated cell exhibits a marker expression profile in accordance with the teachings of the corresponding isolated population provided herein. For example, in some aspects, the isolated multipotent stem cell provided herein expresses a stem cell marker selected from the group consisting of ABCG2, Ankyrin 5 Pax6, Nestin, Mucin 1, CD73, CD9Q, CD166, Bmi-1, CD117, Notch1, Oct4, KLF4, and a combination thereof. Also, for example, the isolated TM cell provided herein expresses a TM cell marker selected from the group consisting of MGP, AQP1, CHI3LI, NCAM, TIMP3, and a combination thereof, at an increased level, as compared to the multipotent stern cell from which the TM cell originated. Further, for example, the isolated corneal keratocyte expresses keratocan at an increased level, as compared to the multipotent stem cell from which the keratocyte originated. Furthermore, for example, the isolated neural cell expresses a neural cell marker selected from the group consisting of GFAP, neurofilament, (β-tubulin III and a combination thereof, at an increased level, as compared to the multipotent stem cell from which the neural cell originated. Moreover, for example, the isolated adipocyte exhibits an increased level of lipoid deposits, or an increased level of an adipocyte marker selected from the group consisting of leptin, adiponectin, FABP4, GLUT4, ALBP/ap2, and a combination thereof, as compared to the multipotent stem cell from which the adipocyte originated.
    • Genetically Modified Cells
  • In exemplary embodiments, the multipotent stem cells or the differentiated cells of the present disclosures are genetically modified to contain a recombinant nucleic acid. By “nucleic acid” as used herein includes “polynucleotide,” “oligonucleotide,” and “nucleic acid molecule,” and generally means a polymer of DNA or RNA, which can be single-stranded or double-stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered inter-nucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. As used herein, the term “recombinant” refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above. For purposes herein, the replication can be in vitro replication or in vivo replication.
  • In exemplary embodiments, the recombinant nucleic acid encodes a protein and the cell expresses the protein. In exemplary embodiments, the recombinant nucleic acid inhibits or prevents expression of a protein by the cell in which the recombinant nucleic acid resides. The protein may be any protein, e.g., an enzyme, signaling protein, a ligand binding protein, a structural protein, a cell surface receptor, a cytokine, a growth factor, a signal transduction factor, a transcription factor, and the like. The protein in some aspects is a protein which is naturally expressed by the cell in which the recombinant nucleic acid resides. In some aspects, the protein is one which is not naturally expressed by the cell in which the recombinant nucleic acid resides. In exemplary aspects, the protein is selected from the group consisting of the proteins listed in Table A set forth below.
    • Pharmaceutical Compositions and Formulations
  • The isolated populations or isolated cells of the present disclosures are optionally formulated into a composition, such as a pharmaceutical composition. In this regard, provided herein is a pharmaceutical composition comprising any of the presently disclosed isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, and a pharmaceutically acceptable carrier. Also provided is a pharmaceutical composition comprising an isolated multipotent stem cell, an isolated TM cell, an isolated corneal keratocyte, an isolated neural cell, or an isolated adipocyte, of the present disclosures and a pharmaceutically acceptable carrier.
  • The carrier is any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the cells, and by the route of administration. The pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public. In one aspect, the pharmaceutically acceptable carrier is one which is chemically inert to the cells, and one which has no detrimental side effects or toxicity under the conditions of use. The choice of carrier will be determined in part by the particular agents comprising the pharmaceutical composition, as well as by the particular route used to administer the pharmaceutical composition. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of the present disclosures.
  • Depending on the route of administration, the particular cell or isolated population of cells intended for use, as well as other factors, the pharmaceutical composition may comprise additional pharmaceutically acceptable ingredients, including, for example, one or more of additives, adsorbents, anticoagulants, antimicrobial preservatives, antioxidants, buffering agents, cryoprotectant, diluents, preservatives, stabilizing agents, therapeutic agents, tonicity agents, toxicity agents, viscosity-increasing or -decreasing agents. Accordingly, in exemplary embodiments, the pharmaceutical composition comprises any one or more of the components in the Handbook of Pharmaceutical Excipients, Third Edition, A. H. Kibbe (Phaniaceutical Press, London, UK, 2000), which is incorporated by reference in its entirety. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety, discloses various components used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof, provided that the component does not adversely affect the viability or functionality of the cells. Supplementary active ingredients also can be incorporated into the compositions.
  • When the compositions include a cryopreserved cells, the composition in some aspects comprises a cryoprotectant. In some embodiments, the cryoprotectant is a glycol, e.g., ethylene glycol, propylene glycol, glycerol, DMSO, formamide, 2-methyl, ˜2,4-pentadiol, sucrose, trehalose, and colloid. Methods of cryopreservation are known in the art and include, but not limited to those described in Lee et al., Ferl Steri193 (3): 976-985 (2008); Berz et al., Am J Hernatal 82(6): 463-472 (2007); Watt et al., Methods Ml. Biol. 368: 237-259 (2007); Warkentin et al., Prog Clin Biol Res 389: 643-647 (1994); Slaper-Cortenbach et al., Prog Clin Biol Res 389: 649-656 (1994), and Magrin et al., Haematologica 76 Suppl 1: 55-57 (1991).
  • In some embodiments, the compositions of the present disclosures comprises a cell culture medium suitable for the viability and functionality of the cells. In exemplary aspects, the composition comprises one or more growth factors and/or cytokines, optionally selected from the group consisting of: platelet derived growth factor (PDGF), a fibroblast growth factor (FGF), transforming growth factor (TGF), epidermal growth factor (EGF), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), c-Kit, tumor necrosis factor (TNF), stromal cell-derived factor (SDF), granulocyte colony stimulating factor (G-CSF), interferon, bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), and K1f4. In exemplary aspects, the composition comprises a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor. In some embodiments, the compositions comprise growth factors and/or cytokines found in aqueous humor. In some embodiments, the compositions comprise a medium comprising serum or components thereof, e.g., fetal bovine serum, human serum albumin. In some embodiments, the compositions are serum-free. In exemplary aspects, the composition comprises a medium comprising fetal bovine serum and/or aqueous humor. In exemplary aspects, the aqueous humor is from a non-human (e.g., cow, pig, horse, mouse, rat, dog, cat, monkey) and the cells of the composition are from a human.
  • In some embodiments, the foregoing component(s), e.g., fetal bovine serum, aqueous humor, may be present in the pharmaceutical composition at any concentration, such as, for example, at least A, wherein A is 0.0001% w/v, 0.001% o w/v, 0.01% w/v, 0.1% w/v, 1% w/v, 2% w/v, 5% w/v, 10% w/v, 20% w/v, 30% w/v, 40% w/v, 50% w/v, 60% w/v, 70% w/v, 80% w/v, or 90% w/v. In some embodiments, the foregoing component(s) may be present in the pharmaceutical composition at any concentration, such as, for example, at most B, wherein B is 90% w/v, 80% w/v, 70% w/v, 60% w/v, 50% w/v, 40% w/v, 30% w/v, 20% w/v, 10% w/v, 5% w/v, 2% w/v, 1% w/v, 0.1% w/v, 0.001% w/v, or 0.0001%. In other embodiments, the foregoing component(s) may be present in the pharmaceutical composition at any concentration range, such as, for example from about A to about B. In some embodiments, A is 0.0001% and B is 90%.
  • The pharmaceutical compositions may be formulated to achieve a physiologically compatible pH. In some embodiments, the pH of the pharmaceutical composition may be at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, at least 8, at least 8.5, at least 9, at least 9.5, at least 10, or at least 10.5 up to and including pH 11, depending on the formulation and route of administration. In certain embodiments, the pharmaceutical compositions may comprise buffering agents to achieve a physiological compatible pH. The buffering agents may include any compounds capable of buffering at the desired pH such as, for example, phosphate buffers (e.g., PBS), triethanolamine, Tris, bicine, TAPS, tricine, HEPES, TES, MOPS, PIPES, cacodylate, MES, and others. In certain embodiments, the strength of the buffer is at least 0.5 mM, at least 1 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 30 mM, at least 40 mM, at least 50 mM, at least 60 mM, at least 70 mM, at least 80 mM, at least 90 mM, at least 100 mM, at least 120 mM, at least 150 mM, or at least 200 mM. In some embodiments, the strength of the buffer is no more than 300 mM (e.g., at most 200 mM, at most 100 mM, at most 90 mM, at most 80 mM, at most 70 mM, at most 60 mM, at most 50 mM, at most 40 mM, at most 30 mM, at most 20 mM, at most 10 mM, at most 5 mM, at most 1 mM).
  • In some aspects, the cells of the composition are in solution, e.g., aqueous solution, In some aspects, the cells of the composition are cryopreserved.
    • Routes of Administration
  • In some embodiments, the pharmaceutical composition comprising the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes is formulated for parenteral administration, intraanterior chamber administration, intraschlemm's canal administration, intravitreous administration, subconjunctival administration, subcutaneous administration, intravenous administration, intramuscular administration, or intra-arterial administration. In exemplary aspects, the pharmaceutical composition is formulated for implantation or injection. In other embodiments, the pharmaceutical composition is administered via nasal, spray, oral, or aerosol administration.
  • Methods of administering stem cells are known in the art. see, for example, any of U.S. Pat. Nos. 5,423,778, 5,550,050, 5,662,895, 5,800,828, 5,800,829, 5,811,407, 5,833,979, 5,834,001, 5,834,029, 5,853,717, 5,855,619, 5,906,827, 6,008,035, 6,012,450, 6,049,026, 6,083,523, 6,206,914, 6,303,136, 6,306,424, 6,322,804, 6,352,555, 6,368,612, 6,479,283, 6,514,522, 6,534,052, 6,541,024, 6,551,338, 6,551,618, 6,569,147, 6,579,313, 6,599,274, 6,607,501, 6,630,457, 6,648,849, 6,659,950, 6,692,738, 6,699,471, 6,736,799, 6,752,834, 6,758,828, 6,787,357, 6,790,455, 6,805,860, 6,852,534, 6,863,900, 6,875,441, 6,881,226, 6,884,427, 6,884,428, 6,886,568, 6,918,869, 6,933,281, 6,933,286, 6,949,590, 6,960,351, 7,011,828, 7,031,775, 7,033,345, 7,033,603, 7,049,348, 7,070,582, 7,074,239, 7,097,832, 7,097,833, 7,135,172, 7,145,055, 7,157,080, 7,166,280, 7,176,256, 7,244,242, 7,452,532, 7,470,425, and 7,494,644, each of which are incorporated by reference in their entirety.
    • Parenteral
  • In some embodiments, the pharmaceutical composition described herein is formulated for parenteral administration. For purposes of the invention, parenteral administration includes, but is not limited to, intravenous, intraanterior chamber administration, intraschlemm's canal administration, intravitreous administration, subconjunctival administration, intraarterial, intramuscular, intracerebral, intracerebroventricular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal, intravesical, and intracavernosal injections or infusions.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The pharmaceutical composition are in various aspects administered via a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2-dimethyl-1,3-dioxalane-4-methanol, ethers, polyethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
  • Oils, which are optionally used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearie acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • The parenteral formulations in some embodiments contain preservatives or buffers. In order to minimize or eliminate irritation at the site of injection, such compositions optionally contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations are in various aspects presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a cryopreserved condition along with a freezing agent, e.g., dimethyl sulfoxide (DMSO).
  • Injectable formulations are in accordance with the invention. The requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Company, Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)).
  • In some embodiments, the cells of the isolated populations are administered via a cell delivery matrix. The cell delivery matrix in certain embodiments comprises any one or more of polymers and hydrogels comprising collagen, fibrin, chitosan, MATRIGEL, polyethylene glycol, dextrans including chemically crosslinkable or photocrosslinkabie dextrans, and the like. In certain embodiments, the cell delivery matrix comprises one or more of: collagen, including contracted and non-contracted collagen gels, hydrogels comprising, for example, but not limited to, fibrin, alginate, agarose, gelatin, hyaluronate, polyethylene glycol (PEG), dextrans, including dextrans that are suitable for chemical crosslinking, photocrosslinking, or both, albumin, polyacrylamide, polyglycolyic acid, polyvinyl chloride, polyvinyl alcohol, poly(n-vinyl-2-pyrollidone), pmy(2-hydroxy ethyl methacrylate), hydrophilic polyuretlianes, acrylic derivatives, pluronics, such as polypropylene oxide and polyethylene oxide copolymer, or the like. The fibrin or collagen in certain embodiments are autologous or allogeneic with respect to the patient.
  • The matrix in some instances comprises non-degradable materials, for example, but not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polyethyleneterephthaiate (PET), poly(butylenes terephthalate (PBT), polyurethane, polyethylene, polycabonate, polystyrene, silicone, and the like, or selectively degradable materials, such as poly (lactic-co-glycolic acid; PLGA), PLA, or PGA. (See also, Middleton et al., Biontatez
    Figure US20120237485A1-20120920-P00001
    .als 21:2335 2346, 2000; Middleton et al., Medical Plastics and Biomaterials, March/April 1998, at pages 30 37; Handbook of Biodegradable Polymers, Donib, Kost, and Domb, eds., 1997, Harwood Academic Publishers, Australia; Rogalla, Minim. Invasive Surg. Nurs. 11:6769, 1997; Klein, Facial Plast. Surg. Clin, North Amer. 9:205 18, 2001; Klein et al., J. Dermatol. Surg. Oncol. 1 1:337 39, 1985; Frey et al., J. Urol. 154:812 15, 1995; Peters et al., J. Biomed. Mater. Res. 43:422 27, 1998; and Kuijpers et al., 3. Biomed. Mater. Res. 51:13645, 2000).
  • In exemplary aspects of the composition, the cells are in a matrix, capsule or gel. In exemplary aspects, the matrix, capsule or gel is implantable.
  • The pharmaceutical composition comprising the isolated populations of multipotent stern cells, TM cells, corneal keratocytes, or neural cells, in certain embodiments, comprises any of the components of a cell delivery matrix, including any of the components described herein.
    • Dose
  • For purposes herein, the amount or dose of the pharmaceutical composition administered to a subject are sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject or animal over a reasonable time frame, For example, the dose of the pharmaceutical composition is sufficient to treat or prevent a medical condition as further described herein (e.g., glaucoma), in a period of from about Ito 4 days or longer, e.g., 5 days, 6 days, 1 week, 10 days, 2 weeks, 16 to 20 days, or more, from the time of administration. In certain embodiments, the time period is even longer. Cell based therapies of the present disclosures have potential to provide sustained or permanent benefit. The dose is determined by the efficacy of the particular pharmaceutical composition and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.
  • Many assays for determining an administered dose are known in the art. In some embodiments, an assay which comprises comparing the extent to which multipotent stem cells are localized to the TM of an eye upon administration of a given dose of such multipotent stem cells to a mammal among a set of mammals of which is each given a different dose of the multipotent stem cells is used to determine a starting dose to be administered to an animal. The extent to which multipotent stem cells are localized to a TM upon administration of a certain dose can be assayed by methods known in the art, including, for instance, the methods described herein.
  • Additionally or alternatively, an assay which comprises comparing the extent to which a particular dose of multipotent stem cells cause attenuation of a medical condition as further described herein (e.g., glaucoma), a decrease in intraocular pressure, an increase in TM cellularity, or increase in aqueous humor outflow from the eye, can be used to determine a starting dose to be administered to a mammal.
  • The dose of the pharmaceutical composition also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular pharmaceutical composition. Typically, the attending physician will decide the dosage of the pharmaceutical composition with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, therapeutic agent(s) of the pharmaceutical composition to be administered, route of administration, and the severity of the condition being treated. By way of example and not intending to limit the invention, the dose of the pharmaceutical composition can be such that at least about 0.5×106 (e.g, at least or about 104, 105, 106, 107, 108) multipotent stem cells are administered to the patient.
    • Controlled Release Formulations
  • The pharmaceutical composition are in certain aspects modified into a depot form, such that the manner in which the pharmaceutical composition is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Pat. No. 4,450,150). Depot forms are in various aspects, an implantable composition comprising the therapeutic or active agent(s) and a porous or non-porous material, such as a polymer, wherein the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes are encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body and the cells are released from the implant at a predetermined rate.
  • Accordingly, the pharmaceutical composition in certain aspects is modified to have any type of in vivo release profile. In some aspects of the invention, the pharmaceutical composition is an immediate release, controlled release, sustained release, extended release, delayed release, or bi-phasic release formulation. In some aspects, the pharmaceutical composition is formulated for sustained, continuous release, e.g., formulated for continuous release of the (same amount of) cells over a sustained period of time, including but not limited to at least 103, 104, 105, 106, 107, 108, 109, 1010, 10″, 1012 cells released from the composition and into the subject over 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 48 hours, 36 hours, 72 hours, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month.
    • Conjugates
  • In some embodiments of the present disclosures, the cells or the isolated populations of cells are attached or linked to a second moiety, such as, for example, a therapeutic agent or a diagnostic agent. The cells (e.g., multipotent stem cells) in some embodiments act as a targeting agent, since the cells are able to specifically localize to the TM. Accordingly, the present disclosures provide in one aspect a composition comprising a conjugate comprising multipotent stem cells attached to a therapeutic agent or a diagnostic agent. Suitable therapeutic agents and diagnostic agents for purposes herein are known in the art and include, but are not limited to, any of those mentioned herein. In alternative embodiments, the cells are conjugated into a matrix and the matrix is conjugated to a second moiety, such as, for example a therapeutic or diagnostic agent.
    • Combinations
  • In some embodiments, the multipotent stem cells, T1 Vi cells, corneal keratocytes, neural cells or adipocytes of the isolated populations provided herein are administered alone, and in alternative embodiments, the multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes of the isolated populations provided herein are administered in combination with another therapeutic agent, e.g., another cell of the present disclosures but of a different type (e.g., a combination of multipotent stem cells, TM cells, corneal keratocytes, neural cells and/or adipocytes), or another therapeutic which is known to achieve the same effect as the cells of the isolated populations or which are known to aid in the growth, survival, expansion, localization, stability, prevention of rejection, therapeutic index, bioefficacy, of the cells of the isolated population. In exemplary embodiments, the cell or isolated population provided herein is administered simultaneously as the other therapeutic agent. In alternative embodiments, the cell or isolated population provided herein is administered either before or after the other therapeutic agent.
  • In some aspects, the other therapeutic agent is an anti-glaucoma agent, including, but not limited to: a beta blocker (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol); an alpha-2-agonist (e.g., apraclonidine, brimonidine); a carbonic anhydrase inhibitor (e.g., acetazolamide, methazolamide, brinzolamide, dorzolamide), a prostaglandin (e.g., bimatoprost, latanoprost, travoprost, unoprostone); a miotic (e.g., carbachol, echothiophate, and pilocarpine), a combination medication (e.g., Cosopt (timolol and dorzolamide)).
  • In some aspects, the isolated populations or cells are administered in conjunction with an anti-glaucoma therapeutic procedure, including a laser surgery, e.g. laser trabeculoplasty, or a glaucoma surgery, e.g., incisional glaucoma surgery, or implantation of a glaucoma drainage device (e.g., glaucoma implant). The laser trabeculoplasty in some aspects is a selective laser trabeculoplasty, a laser peripheral iridotomy, a laser peripheral iridoplasty, or a laser cyclophotocoagulation.
    • Uses
  • The present disclosures additionally provide uses of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes. In exemplary embodiments, the isolated populations, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of decreasing intraocular pressure in an eye. The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to decrease the intraocular pressure in the eye. Methods of assaying intraocular pressure in an eye are known in the art, and include, but not limited to, measurement of pressure with a tonometer, e.g., a Goldmann tonometer.
  • In other exemplary embodiments, the isolated populations, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of increasing cell density in the trabecular meshwork of an eye. The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to increase cell density in the trabecular meshwork of an eye. Methods of assaying cell density or cellularity in the TM of an eye are known in the art. Suitable methods include, but not limited to, immunohistochemistry, microscopy (e.g., confocal), and the methods described in Alvarado et al., Invest Ophthamol V is Sci 21(5): 714-727 (1981), Alvarado et al ., Ophthamology 91(6): 564-579 (1984); and Murphy et al., Invest Ophthamol V is Sci 25(3): 312-322 (1984).
  • In yet other exemplary embodiments, the isolated populations, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or TM cells, are used in a method of increasing outflow of aqueous humor from the eye. The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, in an amount effective to increase outflow of aqueous humor from the eye. Methods of assaying outflow of aqueous humor from an eye are known in the art and include but not limited the tonographic technique described in Grant, Arch Ophthal 44(2): 204-214 (1950), Toris et al., GlaucomA Today, pages 15-22 (September/October 2007), and Brubaker, Trans Am Ophthalmol Soc 80: 391-474 (1982).
  • With regard to the above methods, the increase or decrease achieved upon administration of the cells of the isolated populations, or compositions comprising the same, may be any level of increase or decrease. For example, the method of decreasing intraocular pressure in some aspects achieves at least or about a 10% decrease (e.g., at least or about a 20% decrease, at least or about a 30% decrease, at least or about a 40% decrease, at least or about a 50% decrease, at least or about a 60% decrease, at least or about a 70% decrease, at least or about a 80% decrease, at least or about a 90% decrease, at least or about a 95% decrease), as compared to a control level. The control level in exemplary aspects is the level of the intraocular pressure in subjects to which cells were (or the composition was) not administered or the level of the intraocular pressure exhibited by the subject before administration of the cells or composition. In some aspects, the method of decreasing intraocular pressure achieves a decrease, such that intraocular pressure is substantially restored to normal levels. Also, for example, the method of increasing aqueous humor outflow in some aspects achieves at least or about a 10% increase (e.g., at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase, at least or about a 50% increase, at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or about a 90% increase, at least or about a 95% increase), as compared to a control level. The control level in exemplary aspects is the level of the aqueous humor outflow in subjects to which cells were (or the composition was) not administered or the level of the aqueous humor outflow exhibited by the subject before administration of the cells or composition. In some aspects, the method of increasing aqueous humor outflow achieves an increase, such that aqueous humor outflow is substantially restored to art-recognized normal levels. Further, for example, the method of increasing cellularity or cell density of a TM in some aspects achieves at least or about a 10% increase (e.g., at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase) or at least or about a 50% increase (e.g., at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or about a 90% increase, at least or about a 95% increase), as compared to a control level. The control level in exemplary aspects is the level of TM cellularity or cell density in subjects to which cells were (or the composition was) not administered or the level of TM cellularity of cell density exhibited by the subject before administration of the cells or composition. In some aspects, the method of increasing TM cellularity or cell density achieves an increase, such that the cellularity or cell density is substantially restored to normal levels. As used herein “normal levels” refers to a level within a range of intraocular pressure, range of aqueous humor outflow, or range of TM cellularity or cell density, which range is considered by a physician, e.g., an ophthalmologist, as representative of a healthy subject or an undiseased subject. In exemplary aspects, a normal level of intraocular pressure as measured by a Goldmann tonometer is a measure within the range of 10 to 22.
  • The present disclosures furthermore provide a method of treating or preventing a medical condition in a subject in need thereof. The medical condition in some embodiments is a medical condition that is caused by or associated with decreased cell density in the trabecular meshwork, increased intraocular pressure in an eye, decreased outflow of aqueous humor from the eye, or a combination thereof. The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are muitipotent stem cells or TM cells, in an amount effective to treat or prevent the medical condition.
  • As used herein, the terms “treat,” and “prevent” as well as words stemming therefrom, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the methods of treatment or prevention provided herein can provide any amount of any level of treatment or prevention of a medical condition in a subject. Furthermore, the treatment or prevention provided by the methods of treatment or prevention provided herein in same aspects includes treatment or prevention of one or more conditions or symptoms of the medical condition being treated or prevented. Also, for purposes herein, “prevention” in some aspects encompasses delaying the onset of the medical condition, or a symptom or condition thereof.
  • In exemplary aspects, the medical condition is glaucoma. In some aspects, the glaucoma is open-angle glaucoma, angle-closure glaucoma, congenital glaucoma, or secondary glaucoma. Methods of diagnosing or monitoring glaucoma are known in the art and include but not limited to gonioscopy-mediated examination, tonometry, optic nerve imaging, papillary reflex response, retinal examination, slit lamp examination, visual acuity, visual field measurement.
  • In exemplary aspects, the presently disclosed method treats or prevents a symptom of glaucoma. In exemplary aspects, the symptom of glaucoma is tunnel vision, severe eye pain, cloudy vision, decreased vision, nausea, vomiting, halos around lights, red eye, cloudiness of the front of the eye, enlargement of the eye, light sensitivity, tearing.
  • Because glaucoma is the second most common cause of blindness in the United States, treatment of glaucoma may be considered as a prevention or delay or slowing of blindness. Accordingly, the medical condition prevented by the method of the present disclosures in exemplary aspects is blindness.
  • In alternative aspects, the medical condition is one that is caused by a decrease in keratocytes in a subject or in a tissue thereof. In some aspects, the decrease in keratocytes is due to an increase in keratocyte degeneration, keratocyte cell injury, or keratocyte cell death (e.g., apoptosis, necrosis). The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or corneal keratocytes, in an amount effective to treat or prevent the medical condition.
  • In alternative aspects, the medical condition is one that is caused by a decrease in neural cells in a subject or in a tissue thereof. In some aspects, the decrease in neural cells is due to an increase in neural cell degeneration, neural cell cell injury, or neural cell cell death (e.g., apoptosis, necrosis). The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or neural cells, in an amount effective to treat or prevent the medical condition.
  • In alternative aspects, the medical condition is one that is caused by a decrease in adipocytes in a subject or in a tissue thereof. In some aspects, the decrease in adipocytes is due to an increase in adipocyte degeneration, adipocyte cell injury, or adipocyte cell death (e.g., apoptosis, necrosis). The method comprises administering to a subject in need thereof the isolated population, or composition comprising the same, wherein the cells of the isolated population are multipotent stem cells or adipocytes, in an amount effective to treat or prevent the medical condition.
  • In exemplary aspects of the methods of treatment or prevention provided herein, the administered cells may be obtained through any of the methods of obtaining multipotent stem cells or of obtaining differentiated cells described herein. In relation to the subject receiving the cells, the source of the cells administered to the subject may be any source, as described herein. In some aspects, the source of the cells is a mammal. In specific aspects, the source of the cells is a human. In further aspects, the species of the source of cells is the same species as the subject to which the cells are administered. In some aspects, the source of the cells is the subject to which the cells are administered such that the cells are “autologous” to the subject. In some embodiments, the source of the cells is different from the subject, but the source and patient are of the same species, such that the cells are considered as “allogeneic” cells with reference to the subject.
    • Subjects
  • With regard to the present disclosures, the subject may be any living organism, e.g., an organism comprising a TM. In exemplary aspects, the subject is a mammal. As used herein, the term “mammal” refers to any vertebrate animal of the mammalia class, including, but not limited to, any of the monotreme, marsupial, and placental taxis. In some embodiments, the mammal is one of the mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. In certain embodiments, the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). In certain embodiments, the mammals are from the order Artiodactyla, including Bovines (cows) and S wines (pigs) or of the order Perssodactyla, including Equines (horses). In some instances, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). In particular embodiments, the mammal is a human.
    • Kits
  • The present disclosures furthermore provide kits comprising any of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, described herein, or any of the compositions comprising the cells or isolated populations described herein. In some aspects, the cells of the kit are provided in a container, e.g., a vial, tube, plate, well, flask, and the like. In certain aspects, the cells of the kit are provided in a cryopreserved form. In alternative aspects, the cells of the kit are provided in a ready to use form (e.g., are in solution) and are not cryopreserved. In some aspects, the cells of the kit are provided in a device for administration of the cells to a subject. In some aspects, the cells are provided in an intravenous bag, a syringe, a matrix, e.g., an implantable matrix, a capsule, e.g., an implantable capsule, ready for administration to a subject. In some aspects, the kit comprises a device for administration.
  • In exemplary aspects, the kit comprises a set of instructions for use in accordance with any of the methods described herein. The set of instructions, in some embodiments, comprise instructions for using the cells in a method of obtaining an isolated population of TM cells, corneal keratocytes, neural cells or adipocytes. The set of instructions, in alternative embodiments, comprise instructions for using the cells in a method of decreasing intraocular pressure in an eye, increasing cell density in the TM of an eye, or increasing outflow of aqueous humor from an eye. The set of instructions, in other embodiments, comprise instructions for using the cells in a method of treating or preventing a medical condition, e.g., a medical condition described herein. In exemplary aspects, the kit comprises instructions for administration of the composition comprising the cells to a subject.
    • Devices
  • The present disclosures furthermore provides a device comprising any of the isolated populations of multipotent stem cells, TM cells, corneal keratocytes, neural cells or adipocytes, described herein, or any of the compositions comprising the cells or isolated populations described herein. In exemplary aspects, the device is a device for administration to a subject. Accordingly, in some aspects, the device is an intravenous bag, a syringe, a matrix, e.g., an implantable matrix, or a capsule, e.g., an implantable capsule.
  • The following examples are given merely to illustrate the present invention and not in any way to limit its scope.
    • Example 1
  • The following materials and methods were used in the studies described in Example 2.
    • Antibodies
  • Primary antibodies used in the studies described below included ABCG2 (Clone BXP-21; Chemicon International, Temecula, Calif.), Pax6 (Covance, Princeton, N.J.), mucin 1, ankyrin G, AQP1, MGP, TIMP-3, myocilin (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.), CHI3L1 (R&D Systems, Minneapolis, Minn.), beta-tubulin III, glial fibrillary acidic protein (GFAP) (Chemicon International), and NF200 against neurofilament protein (Sigma-Aldrich, St. Louis, Mo.).
  • Secondary antibodies for Western blotting were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). For fluorescent staining, anti-mouse Alexa 488, anti-rabbit Alexa 488, anti-rabbit Alexa 647, nuclear dye DAPI, and Vybrant DiQ were obtained from Molecular Probes, Inc. (Eugene, Oreg.).
  • Table 1 provides further details on the types of antibodies used.
  • TABLE I
    Antibody Type Source Catalog#
    ABCG2 Mouse monoclonal Chemicon MAB4146
    Pax6 Rabbit polyclonal Covance PRB278P
    Nestin Rabbit polyclonal Chemicon AB5922
    Mucin
    1 Mouse monoclonal Santa Cruz Sc-7313
    Ankyrin G Mouse monoclonal Santa Cruz Sc-12719
    AQP1 Rabbit polyclonal Santa Cruz Sc-20810
    MGP Mouse monoclonal Santa Cruz Sc-81546
    CHI3L1 Goat polyclonal R&D AF2599
    TIMP3 Mouse monoclonal Santa Cruz Sc-101578
    NCAM Mouse monoclonal BD 559049
    Myocilin Rabbit polyclonal Santa Cruz Sc-20976
    • Primary Cell Culture
  • Human corneas were obtained from the Center for Organ Recovery & Education Pittsburgh, Pa.). Donor human corneas including sclera rim and hence trabecular meshwork (TM) that were not usable for transplantation, or corneoscleral rims after surgery were used for experiments. After careful removal of the iris, a cut was made through the inner edge of Schwalbe's line and the pigmented TM tissue was peeled.
  • For explant cultures, the tissue was cut into pieces and put in either a 35 mm dish or a 25 cm2 flask. Medium was added and was left undisturbed for 10-14 days to let the cells migrate out from the explants.
  • For attachment cell cultures, the dissected TM tissue was digested in 0.3 mg/ml collagenase type L in Dulbecco's modified Eagle's medium (DMEM) containing albumin and glutamine overnight at 37° C. incubator. After digestion, the cells were filtered through a 70 gm mesh to remove the tissue and were washed in the same medium twice. Cells were seeded at 2×104 cells/cm2 in TM stem cell growth medium (SCUM), described below.
  • For both cultures, the cells were passaged when they reached about 80-90% confluence by trypsinization and seeding at 2˜5×103 cells/cm2 in SCGM.
  • The primary TM cells were cultured in medium without fetal bovine serum and any growth factors to keep their TM cell characteristics as a control.
  • SCGM was made by supplementing OptiMEM-1 (Invitrogen Life Technologies, Carlsbad, Calif.) with 5% fetal bovine serum (Hyclone, Logan, Utah), 10 ug/mL epidermal growth factor (EGF; Upstate Biotechnologies, Lake Placid, N.Y.), 100 μg/mL bovine pituitary extract (Biomedical Technologies, Stoughton, Mass.), 20 ug/mL ascorbic acid (Sigma-Aldrich, St. Louis, Mo.), 200 μg/mL calcium chloride (Sigma-Aldrich), 0.08% chondroitin sulfate (Sigma-Aldrich), 100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 ug/ml gentamicin (Sigma-Aldrich).
    • Isolation of Stem Cells by Side Population Cell Sorting
  • After 2-3 passages, trypsinized cells were incubated at 1.0×106 cells per ml in pre-warmed DMEM with 2% FBS and 10 μM DyeCycle Violet (DCV) for 100 minutes at 37° C. To inhibit ABCG2-mediated efflux of DCV dye, cells were preincubated for 20 minutes with 25 μg/ml fumitremorgin C(FTC) before DCV incubation. After staining, the cells were washed twice in Hanks' balanced salt solution (HBSS) with 2% FBS and then stored in cold HBSS with 2% FBS on ice. Immediately before sorting, 2 ug/ml propidium iodide was added to identify nonviable cells for flow cytometric analysis. Cells were analyzed on a Beckton Dickinson & Co. (BD) fluorescence activated cell sorting (FACS) Aria flow cytometer high-speed cell sorter, using 405-nm excitation. Cells demonstrating a reduced fluorescence of both blue (450 nm) and red (670 nm), which cells are considered as a “side population,” were collected. Dead cells stained with propidium iodide were omitted from the population.
    • Isolation of Stem Cells by Clonal Expansion
  • Clonogenic assays were performed by limiting dilution (0.3 cells/well in 96-well plate) followed by subcultivation. After obtaining a substantial number of cloned cells, a gene expression profile was obtained to determine which clones were undifferentiated cells. The clones with expression of stem cell markers were passaged for further experiments.
    • Multipotency of TM Stem Cells
  • To analyze their ability to differentiate into different types of cells, the TM stem cells (TMSCs) were cultured under the following different conditions:
  • Corneal keratocytic differentiation: Aliquots of TMSCs (2.5×105) were collected in a conical-bottom 15-mL tube, centrifuged at 1500 rpm (400 g) for 5 minutes to form a pellet. The pellets of each aliquot were cultured in SCGM for 3 days and then transferred into keratocyte differentiation medium (KDM: advanced MEMTM (Invitrogen) with 10 mg/mL fibroblast growth factor 2 [FGF2] and 0.5 mM ascorbic acid-2-phosphate), which was changed every 3 days for up to 3 weeks.
  • Neural induction: TMSCs were seeded onto FNC Coating Mix® (AthenaES, Baltimore, Md.) coated 35 mm dishes at 10,000 cells/cm2 in neural differentiation medium (NDM) containing Advanced D-MEM with 10 mg/ml epithelial growth factor, 10 mg/ml fibroblast growth factor and I μM all-trans retinoic acid, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml gentamicin. The medium was changed every 3 days and fresh all-trans retinoic acid was added each time. The cells were cultured for 3 weeks for induction.
  • Adipogenic differentiation: TMSCs were seeded onto 1% gelatin (Sigma-Aldrich) coated 35 mm dishes at 20,000 cells/cm2 in adipogenic differentiation medium (ADM) consisting of DMEM-Low glucose with 10% FBS, 1 μmM dexamethasone, 0.5 μM methyl-isobutylxanthine, 10 μg/ml recombinant human insulin, 200 μM indomethacin, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml gentanxicin. The cells were cultured in ADM for 7 days, then changed to adipogenic maintenance medium (AMM) containing of DMEM with 15% FBS, 10 μg/ml recombinant human insulin, 100 IU/ml penicillin, 100 streptomycin, and 50 μg/ml gentamicin for 4 days. The medium was changed back to ADM for another 7 days, then changed to AMM for another 4 days and the cells were fixed for histology or lysed for RNA.
  • Trabecular meshwork cell differentiation: Bovine aqueous humor (AH) was collected from enucleated bovine eyes by inserting a 26-gauge needle through the cornea limbus and positioning its tip into the center of the anterior chamber. AH was pooled and centrifuged at 10,000 g for 1 hour at 4° C. to pellet any pigment or cellular debris followed by filtering through 0.22 μm to get rid of any potential contaminations. The AH was kept at −80° C. for later use. TM cell differentiation was induced by culturing the TMSC in 50% stem cell growth medium (SCGM) with 50% AH, 100% AH, or DMEM/F12 plus 10% FBS, The TMSC were cultured in those TM differentiation media and the media were changed every 3 days for up to 10 days.
  • Phagocytosis assay: This assay was performed following the procedures described by Zhang et al 14. In brief, Alexa 488 conjugated Straphylococcus aureus bioparticles (heat- or chemically killed) (Molecular Probes, Inc. Eugene, Oreg.) were incubated with S. aureus bioparticle opsonizing reagent (purified rabbit polyclonal IgG antibody; Molecular Probes) at 37 C for 1 hr for enhancing the uptake of these particles. The differentiated TM cells were incubated with rabbit IgG opsonized Alexa 488 conjugated S. aureus bioparticles at a ratio of 50 bioparticles per cell at 37 C for 1 hr. After incubation, the cells were fixed with 4% paraformaldehyde solution for 15 min at room temperature (RT) and incubated with Alexa Flour 546 goat anti-rabbit IgG secondary antibody at RT for 1 hr. The secondary antibody was believed to bind to the extracellular bioparticles opsonized with rabbit IgG, so that the unphagocytosed bioparticles would be excluded when counting. Cell nuclei were labeled with DAPI at 1 μg/ml for 10 min. Cellular phagocytosis of bioparticles, DAPI nuclei and cellular morphology were visualized and imaged with an Olympus FluoView FV 1000 confocal microscope. The number of phagocytic bioparticles were quantified by counting individual TM cells (DAPI stained nuclei) and total bioparticles ingested by these TM cells. At least ten individual views per condition were counted and averaged. The data were analyzed statistically by otte-way ANOVA followed by the Tukey post-test to assess the significance of differences. Quantitative Reverse Transcription-Polymerase Chain Reaction (qPCR)
  • The anterior part of human eye including the cornea, TM and part of the sclera, was stabilized in RNALater (Ambion, Austin, Tex.) overnight. The tissues of the TM, the TM insert and the corneal stroma, were separated under microscope and then were homogenized. The tissues or cultured cells were lysed with RLT buffer in the RNeasy mini kit (Qiagen, Valencia, Calif.) and RNAs were isolated following the manufacturer's instructions treated with DNAse 1 (Ambion) and concentrated by alcohol precipitation. eDNAs were transcribed from the RNAs using SuperScript μ reverse transcriptase (Invitrogen). qPCR of cDNAs was performed by direct dye binding (SYBR Green; Applied Biosystems) as previously described. 15 Primers for SYBR assays were designed using online software (Primer 3; http://frodo.wi.mit.edu/ with the sequences shown in Table 2.
  • TABLE 2
    Seq.
    Gene No.
    Name DNA Sequence ID
    18S Ribo- Forward: CCCTGTAATTGGAATGAGTCCAC  1
    somal RNA Reverse: GCTGGAATTACCGCGGCT  2
    ABCG2 Forward: TGCAACATGTACTGGCGA.AGA  3
    Reverse: TCTTCCACAAGCCCCAGG  4
    Pax6 Forward: CAATCAAAACGTGTCCAACG  5
    Reverse: TAGCCAGGTTGCGAAGAACT  6
    CD73 Forward: GTTCCTGTAGTCCAGGCCTATG  7
    Reverse: TCAGGAATGCTGCTGTTTAGAA  8
    CD9Q Forward: CCAACTTCACCAGCAAATACAA  9
    Reverse: CCAGTTTGTCTCTGAGCACTGT 10
    CD 166 Forward: GTCTGCTCTTCTGCCTCTTGAT 11
    Reverse: TCATATTTCCATTTGCCAAACA 12
    CD 117 Forward: CGAGTTGGCCCTAGACTTAGAA 13
    Reverse: CTTTGTGATCCGACCATGAGTA 14
    Bmi1 Forward: GCCTTAACGCTGTGTGTATGAC 15
    Reverse: ACCTGGAGATGCCAGAGAGTAG 16
    OCT4 Forward: AAAGGGTGGGGGCAGGGGAG 17
    Reverse: AGTGTGTCTATCTACTGTGTCCCAGGC 18
    Notch1 Forward: AGTCTCTGCAGTGCTGGAAGTA 19
    Reverse: CTTGCAGTACTGGTCGTACAGG 20
    KLF4 Forward: ACCCTGGGTCTTGAGGAAGT 21
    Reverse: TGCCTTGAGATGGGAACTCT 22
    Muc 1 Forward: CCATTCCACTCCACTCAGGT 23
    (Mucin 1) Reverse: CCACATGAGCTTCCACACAC 24
    AnkG  Forward: CATTCCTCCACGCAAGTGTA 25
    (Ankerin G) Reverse: GTGGGTTGGCCAGTTTATGT 26
    AQP1 Forward: CTGCACAGGCTTGCTGTATG 27
    (Aquaporin  Reverse: TGTTCCTTGGGCTGCAACTA 28
    1)
    MGP Forward: GCCGCCTTAGCGGTAGTAAC 29
    TCTCTGCTGAGGGGATATGA 30
    CH13L1 Forward: CCTTGACCGCTTCCTCTGTA 31
    GTGTTGAGCATGCCGTAGAG 32
    Kera  Forward: ATCTGCAGCACCTTCACCTT 33
    (keratocan) Reverse: CATTGGAATTGGTGGTTTGA 34
    Myocilin Forward: AAGCCCACCTACCCCTACAC 35
    Reverse: TCCAGTGGCCTAGGCAGTAT 36
    ELAM1 Forward: ACACCTCCACGGAAGCTATG 37
    Reverse: AATTGCAACCAGGTGTGTGTA 38
    MMP1 Forward: TGGACCTGGAGGAAATCTTG 39
    Reverse: AGAATGGCCGAGTTCATGAG 40
    ap2 Forward: CATGGCCAAACCTAACATGA 41
    Reverse: AATTCCTGGCCCAGTATGAA 42
    Leptin Forward: TCCTGGATTCCTTTCCTTCA 43
    Reverse: CAATCGAGGAGGGCAGAATA 44
  • Amplification of 18S rRNA was performed for each cDNA (in triplicate) for normalization of RNA content. A negative control lacking cDNA was also included in each assay. Relative mRNA abundance was calculated as the Ct for amplification of a gene-specific cDNA minus the average Ct for 18S expressed as a power of 2(2−ΔΔCt). Three individual gene-specific values thus calculated were averaged to obtain mean±SD.
    • Animals
  • Female C57BL/6 mice (Charles River Laboratories International, Inc., Wilmington, Mass.), 9 weeks of age, were used in the experiments described below. AH experimental procedures were reviewed and approved by Institutional Animal Care and Use Committees and handled according to guidelines provided in the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Ophthalmic and Vision Research.
    • TMSC Transplantation
  • At the fourth passage, the cloned TMSC cultured in SCUM were prelabeled with membrane dye Vybrant Di0 (Invitrogen) as described previously 16. In brief, the cells were suspended in DMEM/F12 at 1×106 cells/ml and incubated with Di0 at 50 ug/ml for 20 minutes at 37° C. The cells were washed twice with DMEM/F-12 and resuspended in serum-free DMEM/F12 at 2.5×104 cells/μl for injection. Corneal fibroblasts (at passage 8) cultured in DMEM.F12 with 10% FBS served as controls.
  • TMSCs were transplanted into the anterior chamber of mice following the procedures of McKenna et al., J Immunol 169: 2630-5637 (2002) with subtle modifications. Briefly, all mice were anesthetized by i.p. injection of 2 mg of ketamine hydrochloride and 0.04 mg of xylazine (IVX Animal Health, Inc., St. Joseph, Mo.) in. 0.2 ml of Dulbecco's phosphate buffered salt solution (PBS). The eyes were washed with PBS with antibiotics. The eyes were also anesthetized by topical drops of proparacaine HC 1 (Alcon Laboratories). The right eye of each mouse was used for stem cell or fibroblast injection and the left eye was used as control. The cornea was punctured by inserting a 30-gauge needle outside of the pupil area and parallel to the iris. Aqueous humor was allowed to flow out and was removed by an ophthalmic sponge (Microsponge; Alcon Laboratories). An air bubble was then introduced into the anterior chamber by injecting a 1.5 μl volume of air with a Hamilton micro syringe (Hamilton, Reno, Nev.) fitted with a 33-gauge beveled needle. Next, 50,000 TMSCs or fibroblasts in 2 μl of DMEM/F-12 was injected with a micro syringe fitted with a 33-gauge blunt needle (Hamilton). The air bubble seals the corneal puncture and prevents leakage. After injection, the eyes were treated once with gentamicin sulfate ophthalmic drops. The mice were sacrificed at 1 wk and 4 wks after transplantation. The mouse eyes were enucleated and fixed in 2% PFA at 4° C. overnight for histology, followed by either frozen in optimal cutting temperature embedding compound (Tissue-Tek OCT, Electron Microscopy Sciences, Hatfield, Pa.) and cut into 8 μm thick cryosections on a cryostat for immunofluorescent staining or stored at 4° C. in 50% glycerol and 50% PBS (v/v) for wholemount staining.
    • Histology
  • Cells cultured in plastic plates were rinsed briefly in PBS, fixed for 12-15 minutes in 3% paraformaldehyde (PFA) in PBS at room temperature, rinsed in PBS, and stored at 4° C. in 50% glycerol and 50% PBS (v/v) until stain. Cells cultured in pellets were rinsed and fixed as described above and then embedded in OCT compound and cut into 8 sections, stored at −80° C. until staining. PFA (2%) fixed mouse eyeballs were also embedded in OCT and cut into 8 mm sections for stain. Nonspecific binding was blocked with 10% heat-inactivated goat serum or 1% BSA and anti-mouse CD16/CD32 Fc (BD Pharmingen) for mouse sections. Sections were incubated overnight at 4° C. with primary antibodies. After three washes, secondary antibodies were added followed by incubation for 2 hrs at room temperature. Samples were photographed using a confocal microscope (Olympus) with a 40× oil objective.
  • Oil Red O stain for adipogenic differentiation: Oil red O(Sigma-Aldrich) was prepared at 0.5% in isopropanol, diluted to 0.3% in water and filtered before use. Cells were stained with oil red O for 20 min and rinsed with 60% isopropanol followed by hematoxylin stain for nuclei. Bright-field micrography was performed with a 40× oil objective.
  • Wholemount stain: After fixation in 2% PFA and washed with PBS, the posterior part of the eyeball was removed from 1.5 mm posterior to the limbus including the lens and iris. The anterior part including the cornea and the TM were cut into half for wholemount stain and the cornea was cut in the middle to flatten the tissue. After blocking, the tissue was incubated with primary antibodies overnight at 4° C. Following 5 washes, tissue was incubated with fluorochrome-conjugated secondary antibodies with DAPI (Vector Laboratories) prior to confocal imaging.
    • Confocal Imaging of TM Whole Mounts
  • Images were acquired by sequential scanning to avoid fluorescence crossover on an Olympus Fluoview 100Qx confocal microscope. Z stacks through the tissue were acquired using ImageJ software. All image reconstructions were made using a MetaMorph (Molecular Devices; version: 7.5.4.0).
    • Example 2 Distribution of Stem Cells in Human TM Tissue
  • Human tissue cryosections were stained with stem cell markers ABCG2, Pax6, Mucin 1, and Ankyrin G, as well as with TM markers AQP1, MGP, CHI3L1 and TIMP3.
  • The ATP-binding cassette transporter family 62 (ABCG2) is present at relatively high levels in undifferentiated human embryonic stem cells, and plays a protective role against toxins, drugs, or hypoxia (18). ABCG2 has also been identified as a specific marker for adult stem cells (15, 19-22). PAX6 is a homeobox transcription factor expressed in embryonic ocular precursor cells and epithelial cells (23) and this molecule may contribute to the stem cell phenotype as a proliferation moderator (24) Ankyrin G and Mucin1 are considered as markers for the stem cells of TM since they have been observed with high expression in Schlemm's canal cells (25) which are also called TM insert cells (26). Mucin 1 is a cell surface protein which functions as an interfacing protein to the aqueous fluid. The water channels aquaporin 1 (AQP1) has been detected to be present in the eye tissues of the corneal epithelium, the ciliary epithelium, the posterior iris epithelium and the trabecular meshwork endothelium (27) as well as in cultured human trabecular meshwork cells (1). The exact role of aquaporin 1 (AQP1) expression in TM and Schlemm's canal cell function has not yet been demonstrated, although it was hypothesized to influence osmotic permeability of the TM plasma membrane as well as the resting intracellular volume and, thus possibly paracellular permeability (28). Matrix Gla protein (MGP) encodes a protein involved in inhibition of calcification in cartilage and blood vessels; MGP has conserved the cation sensing mechanism present in vascular smooth muscle that responded to extracellular ionic calcium by upregulating its mRNA. So MGP plays a protective role in the TM and stress its position as an essential player at times of elevated pressure (29). Aqueous humor contains CHI3L1 which has a protective role against inflammation, extracellular matrix (ECM) remodeling and cell death in the outflow pathway (30). The matrix metalloproteinase (MMP) family and their tissue inhibitors, the TI.M1's, are integrally involved in regulating the turnover of TM extracellular matrix (31). AQP1, MGP, CHI3L1 and TIMP 3 are considered as TM markers.
  • Immunofluorescent staining was observed in the TM tissue where the TM markers are expressed (FIG. 1A, right column) and some cells positive to the stem cell markers (FIG. 1A, left column) also were observed. The cells positive to stem cell markers were distributed throughout the TM tissue and not limited to any particular region of the TM. Quantitative RT-PCR was performed to compare gene expression of the cells from TM and insert region and the results demonstrated that there were no obvious differences in the gene expression pattern between the two regions of TM (FIG. 1B); no expression of the cornea! stromal specific gene, keratocan, in TM and insert region indicates that the tissues do not contain keratocytes.
    • Isolation of Side Population Cells
  • Expression of ABCG2 has been implicated in the side population phenotype32. ABCG2 acts to remove Hoechst dye from cells, thus allowing isolation of cells as a “side population” (SP), in which ABCG2 is active, by use of flow cytometry (33, 34). Similarly, DyeCycle Violet (DCV) is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux. DCV therefore is used to isolate SP cells on flow cytometry using violet lasers (35, 36) without the requirement for an ultraviolet laser for Hoechst 33342 emission.
  • The cultured cells were passaged in SCGM containing 5% FSS for 2-4 passages. After trypsinization, the cells were labeled with DCV for 100 min at 37° C., followed by cell sorting on a flow cytometry (FACSAria with FACSDIVA data analysis software; BD Biosciences) with violet lasers. FIG. 2A shows that the cultured TM cells contained a side population (the tail formed within the frame) which were collected by fluorescence activated cell sorting (FACS). To assess the purity of the collected cells, the collected cells were labeled with antibodies specific for one of the following stem cell markers: CD73, CD90, CD166, Bmi1, or antibodies specific for one of the TM cell markers: CHI3L1 and AQP1. The labeled cells were then analyzed via flow cytometry to determine the % labeled cells. The collected cells were 99.9% positive for expression of the stem cells marker CD73, 97.7% positive for expression of the stem cell marker CD9Q, 96.4% positive for expression of the stem cells marker CD 166 and 97.8% positive for expression of the stem cell marker Bzni1. In contrast, the collected cells were only 10.9% positive for expression of the TM cell marker CHI3L1 and 2.63% positive for expression of the TM cell marker AQP 1.
  • The isolated SP and non-SP cells were cultured in SCGM and at passage 8, the cells were lysed for extracting ruRNA. qPCR was done to compare the gene expression of SP and non-SP cells (FIG. 2B). The stem cell genes ABCG2 and mucin 1 (Muc1) of the SP cells was approximately 2-fold higher than that of the non-SP cells; the TM genes AQP1, MOP and CHI3L1 of the SP cells were approximately 4-fold lower as compared to that of the non-SP cells. SP cells demonstrated virtually no expression of the glaucomatous genes myocilin and ELAM-1. The differences are statistically significant (p<0.05) analyzed by one-tailed t-test. However, ankyrin G(AnkG) expression of SP was the same as that of non-SP cells.
    • Cultured TMSC Express Stem Cell Markers.
  • TMSC were cultured in SCGM for 4 passages and the primary TM cells were cultured in medium without fetal bovine serum and any growth factors to keep their TM cell characteristics as control. FIG. 3A-J show the immunofluorescent double staining on TMSC and primary TM cells with stem cell markers ABCG2, Pax6, ankyrin G, Mucin 1; TM cell markers AQP1, MOP, CHI3L1, TIMP3 and glaucomatous marker myocilin. FIG. 3A-E on the upper column show the TMSC were positive to stem cell marker proteins ABCG2, Pax6 (A), ankyrin G (B), mucin 1(C); but not TM cell markers CHI3L1 (B), AQP 1 (C), MGP (D), TIMP3 (E) and not glaucomatous marker myocilin (D). In contrast, the primary TM cells of the lower column (F-J) did not express stem cell markers, but instead expressed TM cell markers. Few cells were positive to myocilin. Results obtained from qPCR (FIG. 3K) demonstrated the differential gene expression pattern between the primary TM cells and the TMSC. TMSC demonstrated increased expression of stem cell genes ABCG2 and ankyrin G, decreased TM cell genes AQP1, MGP, CHI3LI, and decreased glaucomatous genes myocilin and ELAM I, as compared to primary TM cells. The differences were statistically significant as determined by the one-tailed t-test. qPCR and Western Blotting (WB) confirmed similar expression levels. The expression of mucin I differed by very little among primary TM cells and TMSC. FIG. 3L shows the results of Western blotting that compare the different protein expression between corneal stromal fibroblasts and passage-4 TMSC. As evident in this figure, TMSC strongly expressed the stem cell markers ABCG2, Pax6, Mud and weakly expressed the TM cell markers AQP1, MGP and TIMP3.
  • TMSC can be Induced to Differentiate into Trabecular Meshwork Cells.
  • The TMSC were cultured in SCGM, and at passage-4, the TMSC were switched into different media for induction of differentiation into TM cells. The cells were induced in medium containing 50% SCGM with 50% aqueous humor, 100% aqueous humor, or with medium containing 10% FBS. The expression levels of stem cell markers and TM cell markers were analyzed among the induced cells and the TMSC in SCGM by immunofluorescent staining and qPCR. The first column of FIG. 4 (A, E, I, M, Q) represents the stain of TMSC in SCGM; the second column (B, F<J, N, R) represents the stain of induced cells in SCGM/AH; the third column (C, G, K, O, S) represents the stain of cells in aqueous humor; the forth column (D, H, L, P, T) represents the stain of cells in medium containing 10% FBS. The top row of FIG. 4 (A, B, C, D) represents a double-stain of ABCG2 (green) and Pax6 (red); the second row represents a double-stain of ankyrin G (green) and CHI3L1 (red); the third row represents a double-stain of mucin 1 (green) and AQP1 (red); the fourth row represents a double-stain of MGP (green) and myocilin (red); the bottom row represents a stain of TIMP3 (green).
  • These data support that TMSC can be induced to differentiate into TM cells expressing TM markers and exhibiting lost or reduced expression of stem cell markers ABCG2, Pax6, AnkyrinG and mucin1. The TMSC cultured in SCGM remained the stem cell markers ABCG2 (FIG. 4A—green)), Pax6 (FIG. 4A—red)), Ankyrin G (FIG. 4E—green), Mucin1 (FIG. 4I—green), but not the TM differentiation markers CHI3L1 (FIG. 4E—red), AQP1 (FIG. 41—red), MGP (FIG. 4M—green), TIMP3 (FIG. 4Q—green) and not the glaucomatous marker myocilin (FIG. 4M—red). When the stem cells were induced in SCGMIAH for one week (FIGS. 4B, F, J, N, R), some of the cells lost the stem cell markers but gained the express of the TM markers. When the cells were induced in AH (FIGS. 4C, G, K, O, S) or in 10% FBS (FIGS. 4D, H, L, P, T), most of the cells lost the ability to express the stem cell markers but expressed the TM cell markers. Some of the induced cells were positive to the glaucomatous specific marker myocilin (FIG. 4N, 0, P—red).
  • qPCR demonstrated that the transcript level of stem cell genes ABCG2 and Pax6 of the TMSC in SCUM increased at least 2-fold compared to that of the induced cells in SCGM/AH, in AH or in 10% FBS (FIG. 4U), qPCR also demonstrated that the relative gene expression of stem cell markers ABCG2, Pax6, CD73, CD90, CD166, CD117, Bmi1, Oct4, Notch 1, and KLF4 in induced TM cells was 50% or less that in passaged TM cells (FIG. 4V).
  • The transcript level of TM genes AQP1, MGP, and CHI3L1 of the induced TM cells were increased at least 2-fold as compared to that passaged TMSCs (FIG. 4W). The expression of glaucomatous gene myocilin in the TMSC in SCGM was also decreased compared to that of the induced cells. The difference between the TMSC and the induced TM cells was statistically significant by t-test (p<0.05). There was no significant difference in the expression of mucin 1 and ankyrin G between the TMSC and the induced cells. The differences among the induced cells also were not significant.
  • The expression of MMPI (interstitial collagenase) was analyzed via qPCR among passaged TMSCs, induced TM cells and fibroblasts. As shown in FIG. 4X, the expression of MMPI greatly varied among these three cell populations.
    • Phagocytosis by the Induced TM Cells
  • Trabecular meshwork cells have phagocytic activity which eliminates debris, pigment and other materials from the aqueous outflow drainage pathway and maintains the aqueous humor outflow pathway (14, 37, 38). A phagocytosis assay was performed with TMSC cultured in SCGM (FIG. 5A), with induced cells cultured in SCGM/AH (FIG. 5B), in AH (FIG. 5C), or in 10% FBS (FIG. 5D) and with primary TM cells (FIG. 5E) cultured in medium without fetal bovine serum and growth factors.
  • Rabbit IgG-opsonized Alexa 488 conjugated Straphylococcus aureus bioparticles were incubated with the cells at 37° C. for 1 h. After incubation, the cells were fixed in 4% PFA and then incubated with Alex 546 goat anti-rabbit IgG to bind any unphagocytosed extracullular bioparticles. The ingested bioparticles by the cells were green and the non-ingested bioparticles conjugated with the red second antibody showing yellow in FIG. 5A-5E. Only a few green particles were ingested by the TMSC in SCGM (FIG. 5A). In contrast, the induced cells (FIGS. 5B-D) and the primary TM cells (FIG. 5E) ingested many green bioparticles. The green particles, the non-ingested yellow bioparticles, and the number of the nuclei (blue) in each view were counted and at least ten different views were counted in each condition. The number of ingested bioparticles per cell was calculated as the number of ingested green ones, minus the number of non-ingested yellow ones, divided by the number of blue nuclei, FIG. 5F provides the statistical result of the phagocytic assay. The Y-axis shows the number of the bioparticles ingested per cell. The difference between the TMSC cultured in SCGM and the induced cells as well as the primary TM cells is statistically significant (p<0.0001) analyzed by ANOVA followed by Bartlett's test with Prism Graph Pad software (Prism; Graph Pad Software, San Diego, www.graphpad.com). There is no significant difference among the induced cells and the primary TM cells.
  • These data demonstrate that the induced cells function similarly to TM cells. Multipotency of TMSC.
  • One well-documented aspect of adult stem cells is the ability to differentiate into a number of different cell types. This property was examined in the cloned TM stem cells by culturing them in different conditions. The TMSC was cultured in neural differentiation medium (NDM) containing EGF, FGF and retinoic acid for neural induction. By immunofluorescent staining, the cells positive for neurofilament (FIG. 6A), beta-tubulin III (FIG. 6B) and GFAP (FIG. 6C) were present among cells cultured in NDM. At the mean time, the cells cultured in NDM lost the expression of mucin 1. In contrast, the TMSC cultured in SCGM without induction were positive to mucin 1 (FIG. 6H) but negative to neurofilament (FIG. 6E), beta-tubulin III (FIG. 6F) and GFAP (FIG. 6G).
  • The TMSC was cultured in adipogenic differentiation medium (ADM) and adipogenc maintenance medium (AMM) for adipocytic induction. Oil red O stain was perform to identify lipoid deposits which are special to adipocytes. FIG. 6J shows the TM stem cells in SCGM had no lipoid materials with oil red O negative. After induction in ADM and maintaining in AMM, the TM stem cells changed to be positive to oil red O stain with lipoid deposits within the cells.
  • Real-time qPCR was carried out to compare the expression of adipocytic genes ap2 (which encodes ALBP) and leptin among stem cells maintained in SCGM or induced adipocytes in ADM. The expression of ap2 and leptin were increased in adipocytes, as compared to the expression of these genes in the stem cells. The increase was statistically significant as determined by t-test.
  • Our previous experiments showed that the corneal stromal stem cells were able to differentiate into keratocytes by culturing the stem cells as pellets in a medium containing FGF and ascorbic-2-phosphate39. We adopted this method to induce the keratocyte differentiation from TMSC. After culturing over 3 weeks as pellets, the TM stem cells secreted corneal stromal specific extracellular matrices keratan sulfate (FIG. 6K) and keratocan (FIG. 6L).
  • Deposition into trabecular meshwork of TMSC after anterior chamber injection. To detect whether the Passage-4 human TMSC can localize into the TM tissue after introducing into anterior chamber, we prelabeled the TMSC as green and injected 2 μl of 5×104 TMSC into normal mouse anterior chamber. FIGS. 7A and 7B show the immunofluorescent staining on the mouse TM cryosections 2 weeks after hTMSC injection. The injected green cells homed to the TM tissue pointed by white solid arrows (FIGS. 7A, 7B). Some of the green cells were positive to the TM differentiation marker AQP1 (FIG. 7A—red) and some were positive to the stem cell marker ankyrin G (FIG. 7B—red).
  • FIG. 7C-7Q are the wholemount staining on mouse TM tissue with TMSC injection for 1 week (FIGS. 7D, 71, 7N), 4 weeks (FIGS. 7F, 7K, 7P); with fibroblast injection for 1 week (FIGS. 7E, 73, 70), 4 weeks (FIGS. 7C, 7L, 7Q); and normal tissue without any injection as controls (FIGS. 7C, H, M). TM cell antibody AQPI reacts to both mouse and human antigens; TM cell antibody CHZ3L1 is specific to human antigen; stem cell antibody mucin 1 reacts to both mouse and human antigens. Mucin 1 has been identified for the expression on corneal endothelium 40. FIGS. 7C, H, M on the control tissue show that AQPI presented in the mouse TM cells as well as in the corneal endothelial cells (FIG. 7C) but human specific CHI3L1 antibody didn't stain any mouse cells (FIG. 7H); there were some cells positive to mucin 1 in both the TM and the endothelium (FIG. 7M).
  • FIG. 7D, 1, N are stains on the tissue with TMSC injection for 1 week. 1 week after injection, there were some injected green human TMSC positive to AQP1 (FIG. 7D), some positive to human specific antibody CHI3L1 (FIG. 71); the number of cells positive to stem cell marker mucin 1 increased (FIG. 7N) compared to the control without cell injection (FIG. 7M). There were very few injected green cells in the TM region 1 week after injection with human fibroblasts (FIGS. 7E, J, O) and no increase of AQPI expression (FIG. 7E), no human CHI3L1 expression (FIG. 7J), no increased mucin 1 expression (FIG. 7O).
  • 4 weeks after cell injection, the number of injected green cells in the TM region was significant increased compared to that at 1 week after injection. Although more green cells were in the TM region, more injected TMSC were positive to mucin 1 (FIG. 7P) and less cells were positive to the differentiation markers CH13L1 (FIG. 7K) and AQP1 (FIG. 7F). Interestingly, although there were almost no injected fibroblasts in the TM region 1 week after injection, 4 weeks after fibroblast injection, there were more green cells in the TM region that that at 1 week (FIGS. 7G, L, Q). There was no expression of human specific CHI3L1 among the injected green fibroblasts (FIG. 7L), although the green cells were in the TM region where AQP1 (FIG. 7E) and mucin I (FIG. 70) were positive to the original mouse cells.
  • TABLE A
    Protein Name Alternative Names Reference
    14-3-3 Zhao X et al, 2004
    14-3-3-zeta YWHAZ, Tyrosine 3-Monooxygenase/Tryptophan 5- Vittal et al, 2005
    Monooxygenase Activation Protein-zeta, 14-3-3-delta, Exo1,
    FAS, factor activating ExoS
    A20 TNFAIP3 [TNF-alpha-induced protein 3, tumor necrosis factor- Michael et al, 2008
    alpha-induced protein 3
    AAC-11 anti-apoptosis clone 11, API5, Apoptosis inhibitor 5, FIF, Rozsa et al, 2006
    Fibroblast growth factor-2 interacting factor, FGF-2 interacting
    factor, API5L1, API5-like-1
    AATF apoptosis antagonizing transcription factor; Che-1 Rozsa et al, 2006
    Activin A EDF, erythroid differentiation factor, FRP, Follicle stimulating Zhao X et al, 2004;
    hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI Rozsa et al, 2006
    mesoderm inducing factor, INHA, inhibin-alpha, Inhibin-beta-A,
    INHBA
    ADAM10 disintegrin and metalloprotease domain 10, MADM, mammalian Rozsa et al, 2006
    disintegrin metalloprotease, CDw156c, CD156c, kuzbanian,
    EC3.4.24.81
    ADAM12 (disintegrin and metalloprotease domain 12, Meltrin-alpha, (Zhao X et al, 2004)
    MLTNA)
    ADAM19 MADDAM, metalloprotease and disintegrin dendritic antigen Rozsa et al, 2006
    marker, Meltrin-beta, MLTNB
    ADAM28 disintegrin and metalloprotease domain 28, MDC-L, Rozsa et al, 2006
    metalloproteinase-like disintegrin-like cysteine-rich protein L,
    MDC-3, metalloproteinase-like disintegrin-like cysteine-rich
    protein-3, ADAM23, disintegrin and metalloprotease domain 23
    ADAMTS1 Disintegrin and metalloproteinase with thrombospondin motif-1, Luna et al, 2009;
    METH-1 Rozsa et al, 2006;
    Keller et al, 2009
    ADAMTS3 Disintegrin and metalloproteinase with thrombospondin motif-3, Rozsa et al, 2006
    KIAA0366, Procollagen II amino propeptide-processing enzyme,
    PC II-NP, Procollagen II N-proteinase
    ADAMTS4 Disintegrin and metalloproteinase with thrombospondin motif-4, Keller et al, 2009
    Aggrecanase-1, hyalectanase
    ADAMTS5 Disintegrin and metalloproteinase with thrombospondin motif-5, Luna et al, 2009;
    aggrecanase-2, implantin Rozsa et al, 2006;
    Keller et al, 2009
    ADF Adult T-cell leukemia-derived factor; ATL-derived factor; 3B6- Zhao X et al, 200
    IL1, 3B6-IL1-like factor, SASP, surface-associated sulfhydryl
    protein, TCGF[IL2]-receptor inducing factor, IL2-RIF, IL2
    receptor inducing factor, TIA, IL2R/p55 inducing factor
    adipophilin Zhao X et al, 2004
    Adrenomedullin ADM, AM Rozsa et al, 2006;
    Zhao X et al, 2004
    aFGF acidic fibroblast growth factor, FGF-1, Fibroblast growth factor- Luna et al, 2009
    1, FGF-alpha, Fibroblast growth factor-alpha, HBGF-1, heparin
    binding growth factor-1, Endothelial cell growth factor-alpha
    aFGF acidic fibroblast growth factor, FGF-1, Fibroblast growth factor- Alexander et al,
    1, FGF-alpha, Fibroblast growth factor-alpha, HBGF-1, heparin 1998; Wordinger et
    binding growth factor-1, Endothelial cell growth factor-alpha al, 1998
    receptors
    Agrin AGRN Rozsa et al, 2006
    ALK3 Activin receptor-like kinase 3, BMPR1A, bone morphogenetic Luna et al, 2009
    protein receptor type IA, CD292
    alpha-1- Fukuchi et al, 1997
    antichymotrypsin
    alpha-1- Howard et al, 1996
    macroglobulin
    receptors
    alpha-1-proteinase Fukuchi et al, 1997;
    inhibitor Sawaguchi et al,
    1994
    Alpha-2- Alpha-2MG, Alpha-2M, A2M Fukuchi et al, 1997;
    Macroglobulin Howard et al, 1996
    Alpha-B-crystallin crystallin-alpha B or crystallin-alpha 2, alphaBC, CRYAB, Schlunck et al,
    CRYA2, REN-27, NY-REN-27, hspB5, heat shock protein beta-5 2008; Mitton et al,
    1997; Zhao X et al,
    2003; Zhao X et al,
    2004; Vittal et al,
    2005
    ANF Atrial natriuretic factor, natriuretic peptide, atrionatriuretic factor, Chang et al, 1996;
    Alpha-ANP, Atrial natriuretic polypeptide, ANP, Atrial Zhong L et al, 2003
    polypeptide, Atriopeptin, cardionatrin, cardionatrin I, NPPA
    receptors
    angiomotin-like-2 AmotL-2, MASCOT, LCCP, Leman coiled-coil protein Rozsa et al, 2006
    angiopoietin-1 Ang-1, ANGPT1 Fan et al, 2008
    angiopoietin-2 Ang-2, ANGPT2 Borrás et al 2006
    Angiopoietin-like-2 ANGPTL2, ARP-2, angiopoietin-related protein-2 Rozsa et al, 2006
    angiopoietin-like-4 ANGPTL4, ARP-4, angiopoietin-related protein-4, FIAF, fasting Luna et al, 2009;
    induced adipose factor, HFARP, hepatic fibrinogen/angiopoietin- Vittal et al, 2005;
    related protein, PGAR, peroxisome proliferator-activated Rozsa et al, 2006
    receptor-gamma-related protein
    angiopoietin-like-7 ANGPTL7, CDT6, cornea-derived transcript 6, Angiopoietin X, Luna et al, 2009;
    AngX Rozsa et al, 2006
    angiotensin-2 Savaskan et al, 2004
    angiotensin-2 Shen F et al, 2001
    receptors
    Annexin-1 Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Zhao X et al, 2004
    Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation
    inhibiting factor, CB9, chromobindin-9, calpactin-2
    Annexin-2 Annexin A2, ANX2, ANXA2, PAP-4, placental anticoagulant Zhao X et al, 2004;
    protein 4, Lipocortin-2, Endonexin-2, Calpactin-1 Rozsa et al, 2006
    Annexin-5 Annexin A5, ANX5, ANXA5, 35 kDa Calelectrin, 35-gamma Rozsa et al, 2006
    Calcimedin, Anchorin C2, PAP-1, placental anticoagulant
    protein-1, CBP-I, Calphobindin-1, CBP, calphobindin,
    Endonexin-2, ENX2, Lipocortin V, Lipocortin-5, VAC-alpha,
    vascular anticoagulant-alpha, chromobindin-4, 32 kDa
    calcimedin, EEP 32-2, PP4, placental protein-4, CaBP33,
    calcium binding protein 33 kDa, CaBP37, calcium binding
    protein 37 kDa
    antithrombin III Fukuchi et al, 1997
    BAG-1 BCL2-associated athanogene-1, RAP46, receptor-associating Rozsa et al, 2006
    protein 46 kDa, BCL2L6, BCL2-like-6
    BAG-3 BCL2-associated athanogene-3, CAIR-1, CAI stressed-1, BIS Rozsa et al, 2006;
    Luna et al, 2009
    BAK BAK-1, BCL2 antagonist/killer, BCL2 homologous antagonist Ishibashi et al, 2002
    killer, BCL2-like-7, BCL2L7
    BAX BCL2 associated × protein, BCL2L4, BCL2-like-4 Agarwal et al, 1999
    BCL2 B-cell lymphoma/leukemia-2 Agarwal et al, 1999
    BCL2L13 BCL2-like-13, MIL1, BCLrambo (Rozsa et al, 2006)
    BCL3 B-cell lymphoma/leukemia-3 Zhao X et al, 2004
    BCLxL BCL2-like-1, BCL2L1 Agarwal et al, 1999
    BDNF Brain-derived neurotrophic factor Wordinger et al,
    2000
    Beta-2- Beta-2-M, B2M, Ly-m11, BDGF-2, bone-derived growth factor- Rozsa et al, 2006
    Microglobulin 2, CRG-8, cytokine responsive gene-8, Thymotaxin, GIP-2,
    granulocyte inhibitory protein
    betaglycan TGFBR3, TGFR3, TGF-beta receptor type 3, Tumor necrosis Luna et al, 2009
    factor superfamily, member 10
    Receptor for bFGF Receptor for basic fibroblast growth factor, FGF-2, Fibroblast Alexander et al,
    growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF- 1998; Ando et al,
    2, heparin binding growth factor-2 2004; Polansky et
    al, 2000; Tripathi et
    al, 1997; Wordinger
    et al, 1998
    Biglycan Vittal et al, 2005
    BMP2 (bone morphogenetic protein-2, bone morphogenetic protein-2A, (Luna et al, 2009;
    BMP2A, BMP2-alpha) Rozsa et al, 2006)
    BMP2 receptor Receptor for bone morphogenetic protein-2, bone morphogenetic (Xue W et al, 2006)
    protein-2A, BMP2A, BMP2-alpha
    BMP6 (DVR-6, decapentaplegic-Vg-related-6, Vgr-1, vegetal-specific- (Luna et al, 2009)
    related-1)
    BMP7 (bone morphogenetic protein-7, OP-1, osteogenic protein-1, (Fuchshofer et al,
    Eptotermin alfa, Osigraft) 2007)
    BMP7 receptor Receptor for bone morphogenetic protein-7, OP-1, osteogenic (Fuchshofer et al,
    protein-1, Eptotermin alfa, Osigraft 2007; Fuchshofer et
    al, 2009)
    BMPER BMP binding endothelial regulator, Bone morphogenetic protein- (Rozsa et al, 2006)
    binding endothelial cell precursor-derived regulator, CRIM3,
    cysteine-rich BMP regulator-3, Crossveinless-2, Cv-2
    BMPR1A bone morphogenic protein receptor type 1A (Rozsa et al, 2006)
    BNIP2 NIP-2, BCL2/adenovirus E1B 19 kDa protein interacting protein-2 (Ishibashi et al,
    2002)
    BNIP3 BCL2/adenovirus E1B 19 kDa protein nteracting protein-3, NIP-3 (Rozsa et al, 2006)
    BNIP3L BCL2/adenovirus E1B 19 kDa protein interacting protein-3-like, (Rozsa et al, 2006)
    BNIP3A, BCL2/adenovirus E1B 19 kDa protein interacting
    protein-3A, BNIP3-alpha, NIX, Nip3-like protein X
    BNP receptor Receptor for Brain natriuretic peptide, B-type natriuretic peptide, (Chang et al, 1996;
    NPPB, ASIP, Aldosterone Secretion Inhibitory Factor, BNP(1- Zhong Let al, 2003)
    32), BNP-32, Brain natriuretic peptide-36, N-terminal proBNP,
    NT-proBNP, gamma-BNP
    bradykinin receptor Receptor for BK, BDK, BKN, Bradykinin(1-9), BK[1-9], Alpha- (Luna et al, 2009;
    2-thiol proteinase inhibitor, Fitzgerald factor, Flaujeac factor, Webb et al, 2009;
    HMWK, HMWKa, High molecular weight kininogen, HMWK- Abad et al, 2008;
    kallikrein factor, KNG, KNG1, Kininogen, Kininogen-1, Webb et al, 2003,
    LMWK, Low molecular weight kininogen, Williams factor, 2006; Llobet et al,
    Williams-Fitzgerald-Flaujeac factor 1999; Sharif and
    Xu, 1996)
    BTG1 (B-cell translocation gene-1, BTG family member 1) (Rozsa et al, 2006)
    BTG3 (B-cell translocation gene-3, BTG family member 3, ANA, (Rozsa et al, 2006)
    Abundant in Neuroepithelium Area)
    C1 inhibitor (C1INH, Serpin G1) (Rozsa et al, 2006)
    Cadherin-4 Leung YF et al,
    2003
    Cadherin-11 Luna et al, 2009
    Caspase-4 (CASP4, ICErel-2, IL1-beta Convertase-related-2, TX, transcript (Fan et al, 2008)
    X, ICH-2, ICE and CED3 homolog-2)
    caspase-6 CASP6, MCH2, mammalian CED3 homolog-2) (Rozsa et al, 2006)
    caveolin-1 (CAV1, caveolae protein 1, Caveolin, CAV, caveolae protein 22 kDa, (Rozsa et al, 2006)
    Alpha-Caveolin, beta-Caveolin, VIP21, Vesicular Integral-
    membrane Protein of 21 kDa, VIP21/caveolin)
    CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, (Fan et al, 2008;
    GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF- Zhao X et al, 2004;
    2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant Vittal et al, 2005)
    protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF,
    smooth muscle cell chemotactic factor, TDCF, tumor-derived
    chemotactic factors, TSG-8, tumor necrosis factor-stimulated
    gene sequence-8, SCYA2)
    CCL7 CC chemokine ligand 7, chemokine (C-C motif) ligand 7, Luna et al, 2009;
    SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Vittal et al, 2005
    Fibroblast-inducible cytokine, NC28, MARC, mast cell
    activation-related chemokine
    CCL11 CC chemokine ligand 11, chemokine (C-C motif) ligand 11, Vittal et al, 2005
    SCYA11, Eotaxin, Eotaxin-1
    CCL13 CC chemokine ligand 13, chemokine (C-C motif) ligand 13, Vittal et al, 2005
    MCP-4, Monocyte chemotactic protein-4, NCC1, new CC
    chemokine-1, Ck-beta-10, Chemokine-beta-10, SCYL1,
    SCYA13
    CCR2 CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, Rozsa et al, 2006
    CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2,
    chemokine-beta receptor 2, CD192
    CD9 602-29 antigen, ALB6 antigen, BA2, BTCC-1, DRAP-27, (Rozsa et al, 2006)
    Diphtheria toxin receptor associated protein 27 kDa, GIG2,
    MIC3, MRP-1, Motility-related protein-1, NCA, neural cell
    surface antigen, p24, SH-9, TSPAN29, tetraspanin 29
    CD13 (alanyl aminopeptidase, AAP, ANPEP, alpha-aminoacyl-peptide (Coupland et al,
    hydrolase (microsomal), aminopeptidase N, PEPN, APN, APM, 1993)
    aminopeptidase M, EC3.4.11.2, LAP1, microsomal
    aminopeptidase, MY7, MCS-2, gp150)
    CD24 CD24a, 30F1, B2A2, BA-1, HIS50, HSA, beat stable antigen, Zhao X et al, 2004
    J11d, JIId, Ly52, M1/69, Nectadrin, LR-1, SCLC surface antigen
    Cluster-4, CL-4
    CD26 1F7, 2B9, 5F8, ACT-3, ADABP, ADA binding protein, ADCP2, Rozsa et al, 2006;
    adenosine deaminase complexing protein 2, BT5/9, DPCR1, Coupland et al, 1993
    DPP4, dipeptidyl peptidase 4, HAM.4, intestinal dipeptidyl
    peptidase, EC3.4.14.5, OX61, TA1, TA5/9, THAM, thymocyte-
    activating molecule, TP103, WC10 antigen, FAP-beta, Fibroblast
    activation protein-beta
    CD29 FNRB, fibronectin receptor beta subunit, ITGB1, integrin-beta-1, Filla etal, 2006;
    platelet protein GPIIa, VLA-beta, very late activation antigen- Peterson et al, 2005;
    beta, VLA-beta-1, VLA-4 beta subunit Zhou L et al, 1999;
    Zhou L et al, 1996
    CD44 CD44H, AnWj blood group antigen, ECMR-3, extracellular Keller et al, 2007;
    matrix receptor-3, HCAM, homing-associated cell adhesion Jumper et al, 1998;
    molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood Li Z and Zhang H,
    group antigen, In blood group antigen, Ly24, MC56, MDU2, 2004; Vittal et al,
    MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic 2005
    glycoprotein-1
    CD46 gp45-70, HuLy-m5, MCP, membrane cofactor protein, measles Rozsa et al, 2006
    virus receptor, MIC10, TLX, TRA-2-10, trophoblast-leukocyte
    common antigen, trophoblast-lymphocyte cross-reactive antigen
    CD49a ITGA1, integrin-alpha-1, VLA-1, very late activation antigen 1 (Zhou L et al, 1996;
    Zhou L et al, 1999)
    CD49b Br alloantigen, DX5, ECMR-2, extracellular matrix receptor-2, (Luna et al, 2009;
    GPIa, HPA-5, human platelet antigen-5, ITGA2, integrin-alpha- Dickerson et al,
    2, platelet glycoprotein Ia/IIa, VLA-2, very late activation 1998; Filla etal,
    antigen 2, VLAA2, VLA2 receptor alpha 2 subunit, Zav 2006; Zhou L et al,
    alloantigen 1996)
    CD49c CSAT antigen band 2 protein, FRP-2, fusion regulatory protein- (Dickerson et al,
    2, GAP-B3, galactoprotein B3, ITGA3, integrin-alpha-3, 1998; Zhou L et al,
    MSK18, VLA-3, very late activation antigen 3, VLAA3, VLA-3 1999; Zhou Let al,
    receptor alpha 3 subunit 1996)
    CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4,
    VLAA4, VLA4 receptor alpha 4 subunit) (Dickerson et al, 1998;
    Peterson et al, 2005; Zhou L et al, 1999; Zhou L et al, 1996)
    CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha- (Luna et al, 2009;
    5, VLA-5, very late activation antigen 5, VLA-5-alpha) Dickerson et al,
    1998; Peterson et al,
    2005; Zhou L et al,
    1999; Zhou L et al,
    1996)
    CD49f (ITGA6, integrin-alpha-6, platelet gpI, VLA-6, very late (Luna et al, 2009;
    activation antigen 6, VLA-6 alpha chain) Zhou L et al, 1999;
    Zhou L et al, 1996)
    CD29 (FNRB, fibronectin receptor beta subunit, ITGB1, integrin-beta- (Junglas et al, 2009)
    1, platelet protein GPIIa, VLA-beta, very late activation antigen-
    beta, VLA-beta-1, VLA-4 beta subunit)
    CD44 (CD44H, AnWj blood group antigen, ECMR-3, extracellular (Fan et al, 2008;
    matrix receptor-3, HCAM, homing-associated cell adhesion Miller et al, 2007;
    molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood Lin et al, 2007)
    group antigen, In blood group antigen, Ly24, MC56, MDU2,
    MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic
    glycoprotein-1)
    CD51 (ITGAV, integrin-alpha-V, L230, MSK8 vitronectin receptor (Junglas et al, 2009;
    VNRA, vitronectin receptor alpha subunit) Dickerson et al,
    1998; Zhou L et al,
    1999; Zhou L et al,
    1996)
    CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular (Rozsa et al, 2006)
    adhesion molecule 1, IFN-gamma regulated human melanoma-
    associated antigen, Ly47, MALA-2, Me14-D12, P3.58)
    CD55 (CD55a, CD55b, complement decay-accelerating factor, decay- (Rozsa et al, 2006;
    accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM- Michael et al, 2008)
    DAF, DAF1, decay-accelerating factor 1, DAF2, decay-
    accelerating factor 2, Cromer blood group antigen)
    CD61 (CD61A, F4, F11, GPIIb/IIIa, HPA-1, human platelet antigen-1, (Filla etal, 2006;
    HPA-4, human platelet antigen-4, ITGB3, integrin-beta-3, Pen Zhou L et al, 1999;
    alloantigen, Pen(a), Pen(b), PL(A1), platelet fibrinogen receptor Zhou L et al, 1996;
    beta subunit, platelet glycoprotein IIIa, GP3A, Yuk alloantigen, Rozsa et al, 2006)
    Yuk(a), Yuk(b), Zw alloantigen, Zw(a), Zw(b))
    CD62E (ELAM, ELAM-1, endothelium leukocyte adhesion molecule 1, (Luna et al, 2009; Li
    ESEL, E-selectin, selectin-E, SELE, GMP-140, GRMP, et al, 2007; Zhou Q
    granulocyte membrane protein, LECAM-2, leukocyte adhesion et al, 2007)
    molecule 2, platelet alpha-granule membrane protein)
    CD63 (81H, AD1, GP55, granulophysin, LIMP, lysosomal integral (Rozsa et al, 2006)
    membrane protein, LIMP-1, lysosomal integral membrane
    protein-1, ME491, melanoma associated antigen ME491, MLA1,
    melanoma-associated antigen 1, NGA, neuroglandular antigen,
    NKI-C3, OMA81H, ocular melanoma-associated antigen 81H,
    PLTGP40, platelet glycoprotein gp40, TSPAN30, tetraspanin 30)
    CD87 (MO3, PLAUR, plasminogen activator urokinase receptor, UPA- (Rozsa et al, 2006)
    R, urokinase plasminogen activator receptor, URKR, urokinase
    receptor)
    CD95 FAS, APO-1, apoptosis antigen-1, APT1, TNFRSF6, TNF Agarwal et al, 1999;
    receptor superfamily member 6, FASTM, FASL receptor Rozsa et al, 2006
    CD104 (A6 Antigen, ITGB4, integrin-beta-4, TSP-180, tumor-specific (Zhou L et al, 1999)
    protein 180)
    CD105 (E9 protein, endoglin, HHT1, hereditary hemorrhagic (Vittal et al, 2005)
    telangiectasia type 1, ORW, Osler-Rendu-Weber syndrome,
    ORW1, SH-2)
    CD106 (alpha-4-beta-1 ligand, INCAM-110, inducible cellular adhesion (Michael et al, 2008;
    molecule 110 kDa, VCAM-1, vascular cellular adhesion Zhao X et al, 2004;
    molecule 1) Vittal et al, 2005)
    CD107a (LAMP-1, lysosome-associated membrane glycoprotein-1, (Rozsa et al, 2006)
    LAMPA, lysosome-associated membrane glycoprotein A,
    LGP120, lysosomal glycoprotein 120)
    CD141 (thrombomodulin, TM, THBD, THRM, Alpha-Thrombomodulin, (Luna et al, 2009;
    Beta-Thrombomodulin, fetomodulin, FM) Borrás et al 2006;
    Rozsa et al, 2006;
    Zhao X et al, 2004)
    CD143 (ACE, angiotensin converting enzyme, angiotensin-1 converting (Savaskan et al,
    enzyme, dipeptidyl carboxypeptidase, dipeptidyl 2004)
    carboxypeptidase 1, EC3.4.15.1, kininase 2, peptidase P, peptidyl
    dipeptidase A)
    CD146 (A32, BT14, L101, gp130 antigen, MCAM, Melanoma cell (Rozsa et al, 2006;
    adhesion molecule, MelCAM, melanoma adhesion molecule, Vittal et al, 2005
    MUC18, P1H12, S-endo 1, Gicerin, 1-gicerin, s-gicerin))
    CD164 (endolyn, endolyn-78, MGC-24, multiglycosylated core protein- (Rozsa et al, 2006)
    24, MGC-24v, MUC-24)
    CD166 (2117 antigen, ALCAM, Activated leukocyte cell adhesion (Rozsa et al, 2006)
    molecule, BEN, CD6L-100, DM-GRASP, F84.1 antigen, HCA,
    Hematopoietic cell antigen, JC7, KG-CAM, MEMD, melanoma
    metastasizing clone D, metastasizing melanoma protein D,
    MuSC, Neurolin, SC-1)
    CD225 (fragilis, IFI17, interferon-induced protein 17, IFITM1 (Zhao X et al, 2004;
    interferon-induced transmembrane protein 1, 9-27, Interferon- Rozsa et al, 2006)
    inducible protein 9-27, Leu13)
    CD249 (6C3, aminopeptidase A, angiotensinase A, APA, L-alpha- (Coupland et al,
    aspartyl(L-alpha-glutamyl)-peptide hydrolase, BP-1, BP-1/6C3 1993)
    antigen, EAP, EC3.4.11.7, glutamyl aminopeptidase, gp160,
    RC38, ENPEP)
    CED6 (engulfment adaptor PTB domain containing 1, gulp, GULP1) (Zhao X et al, 2004)
    Chemerin receptor (RARRES2, retinoic acid receptor responder 2, tazarotene- (Luna et al, 2009)
    induced gene-2, TIG-2) receptors (ChemR23, chemokine
    receptor 23, CMKLR1, chemokine-like receptor 1, Dez)
    CHI3L1 (chitinase 3-like-1, cartilage glycoprotein 39, gp39; gp39k HC- (Rozsa et al, 2006;
    gp39, chondrocyte protein YKL40, YKL40, Chondrex) Zhao X et al, 2004)
    CHI3L2 (chitinase 3-like-2, YKL39) (Rozsa et al, 2006
    CNTF receptor Receptor for: Ciliary neuronotrophic factor, ciliary neurotrophic Liu X et al, 2001
    factor, MANS, membrane-associated neurotransmitter
    stimulating factor
    collagen type 4 (COL4A1, collagen-4, collagen-4-alpha-1, Arresten, Canstatin, Junglas et al, 2009;
    Tumstatin) Zhao X et al, 2004
    collagen type 14 (collagen-14, COL14A1, collagen-14-alpha-1, undulin) Vittal et al, 2005;
    Zhao X et al, 2004
    collagen type 15 (Collagen-15, COL15A1, collagen-15-alpha-1, Restin, Restin-1, Rozsa et al, 2006;
    Restin-2, Restin-3, Restin-4) Fuchshofer et al,
    2007
    complement factor (ECI, Eosinophil cytotoxicity inhibitor, C3-beta-c, complement Michael et al, 2008
    C3 factor C3b, ETF-3, embryotrophic factor-3, HSE-MSF, hepatic
    sinusoidal endothelial cell-derived migration stimulating factor
    CSPG2 (chondroitin sulfate proteoglycan 4) (Zhao X et al, 2004)
    CSRP2 (Cysteine and glycine rich protein 2) (Zhao X et al, 2004)
    CTGF (Connective tissue growth factor, Hcs24, hypertrophic (Junglas et al, 2009;
    chondrocyte-specific gene product 24, Fisp-12, fibroblast Fuchshofer et al,
    inducible secreted protein-12, IGFBP8, Insulin-like growth factor 2007; Rozsa et al,
    binding protein-8, IGFBPrP2, Insulin-like growth factor binding 2006; Vittal et al,
    protein related protein-2, Ecogenin, endochondral ossification 2005)
    genetic factor, CCN2)
    CTGF Receptor Receptor for: Connective tissue growth factor, Hcs24, (Junglas et al, 2009)
    hypertrophic chondrocyte-specific gene product 24, Fisp-12,
    fibroblast inducible secreted protein-12, IGFBP8, Insulin-like
    growth factor binding protein-8, IGFBPrP2, Insulin-like growth
    factor binding protein related protein-2, Ecogenin, endochondral
    ossification genetic factor, CCN2
    C-type natriuretic Receptor for: CNP, ANP-C, NPPC (Chang et al, 1996;
    peptide Receptor Zhong L et al, 2003)
    CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, (Luna et al, 2009)
    C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1)
    CXCL1 (CXC chemokine ligand 1, chemokine (C-X-C motif) ligand 1, (Michael et al, 2008
    SCYB1, CINC-1, Cytokine induced neutrophil chemoattractant-
    1, fsp, fibroblast secretory protein, GRO1, GRO-alpha, KC,
    MGSA, melanoma growth stimulatory activity, MGSA-alpha,
    melanoma growth stimulatory activity-alpha, NAP-3, neutrophil-
    activating protein-3, N51)
    CXCL3 (CXC chemokine ligand 3, chemokine (C-X-C motif) ligand 3, (Michael et al,
    CINC-2-beta, Cytokine induced neutrophil chemoattractant-2- 2008)
    beta, DCIP-1, DC inflammatory protein-1, GRO3, GRO-gamma,
    growth regulated oncogene-gamma, growth-related oncogene-3,
    MGSA-gamma, melanoma growth stimulatory activity-gamma,
    MIP-2-beta, macrophage inflammatory protein-2-beta)
    CXCL5 (CXC chemokine ligand 5, chemokine (C-X-C motif) ligand 5, (Michael et al,
    ENA-78, Epithelial neutrophil-activating protein 78, epithelial 2008)
    cell-derived neutrophil attractant-78, LIX, LPS induced CXC
    chemokine, AMCF-2, Alveolar macrophage chemotactic factor-
    2, SCYB5)
    CXCL6 (CXC chemokine ligand 6, chemokine (C-X-C motif) ligand 6, (Michael et al,
    GCP-2, granulocyte chemotactic peptide-2, CKA-3, chemokine 2008)
    alpha 3, SCYB6)
    CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, (Vittal et al, 2005;
    IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced Zhao X et al, 2004)
    in hepatomas, SDF-1-alpha, SDF-1-beta, SDF, SDF-1, Stromal
    cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal
    cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating
    factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic
    lymphoma cell stimulating factor-alpha, Thymic lymphoma cell
    stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA
    repressed gene-1, SCYB12)
    Cystatin B (Rozsa et al, 2006)
    Cystatin C (CST3, Cystatin-3, Gamma-TRACE, post-gamma globulin)) (Rozsa et al, 2006;
    Leung YF et al,
    2003
    DAP-3 (Death associated protein 3, MRP-S29, mitochondrial ribosomal (Rozsa et al, 2006
    protein S29))
    DDR2 (discoidin domain receptor 2, NTRKR3, neurotrophic tyrosine (Luna et al, 2009)
    kinase receptor-related 3, tyro10, CD167b)
    Dickkopf-1 (dkk-1, dickkopf-related protein 1, Sk) (Luna et al, 2009)
    dickkopf-2 (dickkopf-related protein 2, dkk-2) (Zhao X et al, 2004)
    DR6 (death receptor-6, TNFRSF21, TNF receptor superfamily (Zhao X et al, 2004)
    member 21)
    DRAK1 (DAP kinase-related apoptosis-inducing protein kinase-1, (Rozsa et al, 2006)
    STK17A, serine/threonine protein kinase 17A)
    EBAF (Endometrial bleeding associated factor, TGF-beta-4, TGFB4, (Zhao X et al, 2004)
    lefty A, lefty-2)
    EGF (epidermal growth factor, EGF-URO, HMGF, human milk (He and Li, 2001;
    growth factor, PGF, prostatic growth factor, beta-Urogastrone, He X and Li M,
    URO, URG, Urogastrone, tooth-lid factor) 1997)
    EGF Receptor Receptor for: epidermal growth factor, EGF-URO, HMGF, (Alexander et al,
    human milk growth factor, PGF, prostatic growth factor, beta- 1998; Dai W and Li
    Urogastrone, URO, URG, Urogastrone, tooth-lid factor (erb, M, 1997; He X and
    erbB1, HER1) Li M, 1997;
    Wordinger et al,
    1998)
    Egr-1 (Early growth response gene-1, ETR103, d2, zif268, NGFI-A, (Fan et al, 2008)
    nerve growth factor-inducible A, Krox-24, GOS-30, G0/G1
    switch gene 30, TIS8, TPA-inducible sequence-8, tetradecanoyl
    phorbol acetate-inducible sequence-8)
    egr-3 (Early growth response gene-3) (Luna et al, 2009)
    Endocan ESM-1, endothelial cell-specific molecule 1 Luna et al, 2009;
    Fan et al, 2008;
    Zhao X et al, 2004
    endothelin-1 (ET-1(1-21), ET-1) (Zhang X et al,
    2003)
    endothelin-1 (ET-1(1-21), ET-1) receptors (Rozsa et al, 2006;
    Receptor Zhao X et al, 2004
    endothelin-1 Thieme et al, 2005;
    receptiors Haque et al, 1998;
    Kageyama et al,
    1996; Kohmoto et
    al, 1994; Rosenthal
    et al, 2005; Tao W
    et al, 1998; Zhang X
    et al, 2003; Fan et
    al, 2008; Abad et al,
    2008)
    EphA4 (Eph receptor A4, Sek, Sek1, HEK8, human embryo kinase-8, (Fan et al, 2008;
    tyrol, tyrosine-protein kinase 1) Rozsa et al, 2006)
    ephrin B2 (EFNB2, HTK ligand, HTKL, EPLG5, EPH-related receptor (Vittal et al, 2005)
    tyrosine kinase ligand-5, LERK5, Ligand of eph-related kinase-5,
    NLERK1)
    Epiregulin (EREG, EPR) (Rozsa et al, 2006)
    Erythropoietin (Epo, Ep, ECSA, erythroid colony stimulating activity, ESF, (Rozsa et al, 2006;
    Receptor erythropoiesis stimulating factor) receptor Vittal et al, 2005)
    FADD (FAS-associated death domain protein, MORT-1, CAP1, (Luna et al, 2009)
    cytotoxicity-dependent APO-1-associated protein 1, CAP2,
    cytotoxicity-dependent APO-1-associated protein 2)
    FAM3C (cytokine-like protein family with sequence similarity 3 member (Rozsa et al, 2006)
    C; Interleukin-like EMT inducer, ILEI)
    FAP-alpha (fibroblast activation protein, Fibroblast activation protein-alpha, (Zhao X et al, 2004)
    FAP, FAPA, seprase, Seprase-s, seprase-1)
    ferritin (H-Ferritin, FTH1, FTH, L-Ferritin, FTL, CD-GF, carcinoma- (Ishibashi et al,
    derived growth factor) 2002)
    FGF-5 (Fibroblast growth factor-5, HBGF-5, heparin binding growth (Fuchshofer et al,
    factor-5, SMAG-82, smooth muscle cell activation-induced gene- 2009)
    82
    FGFR1 (fibroblast growth factor receptor-1, BFGFR, basic fibroblast (Rozsa et al, 2006)
    growth factor receptor, FGFBR, FGFB receptor, flt-2, fms-like
    tyrosine kinase-2, flg, fms-like gene, N-sam, CekI, chicken
    embryonic kinase 1, KAL2, Kallmann syndrome 2, CD331)
    fibroleukin (T49, pT49, FGL2, fibrinogen-like-2, HEP64) (Rozsa et al, 2006;
    Zhao X et al, 2003)
    Fibromodulin (FMOD, collagen binding 59 kDa protein) (Vittal et al, 2005)
    fibronectin (FN, fibronectin-1, FN1, LETS, large external transformation- (Junglas et al, 2009;
    sensitive protein, Fibroblast surface antigen, SF antigen, SFA, Yu et al, 2008; Lin
    CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A, et al, 2007; Vittal et
    MSF, migration stimulating factor, Z protein) al, 2005; Fuchshofer
    et al, 2007; Sato and
    Roy, 2002; Steely et
    al, 1992; Worthen
    and Cleveland,
    1982; Yue et al,
    1990; Zhou L et al,
    1998)
    fibronectin receptor (FN, fibronectin-1, FN1, LETS, large external transformation- (Calthorpe and
    sensitive protein, Fibroblast surface antigen, SF antigen, SFA, Grierson, 1990)
    CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A,
    MSF, migration stimulating factor, Z protein) receptors
    Fibulin-1 (FBLN1, BM-90) (Ishibashi et al,
    2002)
    Fibulin-5 (FBLN5, DANCE, developmental arteries and neural crest EGF- (Zhao X et al, 2004)
    like, EVEC, embryonic vascular EGF-like repeat-containing
    protein)
    follistatin (FST, Follicle stimulating hormone suppressing protein, FSP, (Rozsa et al, 2006)
    Activin-binding protein)
    follistatin-like-1) (TSC-36, TGF-beta-stimulated clone-36, follistatin-related (Rozsa et al, 2006)
    protein, FRP, follistatin-like, occ1, Flik, XFRP, Xenopus laevis
    follistatin-related protein
    FLRG (follistatin-related gene, follistatin-like-3, FSTL3) (Fuchshofer et al,
    2009; Rozsa et al,
    2006; Zhao X et al,
    2004; Ishibashi et al,
    2002)
    FPR1 (formyl peptide receptor-1, fMLP receptor, FRP, N-formyl (Rozsa et al, 2006)
    peptide receptor, formyl peptide receptor)
    frizzled-7 (FzD7, Fz7, FzE3) (Zhao X et al, 2004)
    gadd45-alpha) (growth arrest and DNA damage induced gene-45-alpha, (Rozsa et al, 2006)
    gadd45A, DDIT1, DNA damage-inducible transcript-1
    gadd45-beta (growth arrest and DNA damage induced gene-45-beta, gadd45B, (Rozsa et al, 2006)
    MyD118)
    gadd153 (growth arrest and DNA damage induced gene-153, DDIT3, (Leung YF et al,
    DNA damage-inducible transcript-3, CHOP, C/EBP-homologous 2003)
    protein, CHOP-10, C/EBP-homologous protein-10, C/EBP-zeta,
    CCAAT/enhancer binding protein zeta)
    galanin (GAL, GALN, GLNN) (Luna et al, 2009)
    Galectin-1 (Gal-1, LGALS1, galactose-specific soluble lectin 1, L-14-I, (Zhao X et al, 2004)
    Lactose-binding lectin 1, S Lac lectin 1, Galaptin)
    GAP43 (growth associated protein 43, B-50, 3D5 antigen, F1, pp46, P57, (Rozsa et al, 2006)
    7-5, p54(Ca)p, GAP48, neuromodulin)
    gas-1 (Growth arrest-specific gene-1) (Fan et al, 2008;
    Zhao X et al, 2004;
    Leung YF et al,
    2003; Borrás et al
    2006)
    gas-7 (Growth arrest-specific gene-7) (Rozsa et al, 2006)
    glypican-4 (GPC4, K-glypican) (Luna et al, 2009;
    Zhao X et al, 2004)
    gp130 (IL6ST, IL6 signal transducer, CD130) (Rozsa et al, 2006)
    gremlin-2 (GREM2, PRDC, protein related to DAN and cerberus, (Rozsa et al, 2006)
    CKTSF1B2, DAND3)
    HB-EGF (Heparin binding EGF-like factor, Heparin binding EGF-like (Fuchshofer et al,
    growth factor, par-2, prostate apoptosis response protein 2, DTR, 2009; Zhao X et al,
    Diphtheria toxin receptor) 2004)
    HDGF (hepatoma-derived growth factor, HuHGF, HMG1L2, high (Rozsa et al, 2006)
    mobility group protein 1-like-2)
    HGF receptor (hepatocyte growth factor, HGF/SF, Hepatocyte growth (Rozsa et al, 2006;
    factorscatter factor, F-TCF, fibroblast tumor cytotoxic factor, Zhao X et al, 2004)
    HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic
    factor)
    HGF receptor (hepatocyte growth factor, HGF/SF, Hepatocyte growth (Alexander et al,
    factorscatter factor, F-TCF, fibroblast tumor cytotoxic factor, 1998; Wordinger et
    HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic al, 1998)
    factor) receptors (met)
    HMG-1 (high mobility group protein-1, HMGB1, high mobility group (Ishibashi et al,
    box-1, amphoterin, DEF, Differentiation enhancing factor, 2002)
    Neurite growth-promoting protein, SBP-1, Sulfoglucuronyl
    carbohydrate binding protein-1)
    hsp27 (hsp27a, hsp27b, hsp27c, heat shock protein 27, HSPB1, heat (Zhao X et al, 2004;
    shock 27 kDa protein 1, estrogen-regulated protein 24K, p29 Rozsa et al, 2006)
    estrogen receptor-associated protein, estrogen receptor-related
    protein, GC1, germ cell-dependent phosphoprotein-1)
    hsp70 heat shock protein 70 Luna et al, 2009
    HSPA5 (heat shock regulated protein 78, GRP78) (Leung YF et al,
    70 kDa protein 5, 2003)
    glucose
    HVEM (Herpesvirus entry mediator, HveA, Herpes simplex virus entry (Tiwari et al, 2005)
    protein A, HveAt, TR2, TNF receptor-like-2, ATAR, another
    TRAF-associated receptor, TNFRSF14, TNF receptor
    superfamily member 14, LIGHTR, LIGHT receptor)
    ID4 (Inhibitor of DNA binding-4, inhibitor of DNA (Rozsa et al, 2006)
    binding/differentiation-4, IDB4)
    IFI16 (interferon-induced protein 16, interferon-gamma-inducible (Rozsa et al, 2006)
    protein-16)
    IFITM3 (interferon-induced transmembrane protein 3) (Rozsa et al, 2006)
    IFN-gamma receptor 2 (interferon-gamma transducer 1) (Luna et al, 2009)
    IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano (Cao Y et al, 2002;
    growth factor, MGF, ILGF1, somatomedin C, NSILA, non- Rozsa et al, 2006;
    suppressible insulin-like activity, Somatomedin A, Somatomedin Zhao X et al, 2003)
    C, sulfation factor)
    IGF-1 receptor (Insulin-like growth factor-1, Erythropoietic factor, mechano (Ando et al, 2004;
    growth factor, MGF, ILGF1, somatomedin C, NSILA, non- Cao Y et al, 2002;
    suppressible insulin-like activity, Somatomedin A, Somatomedin Wordinger et al,
    C, sulfation factor) receptors (IGF1R, CD221) 1998)
    IGF-2 (Insulin-like growth factor-2, Growth-promoting activity for (Rozsa et al, 2006)
    vascular endothelial cells, T3M-11-derived growth factor,
    ILGF2, MSA, multiplication stimulating activity, NSILA, non-
    suppressible insulin-like activity, Somatomedin A, sulfation
    factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP,
    Somatomedin/insulin-like growth factor-like polypeptides)
    IGF-2 receptor (Insulin-like growth factor-2, Growth-promoting activity for (Rozsa et al, 2006)
    vascular endothelial cells, T3M-11-derived growth factor,
    ILGF2, MSA, multiplication stimulating activity, NSILA, non-
    suppressible insulin-like activity, Somatomedin A, sulfation
    factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP,
    Somatomedin/insulin-like growth factor-like polypeptides)
    receptors (IGF2R, CD222, mannose-6-phosphate receptor; MPR,
    CIM6PR, cation-independent mannose 6-phosphate receptor,
    MPRI, MPR300)
    IGFBP2 (Insulin-like growth factor binding protein-2) (Fan et al, 2008;
    Ishibashi et al, 2002;
    Leung YF et al,
    2003; Rozsa et al,
    2006; Vittal et al,
    2005)
    IGFBP3 (Insulin-like growth factor binding protein-3, BP-53, Growth (Fan et al, 2008;
    hormone dependent binding protein, Binding protein-29) Rozsa et al, 2006;
    Zhao X et al, 2004
    IGFBP4 (Insulin-like growth factor binding protein-4, Colon cancer cell (Ishibashi et al,
    growth inhibitor, HT29-IGFBP, HT29 insulin-like growth factor 2002; Rozsa et al,
    binding protein) 2006; Vittal et al,
    2005)
    IGFBP5 (Insulin-like growth factor binding protein-5) (Michael et al, 2008;
    Rozsa et al, 2006)
    IGSF4 [immunoglobulin superfamily gene 1] (Zhao X et al, 2004)
    IL1-alpha (IL1A, interleukin-1-alpha, BAF, B-cell activating factor, BCAF, (Luna et al, 2009; Li
    B-cell activating factor, EP, endogenous pyrogens, LAF, et al, 2007)
    lymphocyte activating factor, LEM, leukocyte endogenous
    mediator, MCF, mononuclear cell factor, MNCF, mononuclear
    cell factor, MP, mitogenic protein, TRF-3, T-cell replacing
    factor-3, Tumor inhibitory factor-2)
    IL1-alpha receptor (IL1A, interleukin-1-alpha, BAF, B-cell activating factor, BCAF, (Kelley et al, 2007;
    B-cell activating factor, EP, endogenous pyrogens, LAF, Li XY et al, 2006;
    lymphocyte activating factor, LEM, leukocyte endogenous Alexander et al,
    mediator, MCF, mononuclear cell factor, MNCF, mononuclear 1998; Fleenor et al,
    cell factor, MP, mitogenic protein, TRF-3, T-cell replacing 2003; Pang et al,
    factor-3, Tumor inhibitory factor-2) receptors (IL1R, IL1RA, 2003; Wordinger et
    IL1R1, IL1 receptor type 1, IL1RB, IL1R2, IL1 receptor type 2, al, 1998; Keller et
    CD121a, CD121b) al, 2009)
    IL1-beta (IL1B, interleukin-1-beta, Catabolin, H1, Hematopoietin-1, IFN- (Fan et al, 2008)
    beta inducing factor, Interleukin-beta, OAF, osteoclast activating
    factor)
    IL1-beta receptor (IL1B, interleukin-1-beta, Catabolin, H1, Hematopoietin-1, IFN- (Alexander et al,
    beta inducing factor, Interleukin-beta, OAF, osteoclast activating 1998; Wordinger et
    factor) receptors (IL1R, IL1RA, IL1R1, IL1 receptor type 1, al, 1998)
    IL1RB, IL1R2, IL1 receptor type 2, CD121a, CD121b)
    IL1-beta Convertase (ICE, IL1BC, IL1-beta converting enzyme, Caspase-1, CASP1) (Agarwal et al,
    1999)
    IL4 receptor Interleukin-4, BCDF-epsilon, B-cell differentiation factor- Rozsa et al, 2006
    epsilon, BCDF-gamma, B-cell differentiation factor-gamma,
    BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell
    growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1,
    BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell
    growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE
    enhancing factor, IgG1-enhancing factor, IgG1-induction factor,
    LMW-BCGF, low molecular weight B-cell growth factor,
    MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell
    growth factor-2, MFF, macrophage fusion factor, Pitrakinra,
    TCGF-2, T-cell growth factor-2) receptors (CD124)
    IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor- (Liton et al, 2009;
    2, CDF, CAT development factor, choline acetyltransferase Luna et al, 2009; Li
    development factor, Cytolytic differentiation factor for T- et al, 2007; Rozsa et
    lymphocytes, FDGI, fibroblast-derived growth inhibitor, HGF, al, 2006)
    hybridoma growth factor, HPGF, hybridoma/plasmacytoma
    growth factor, HSF, hepatocyte stimulating factor, HSF-1,
    hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-
    1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF,
    myeloma growth factor, NKAF, natural killer cell activating
    factor, TAF, T-cell activating factor, Thymocyte growth factor,
    TSF, thymocyte stimulating factor)
    IL6 receptor (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor- (Liton et al, 2009)
    2, CDF, CAT development factor, choline acetyltransferase
    development factor, Cytolytic differentiation factor for T-
    lymphocytes, FDGI, fibroblast-derived growth inhibitor, HGF,
    hybridoma growth factor, HPGF, hybridoma/plasmacytoma
    growth factor, HSF, hepatocyte stimulating factor, HSF-1,
    hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-
    1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF,
    myeloma growth factor, NKAF, natural killer cell activating
    factor, TAF, T-cell activating factor, Thymocyte growth factor,
    TSF, thymocyte stimulating factor) receptors (CD126)
    IL-8 interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil- (Luna et al, 2009;
    activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC Michael et al, 2008;
    chemokine ligand 8, chemokine (C-X-C motif) ligand 8, Li et al, 2007;
    EDNAP, endothelial-derived neutrophil-activating peptide, EMF- Ishibashi et al,
    1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial 2002)
    cell neutrophil-activating peptide, FDNAP, Fibroblast-derived
    neutrophil-activating peptide, FINAP, fibroblast-derived
    neutrophil-activating protein, GCF, granulocyte chemotactic
    factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte
    adhesion inhibitor, LCF, lymphocyte chemotactic factors,
    LDNAP, leukocyte-derived neutrophil-activating peptide, LIF,
    leukocyte inhibitory factor, LUCT, lung carcinoma-derived
    chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating
    peptide, MDNAP, monocyte-derived neutrophil-activating
    peptide, MDNCF, monocyte-derived neutrophil chemotactic
    factor, MOC, monocyte-derived chemotaxin, MONAP,
    monocyte-derived neutrophil-activating peptide, NAF,
    neutrophil-activating factor, NAP-1, neutrophil-activating
    protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil
    chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-
    cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated
    gene sequence-1)
    IL10 receptor Receptor for interleukin-10, B-TCGF, B-cell derived T-cell (Rozsa et al, 2006)
    growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF,
    T-cell growth inhibitory factor
    IL12 IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12- (Zhao X et al, 2004)
    p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF,
    cytotoxic lymphocyte maturation factor, NKSF, natural killer cell
    stimulatory factor, NKSF1, natural killer cell stimulatory factor-
    1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL
    maturation factor, TSF, T-cell stimulating factor
    IL13 receptors Receptor for Interleukin-13, NC30, P600 (Rozsa et al, 2006)
    insulin receptors (CD220, INSR) (Kim, 2007)
    integrin alpha
    integrin beta
    IRAK1 (IL1 receptor-associated kinase-1, IRAK, IL1 receptor-associated (Rozsa et al, 2006)
    kinase)
    ITGBL1 integrin beta-1 Rozsa et al, 2006
    ITM2B (integral membrane protein 2B; BRI) (Rozsa et al, 2006)
    jagged-1 (JAG1, jagged, Serrate-1) (Ishibashi et al,
    2002)
    JAM3 (Junctional adhesion molecule 3, JAM-C, Junctional adhesion (Rozsa et al, 2006)
    molecule C, Gi11 antigen)
    KGF receptors Receptor for keratinocyte growth factor, HBGF-7, heparin (Alexander et al,
    binding growth factor-7, FGF-7, fibroblast growth factor-7 1998)
    Leptin receptor (receptors for ob, ob/ob, obese protein, obesity factor) (OBR, (Zhao X et al, 2004;
    CD295, db, db/db, fatty, fa, fa/fa) Rozsa et al, 2006)
    LIF (ABAE cell growth-inhibitory activity; CDF, cholinergic (Rozsa et al, 2006)
    differentiation factor, CNDF, cholinergic neuronal differentiation
    factor, D-Factor, differentiation stimulating factor, DIA,
    differentiation inhibiting activity, DIF, differentiation inducing
    factor, DRF, Differentiation-retarding factor, ES cell growth
    factor, ESCGF, embryonic stem cell growth factor, GATS,
    growth stimulatory activity for TS1 cells, HILDA, human
    interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2,
    HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase
    inhibitor, M1 differentiation inducing activity, MCGEF, mast cell
    growth-enhancing factor, MLPLI, melanoma-derived lipoprotein
    lipase inhibitor, OAF, osteoclast activating factor)
    LIF receptor (ABAE cell growth-inhibitory activity; CDF, cholinergic (Alexander et al,
    differentiation factor, CNDF, cholinergic neuronal differentiation 1998)
    factor, D-Factor, differentiation stimulating factor, DIA,
    differentiation inhibiting activity, DIF, differentiation inducing
    factor, DRF, Differentiation-retarding factor, ES cell growth
    factor, ESCGF, embryonic stem cell growth factor, GATS,
    growth stimulatory activity for TS1 cells, HILDA, human
    interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2,
    HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase
    inhibitor, M1 differentiation inducing activity, MCGEF, mast cell
    growth-enhancing factor, MLPLI, melanoma-derived lipoprotein
    lipase inhibitor, OAF, osteoclast activating factor) receptors
    (CD118)
    LTBP1 (Latent TGF-beta binding protein-1) (Fuchshofer et al,
    2009)
    LTBP2 (Latent TGF-beta binding protein-2) (Fuchshofer et al,
    2009; Vittal et al,
    2005)
    MAGEH1 (melanoma antigen family H1, Melanoma-associated antigen H1, (Rozsa et al, 2006)
    APR1, Apoptosis-related protein-1)
    Metallothionein-3 (MT-3, GIF, growth inhibition factor, GIFB, growth inhibitory (Rozsa et al, 2006)
    factor brain, GRIF, neuronal growth inhibition factor)
    metallothioneins (Fan et al, 2008;
    Vittal et al, 2005;
    Leung YF et al,
    2003)
    MFG-E8 (Milk fat globule epidermal growth factor-8, Lactadherin, BA46, (Rozsa et al, 2006)
    GP55, Component 15/16, MGP57/53, medin, FDC-M1, SED1,
    secreted EGF repeat and discoidin domains containing protein 1)
    MIC1 (macrophage inhibitory cytokine-1, GDF15, (Rozsa et al, 2006;
    growth/differentiation factor-15, PL74, PTGF-beta, Placental Vittal et al, 2005)
    Transforming Growth Factor-beta, PDF, prostate-derived factor,
    PLAB, Placental bone morphogenetic protein, NAG-1, NSAID
    activated gene-1)
    MMP-1 (matrix metalloproteinase-1, collagenase, collagenase-1, CL-1, (Alexander et al,
    CLG1, fibroblast collagenase, fibroblast-type collagenase, 1998; Borrás et al
    interstitial collagenase, tissue collagenase, EC3.4.23.7) 2006; Oh et al,
    2006; Pang et al,
    2003; Rozsa et al,
    2006)
    MMP-2 (matrix metalloproteinase-2, EC3.4.24.24, 70 kDa gelatinase, 72 kDa (Fatma et al, 2009;
    gelatinase, 72 kDa metalloproteinase, collagenase type 4, Junglas et al, 2009;
    collagenase type 4A, 72 kDa type IV collagenase, Gelatinase 72 kDa, Yu et al, 2008;
    Gelatinase A, Type IV collagenase. Type IVA collagenase, Sanka et al, 2007;
    neutrophil gelatinase) WuDunn, 2001;
    Conley et al, 2004;
    Husain et al, 2007;
    Kashiwagi et al,
    2001; Oh et al,
    2006; Shearer and
    Crosson, 2001;
    Shearer and
    Crosson, 2002)
    MMP-3 (matrix metalloproteinase-3, stromelysin-1, STMY1, STR1, SL- (Luna et al, 2009;
    1, transin, transin-1, collagenase activating protein, Kelley et al, 2007;
    procollagenase activator, proteoglycanase) Fleenor et al, 2003;
    Oh et al, 2006; Pang
    et al, 2003;
    Alexander et al,
    1998; WuDunn,
    2001)
    MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kDa (Junglas et al, 2009;
    gelatinase, 92 kDa type IV collagenase, or PMNL gelatinase, Alexander et al,
    polymorphonuclear leukocyte gelatinase, gelatinase type IV-B, 1998; Webb et al,
    collagenase type 5, collagenase-5, CL-5) 2006; Pang et al,
    2003)
    MMP-10 (matrix metalloproteinase-10, stromelysin-2, STMY2, SL-2, ST- (Luna et al, 2009)
    2, transin-2, EC3.4.24.22)
    MMP-11 (matrix metalloproteinase-11, stromelysin-3, STMY3, SL-3, ST- (Oh et al, 2006)
    3)
    MMP-12 (matrix metalloproteinase-12, macrophage elastase, macrophage (Oh et al, 2006)
    metalloelastase, EC3.4.24.65, MME, HME)
    MMP-14 (matrix metalloproteinase-14, MT1-MMP, Membrane-type (Sanka et al, 2007;
    matrix metalloproteinase-1, MT-MMP-1, MMP-X1) Miller et al, 2007;
    Oh et al, 2006)
    MMP-15 (matrix metalloproteinase-15, MT2-MMP, Membrane-type (Oh et al, 2006;
    matrix metalloproteinase-2, MT-MMP-2) Vittal et al, 2005)
    MMP-16 (matrix metalloproteinase-16, MT3-MMP, Membrane-type (Oh et al, 2006;
    matrix metalloproteinase-3, MT-MMP-3) Rozsa et al, 2006;
    Vittal et al, 2005)
    MMP-17 (matrix metalloproteinase-17, MT4-MMP, Membrane-type (Oh et al, 2006)
    matrix metalloproteinase-4, MT-MMP-4)
    MMP-19 (matrix metalloproteinase-19, RASI-1, rheumatoid arthritis (Oh et al, 2006)
    synovium inflamed-1)
    MMP-24 (matrix metalloproteinase-24, MT5-MMP, Membrane-type (Oh et al, 2006)
    matrix metalloproteinase-5, MT-MMP-5)
    MNSF-beta monoclonal nonspecific suppressor factor, hNSF, NSF, (Rozsa et al, 2006)
    Nonspecific suppressor factor, MNSF-beta, Fau protein, Ubi-L,
    FBR-MuSV-associated ubiquitously expressed gene, fox, dD3,
    asr1, arsenite resistance-1)
    Mortalin (p66-mot-1, PBP74, peptide binding protein 74, grp75, glucose (Luna et al, 2009)
    regulated protein 75)
    Mx (myxovirus resistance 1, Mx1, MxA, IFI-78k, interferon- (Michael et al, 2008;
    inducible 78 kDa protein; IFI-78) Zhao X et al, 2004)
    MyD88 (Rozsa et al, 2006)
    Myocilin (MYOC, TIGR, trabecular meshwork inducible GC response, (Clark et al, 2001;
    trabecular meshwork inducible glucocorticoid response, GLC1A, Fan et al, 2008;
    JOAG, JOAG1) Fautsch et al, 2005;
    Hardy et al, 2005;
    Hoffman et al, 2009;
    Ishibashi et al, 2002;
    Kirstein et al, 2000;
    Lin et al, 2007;
    Nguyen et al, 1998;
    Obazawa et al,
    2004; Pfeffer et al,
    2009; Polansky et
    al, 2000; Rozsa et
    al, 2006; Sakai et al,
    2007; Schlunck et
    al, 2008; Sohn et al,
    2002; Takahashi et
    al, 1998; Takahashi
    et al, 2000;
    Taniguchi et al,
    2000; Ueda et al,
    2000; Wentz Hunter
    et al, 2002; Zhao X
    et al, 2003)
    Myocilin receptors Receptor for (MYOC, TIGR, trabecular meshwork inducible GC (Wentz Hunter et al,
    response, trabecular meshwork inducible glucocorticoid 2004)
    response, GLC1A, JOAG, JOAG1)
    NALP1 (NACHT-LRR-PYD-containing protein-1, DEFCAP, death (Rozsa et al, 2006)
    effector filament-forming CED4-like apoptosis protein, CARD7,
    caspase recruitment domain-containing protein-7, KIAA0926,
    NAC, nucleotide-binding domain and CARD containing protein,
    NLRP1, NLR family, pyrin-domain containing 1)
    N-cadherin (Neural cadherin, Cadherin-2, CDH2, A-CAM, adherens junction (Zhao X et al, 2004)
    cell adhesion molecule, CDHN, neural calcium-dependent
    adhesion protein, CD325)
    NELL-2 (NEL-like 2, neural epidermal growth factor-like 2, NEL-like (Vittal et al, 2005)
    protein 2, NRP2, Nel-related protein 2)
    Neuregulin-1 (NRG-1, GGF, Glial growth factor, GGF-1, glial growth factor-1, (Zhao X et al, 2004)
    NDF, neu differentiation factor, Acetylcholine receptor inducing
    activity, ARIA, Heregulin, heregulin-alpha, HGL, HRGA)
    neuron-specific (NSE, Gamma-enolase, EC4.2.1.11, Enolase-2, ENO2, (Rozsa et al, 2006)
    enolase phosphopyruvate hydratase)
    neuropeptide Y Receptor for NPY, Y Neuropeptide (Luna et al, 2009)
    receptors
    neuropilin-1 Neuropilin, NPN-1, NP-1, NRP1, A5-antigen, BDCA4, Blood Fuchshofer et al,
    dendritic cell antigen 4, VEGF-165R, CD304) 2009; Zhao X et al,
    2004; Rozsa et al,
    2006
    Nexin-1 PN-1-alpha, Glial-derived neurite promoting factor, GdNPF, Rozsa et al, 2006
    Glia-derived nexin, GDN, NPF, neurite-promoting factor, Serpin
    E2
    NG2 (neuronal/glial 2, AN2, MCSP, melanoma chondroitin sulfate (Luna et al, 2009;
    proteoglycan, mel-CSPG, MCSPG, melanoma chondroitin Vittal et al, 2005)
    sulfate proteoglycan, CSPG4, chondroitin sulfate proteoglycan 4)
    NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF- (Wordinger et al,
    alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, 2000)
    NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-
    gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3)
    NKEF-B (Natural killer enhancing factor B, Peroxiredoxin-2, PRDX2, (Miyamoto et al,
    PRX2, TDPX1, thioredoxin-dependent peroxide reductase-1, 2009; Vittal et al,
    Calpromotin, PRP, protector protein, Torin, TSA, thiol-specific 2005)
    antioxidant protein)
    NKG7 (natural killer cell group 7 sequence, natural killer cell protein 7, (Vittal et al, 2005)
    GIG1, G-CSF-induced gene 1 protein)
    Norrin (NDP, Norrie disease protein, EVR2, exudative vitreoretinopathy (Rozsa et al, 2006)
    2 protein, FEVR, familial exudative vitreoretinopathy)
    NRAGE (Neurotrophin receptor-interacting MAGE homolog, MAGED1, (Rozsa et al, 2006)
    melanoma antigen family D1, Melanoma-associated antigen D1,
    Dlxin-1)
    NT-3 (neurotrophin-3, neuronotrophin-3, neurotrophic factor-3, NTF-3, (Wordinger et al,
    HDNF, hippocampus-derived neurotrophic factor, NGF-2, Nerve 2000)
    growth factor-2)
    NT-4 (neurotrophin-4, neuronotrophin-4, neurotrophic factor-4) (Wordinger et al,
    2000)
    OIP-1 (osteoclast inhibitory peptide-1, TSA-1, thymic shared antigen-1, (Rozsa et al, 2006)
    Sca-2, stem cell antigen-2, 9804, RIG-E, retinoic acid induced E,
    LY6E, lymphocyte antigen 6E, lymphocyte antigen 67, Ly67)
    osteoglycin (OGN, OIF, osteoinductive factor, KSPG25, Mimecan) (Luna et al, 2009;
    Vittal et al, 2005;
    Zhao X et al, 2004)
    osteoprotegerin (OPG, FDCR-1, FDC-derived receptor-1, OCIF, (Rozsa et al, 2006)
    osteoclastogenesis inhibitory factor, OCIF/OPG, OPG/OCIF,
    TNFRSF11B, TNF receptor superfamily member 11B, TR1,
    TNF receptor-like-1)
    PAI-1 Plasminogen activator inhibitor-1, PAI, plasminogen activator Fuchshofer et al,
    inhibitor, endothelial plasminogen activator inhibitor, Serpin E1, 2007; Fuchshofer et
    MSF, monocyte suppressor factor, EIP-1, EGF-inducible protein al, 2009; Junglas et
    1, mesosecrin al, 2009; Vittal et al,
    2005; Fukuchi et al,
    1997; Rozsa et al,
    2006; Zhao X et al,
    2004
    PAPP-A pregnancy-associated plasma protein-A, Pappalysin-1, IGFBP4 Rozsa et al, 2006
    protease
    PDGF receptors Receptor for platelet-derived growth factor, PDGF-1, PDGF-2, (Alexander et al,
    PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast- 1998; Vittal et al,
    derived growth factor, GDGF, glioma-derived growth factor-1, 2005; Ando et al,
    GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid- 2004; Wordinger et
    suppressible mitogenic activity, MDF, mesangial cell al, 1998; Shearer
    proliferating factor, MDGF, monocyte-derived growth factor, and Crosson, 2001;
    OBIF, osteoblastogenesis inhibitory factor, ODGF, Usui et al, 2003;
    osteosarcoma-derived growth factor, T47D factor) Zhao X et al, 2004)
    PDGF-D (platelet-derived growth factor-D, Iris-expressed growth factor, (Zhao X et al, 2004)
    IEGF, SCDGF-B, Spinal cord-derived growth factor-B)
    Pentraxin-3 Pentaxin-3, PTX3, TNFAIP5, tumor necrosis factor-alpha- Luna et al, 2009;
    induced protein 5, pentraxin-related gene rapidly induced by IL1- Zhao X et al, 2004
    beta, TSG-14, tumor necrosis factor-stimulated gene sequence-14
    periostin POSTN, OSF-2, osteoblast-specific factor-2, periostin-like factor, Zhao X et al, 2004;
    PLF Vittal et al, 2005
    PERP p53 apoptosis effector related to PMP-22, TP53 apoptosis Rozsa et al, 2006
    effector, KCP1, keratinocyte-associated protein 1, THW
    plexin-C1 PLXNC1, VESPR, virus-encoded semaphorin protein receptor,
    CD232
    perforin-1 pore-forming protein-1, perforin, pore-forming protein, PFP, Fan et al, 2008
    PFN, PRF1, PFN1
    PRELP proline/arginine-rich end leucine-rich repeat protein, prolargin Rozsa et al, 2006)
    proenkephalin Michael et al, 2008
    PTHrP parathyroid hormone-like related protein, PTH-related protein, (Luna et al, 2009)
    parathyroid hormone-related protein, PTHR, PTH-related
    peptide, Parathyroid hormone-related peptide, parathyroid
    hormone-like hormone, PTHLH
    RGS4 regulator of G-protein signaling 4 Rozsa et al, 2006
    S100A10 Calpactin-1 light chain, CAL1L, Calpactin p11, CLP11, p11, Rozsa et al, 2006
    42C, NGF-induced protein 42C, Annexin-2 ligand, ANX2LG
    S100A11 monocyte activating polypeptide, Meth A factor) (Zhao X et al,
    (calgizzarin, S100C, 2004)
    MLN70, EMAP-1,
    Endothelial-
    monocyte activating
    polypeptide-1,
    EMAP, Endothelial
    S100A12 ( ) ( ) p6, CGRP, calgranulin-related protein, Calgranulin C, CAAF-1, Fan et al, 2008
    calcium-binding protein in amniotic fluid-1, ENRAGE,
    extracellular newly identified RAGE-binding protein, CO-Ag
    S100A13 Rozsa et al, 2006
    SDF-3 Stromal cell-derived factor-3 Rozsa et al, 2006
    Secretoneurin SN, Chromogranin C, CHGC, SCG2, SgII, Secretogranin-2, Leung YF et al,
    gonadotrope polypeptide, GP-87, TSP86/84, tyrosine-sulfated 2003; Rozsa et al,
    protein 86/84 kDa 2006; Ishibashi et al,
    2002
    Semaphorin 3A SEMA3A, SEMA1, Semaphorin 3, sema III, collapsin-1, coll-1, Rozsa et al, 2006
    Hsema-I, Semaphorin D, Sem D, SEMAD
    Semaphorin 3F SEMA3F, Semaphorin 4, SEMA4, sema IV, Semaphorin K, Rozsa et al, 2006
    SEMAK
    Semaphorin 6A SEMA6A, Semaphorin Q, SEMAQ Rozsa et al, 2006;
    Fan et al, 2008
    serum amyloid A serum amyloid A, SAA, SAA1, serum amyloid A1, SAA2, serum Fan et al, 2008;
    amyloid A2, SAAL, A-SAA, acute phase serum amyloid A Rozsa et al, 2006
    sFRP1 secreted frizzled-related protein 1, FrzA, frizzled A, SARP-2, Rozsa et al, 2006;
    secreted apoptosis-related protein-2, FRP, frizzled-related protein Zhao X et al, 2004
    sFRP2 secreted frizzled-related protein 2, FRP2, frizzled-related protein Fan et al, 2008
    2, SARP-1, secreted apoptosis-related protein-1, SDF-5, stromal
    cell derived factor-5
    SLPI secretory leukocyte protease inhibitor, antileukoproteinase, ALP, Rozsa et al, 2006
    BLPI, Bronchial leukocyte proteinase inhibitor, BMI bronchial
    mucus inhibitor, CUSI, cervical mucus inhibitor, HUSI-I, human
    seminal plasma inhibitorI, MPI, Mucus proteinase inhibitor,
    seminal plasma inhibitor
    SMAD1 Sma and Mad related protein-1, Mad, Mothers against Rozsa et al, 2006
    decapentaplegic, Sma, MADH1, Mothers against
    decapentaplegic homolog 1, Mothers against DPP homolog 1,
    MADR1, Mad-related protein 1, BSP1, TGF-beta signaling
    protein-1, JV41
    SMAD7 Sma and Mad related protein-7, MADH7, Mothers against DPP Fuchshofer et al,
    homolog 7, Mothers against DPP homolog 7, CRCS3, colorectal 2009
    cancer susceptibility 3
    SOCS5 Suppressor of cytokine signaling-5, CIS6, Cytokine inducible Rozsa et al, 2006
    SH2-containing protein-6
    SOCS6 Suppressor of cytokine signaling-6, CIS4, Cytokine inducible Rozsa et al, 2006
    SH2-containing protein-4
    SPARC secreted protein acidic and rich in cysteine, osteonectin, BM-40, Rhee et al, 2003;
    43K glycoprotein Rozsa et al, 2006;
    Vittal et al, 2005
    sprouty-1 Spry-1 Fan et al, 2008
    sprouty-4 Spry-4 Rozsa et al, 2006
    stanniocalcin 2 STC2, STCRP, stanniocalcin-related protein Fan et al, 2008
    STAT1 signal transducer and activator of transcription-1, STAT1-alpha, Rozsa et al, 2006
    STAT1-beta, p91, Stat91, p84
    SUMO1 small ubiquitin-related modifier-1, Sentrin, Sentrin-1, UBL1, Fan et al, 2008
    ubiquitin-like-1, PIC1, PML interacting clone-1, SMT3H3, SMT
    homolog 3, GMP1, GAP-modifying protein 1, SMT3C
    Syndecan-1 CD138, syndecan, SDC1, Synd1, SD-1, 104-9 antigen, 1D4 Luna et al, 2009
    antigen, B-B2 antigen, B-B4 antigen, Mi15
    TFPI-2 tissue factor pathway inhibitor-2, MSPI, matrix-associated serine Fuchshofer et al,
    protease inhibitor 2009
    TGF-alpha receptor transforming growth factor-alpha, TGFA, TGF-A, MDGF-2, Wordinger et al,
    milk-derived growth factor-2, TCGF, transformed cell growth 1998
    factor, wa-1, waved-1 receptors
    TGF-beta transforming growth factor-beta, TGFB, B-TGF, Aqueous humor Fatma et al, 2009
    lymphocyte inhibitory activity, DIF, differentiation-inhibiting
    factor, EGI, epithelial cell-specific growth inhibitor; epithelial
    growth inhibitor, EIF, Epstein-Barr virus inducing factor,
    Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-
    cell suppressor factor, MDGF, milk-derived growth factor, MGF,
    milk growth factor, Polyergin, Simian BSC-1 cell growth
    inhibitor, SP factor, TCGF, transformed cell growth factor, TGI,
    tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1
    TGF-beta-1 transforming growth factor-beta-1, CIF-A, cartilage inducing Liton et al, 2009; Li
    factor A, ISF, immunosuppressive factor, MGF-b, milk growth J et, 1996
    factor, PDGI, platelet-derived endothelial cell growth inhibitor
    TGF-beta-1 receptor transforming growth factor-beta-1, CIF-A, cartilage inducing Liton et al, 2009; Li
    factor A, ISF, immunosuppressive factor, MGF-b, milk growth J et, 1996;
    factor, PDGI, platelet-derived endothelial cell growth inhibitor Nakamura et al,
    receptors 2002; Zhao X et al,
    2004
    TGF-beta-2 transforming growth factor-beta-2, TGFB2, G-TsF, Rozsa et al, 2006;
    Glioblastoma-derived T-cell suppressor factor, CIF-B, cartilage Cao Y et al, 2004
    inducing factor B, Corneal epithelial inhibitor of stromal cell
    collagenase synthesis, DSF, decidual suppressor factor, MGF-a,
    milk growth factor
    TGF-beta-2 receptor transforming growth factor-beta-2, TGFB2, G-TsF, Fuchshofer et al,
    Glioblastoma-derived T-cell suppressor factor, CIF-B, cartilage 2009; Da et al,
    inducing factor B, Corneal epithelial inhibitor of stromal cell 2004; Fuchshofer et
    collagenase synthesis, DSF, decidual suppressor factor, MGF-a, al, 2006, 2007; Li J
    milk growth factor receptors et, 1996; Zhao X et
    al, 2004; Junglas et
    al, 2009; Keller et
    al, 2009
    TGF-beta-3 transforming growth factor-beta-3, TGFB3 Luna et al, 2009;
    Rozsa et al, 2006
    TGF-beta receptor transforming growth factor-beta, TGFB, B-TGF, Aqueous humor Alexander et al,
    lymphocyte inhibitory activity, DIF, differentiation-inhibiting 1998; Usui et al,
    factor, EGI, epithelial cell-specific growth inhibitor; epithelial 2003; Wordinger et
    growth inhibitor, EIF, Epstein-Barr virus inducing factor, al, 1998; Rozsa et
    Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T- al, 2006
    cell suppressor factor, MDGF, milk-derived growth factor, MGF,
    milk growth factor, Polyergin, Simian BSC-1 cell growth
    inhibitor, SP factor, TCGF, transformed cell growth factor, TGI,
    tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1
    receptors
    Thrombospondin-1 Thrombospondin, TSP1, TSP, THBS1 Fatma et al, 2009;
    Zhao X et al, 2004;
    Fuchshofer et al,
    2007
    thrombospondin-2 TSP2, THBS2 Fan et al, 2008;
    Rozsa et al, 2006
    thymopoietin Tpo, TP, TMPO, TP-5, thymopentin, thymopoietin 32-36, Zhao X et al, 2004
    Lamina-associated polypeptide 2, LAP2
    thyroid hormone Duncan et al, 1999
    receptors
    TIEG-1 TGF-beta-inducible early-response gene-1, KLF10, Kruppel-like Luna et al, 2009
    factor 10, early growth response alpha, EGR-alpha
    TIMP-1 tissue inhibitor of metalloproteinases-1, TIMP metallopeptidase Sanka et al, 2007;
    inhibitor 1, TIMP, tissue inhibitor of metalloproteinases, HCI, Alexander et al,
    human collagenase inhibitor, CLGI, 3/10, 16C8, Fibroblast 1998; Conley et al,
    elongation factor, fibroblast collagenase inhibitor, B1 2004; Fautsch et al,
    anticollagenase, Beta-1 anticollagenase, EPA, erythroid 2005; Jin and Wu,
    promoting activity, embryogenin-1, TPA-S1, TPA-induced 2002; Oh et al,
    protein S1 2006; Pang et al,
    2003; WuDunn,
    2001
    TIMP-2 tissue inhibitor of metalloproteinases-2, TIMP metallopeptidase Luna et al, 2009;
    inhibitor 2, CSC-21K, MI, CHIAMP, Chondrocyte-derived Sanka et al, 2007;
    inhibitor of angiogenesis and metalloproteinase activity Alexander et al,
    1998; Jin and Wu,
    2002; Oh et al,
    2006; Rozsa et al,
    2006;, 2001
    TIMP-3 tissue inhibitor of metalloproteinases-3, TIMP metallopeptidase Jin and Wu, 2002;
    inhibitor 3, mitogen-inducible gene 5, mig-5; SFD, Sorsby Oh et al, 2006
    fundus dystrophy
    TIMP-4 tissue inhibitor of metalloproteinases-4, TIMP metallopeptidase Oh et al, 2006
    inhibitor 4
    Tissue factor TF, TFA, thromboplastin, tissue thromboplastin, CD142, factor Rozsa et al, 2006
    III, factor 3, F3, FIII, coagulation factor III
    TNFAIP1 tumor necrosis factor-alpha-induced protein 1, TNF-alpha- Rozsa et al, 2006
    induced protein 1, TNFAIP, tumor necrosis factor-alpha-induced
    protein, TNF-alpha-induced protein, B12, EDP1, endothelial
    TNF-alpha-induced protein 1
    TNFAIP2 tumor necrosis factor-alpha-induced protein 2, TNF-alpha- Vittal et al, 2005
    induced protein 2, B94
    TNFAIP8 tumor necrosis factor-alpha-induced protein 8, TNF-alpha- Rozsa et al, 2006
    induced protein 8, NDED, NF-kappa-B-inducible DED-
    containing protein, GG2-1, SCC-S2
    TNF-alpha Receptor tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily Kelley et al, 2007;
    member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, Alexander et al,
    differentiation inducing factor, EP, endogenous pyrogens, 1998; Wordinger et
    Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774- al, 1998; Pang et al,
    derived cytotoxic factor, MCF, macrophage cytotoxic factor, 2003; Keller et al,
    MCT, macrophage cytotoxin, MD-FGF, monocyte-derived 2009
    fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF,
    Released cytotoxic factor receptors
    TNF-beta receptor tumor necrosis factor-beta, TNFB, Coley's toxin, LT, Alexander et al,
    lymphotoxin, lymphotoxin-alpha, LT-alpha, LTA, Necrosin, 1998
    NKCF, natural killer cytotoxic factor, NK-CIA, Natural killer
    colony-inhibiting activity, TNFSF1, TNF ligand superfamily
    member 1 receptors
    tPA tissue plasminogen activator, tissue-type plasminogen activator, Luna et al, 2009;
    PLAT, plasminogen activator, tissue Rozsa et al, 2006;
    Shuman et al, 1988
    TRAF1 Tumor necrosis factor receptor-associated factor-1, EBI-6, EBV Rozsa et al, 2006
    induced gene-6
    TRAIL TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, Luna et al, 2009;
    TL2, TNF-like-2, TNF ligand superfamily member 10, Rozsa et al, 2006;
    TNFSF10, Ly81, CD253 Zhao X et al, 2003
    TRAIL receptor-4 (TRAIL receptor-4, TRAIL-R4, DcR-2, Decoy receptor-2, Zhao X et al, 2004
    TRUNDD, TRAIL receptor with a truncated death domain,
    TNFRSF10D, TNF receptor superfamily member 10D, CD264)
    (receptor for TNF-related apoptosis inducing ligand, APO-2
    ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily
    member 10, TNFSF10, Ly81, CD253)
    transferrin TRF, serotransferrin, siderophilin, DF-77, GPBP, Rozsa et al, 2006
    granulocyte/pollen-binding protein, Lung-derived growth factor
    receptors
    trkA tropomyosin-related kinase A, NTRK1, neurotrophic tyrosine Wordinger et al,
    kinase receptor 1 2000
    trkB tropomyosin-related kinase B, NTRK2, neurotrophic tyrosine Wordinger et al,
    kinase receptor 2 truncated 2000
    trkC tropomyosin-related kinase C, NTRK3, neurotrophic tyrosine Wordinger et al,
    kinase receptor 3 2000
    Tryptophanyl-tRNA TrpRS, WARS, Tryptophan-tRNA Ligase Ishibashi et al, 2002;
    synthetase Leung YF et al,
    2003
    TSC-22 TGF-beta-stimulated clone-22, TSC22D1, TSC22 domain family Leung YF et al,
    member 1 2003
    TSG-6 tumor necrosis factor-stimulated gene sequence-6, TNFAIP6, Luna et al, 2009;
    tumor necrosis factor-alpha-induced protein 6, TNFIP6, tumor Fuchshofer et al,
    necrosis factor-induced protein 6, PS4 2009; Rozsa et al,
    2006; Zhao X et al,
    2004
    TSLP thymic stromal derived lymphopoietin, Thymic stromal Luna et al, 2009
    lymphopoietin
    VEGF vascular endothelial growth factor, VEGF-A, vascular Fuchshofer et al,
    endothelial growth factor A, VEGF-1, vascular endothelial 2009; Rozsa et al,
    growth factor-1, VEG/PF, vascular endothelial growth 2006
    factor/vascular permeability factor, GD-VEGF, glioma-derived
    vascular endothelial growth factor, VAS, Vasculotropin,
    Vascular endothelial cell proliferation factor, VPF, vascular
    permeability factor, FSdGF, Folliculo stellate cell-derived growth
    factor
    VEGF Receptor vascular endothelial growth factor, VEGF-A, vascular Alexander et al,
    endothelial growth factor A, VEGF-1, vascular endothelial 1998; Ando et al,
    growth factor-1, VEG/PF, vascular endothelial growth 2004
    factor/vascular permeability factor, GD-VEGF, glioma-derived
    vascular endothelial growth factor, VAS, Vasculotropin,
    Vascular endothelial cell proliferation factor, VPF, vascular
    permeability factor, FSdGF, Folliculo stellate cell-derived growth
    factor receptors
    VEGF-C vascular endothelial growth factor C, VEGF-2, Vascular Luna et al, 2009;
    endothelial growth factor-2, flt-4 ligand, flt-4L Rozsa et al, 2006
    Wnt-2b Wnt-13, Wnt-2b1, Wnt-2b2 Rozsa et al, 2006
    Wnt-5a Rozsa et al, 2006
    Abad E et al., Investigative Ophthalmology and Visual Science 49(2): 677-686 (2008);
    Agarwal R et al., Experimental Eye Research 68(5): 583-590 (1999);
    Alexander JP et al Current Eye Research 17(3): 276-285 (1998);
    Ando A et al., Nippon Ganka Gakkai Zasshi 108(9): 549-553 (2004);
    Borrás T et al., Experimental Eye Research 82(6): 1002-1010 (2006);
    Calthorpe CM and Grierson I, Experimental Eye Research 51(1): 39-48 (1990);
    Cao Y et al., Zhonghua Yan Ke Za Zhi 40(4): 254-257 (2004);
    Cao Y et al., Journal of Huazhong University of Science and Technology Medical Sciences 24(1): 87-9, 94 (2004);
    Cao Y et al., Journal of Huazhong University of Science and Technology Medical Sciences 22(1): 69-72 (2002);
    Chang AT et al., Current Eye Research 15(2): 137-143 (1996);
    Clark AF et al., Investigative Ophthalmology and Visual Science 42(8): 1769-1780 (2001);
    Conley SM et al., Investigative Ophthalmology and Visual Science 45(2): 473-479 (2004);
    Coupland SE et al., Graefes Archive of Clinical and Experimental Ophthalmology 231(9): 533-540 (1993);
    Da B et al., Journal of Huazhong University of Science and Technology Medical Sciences 24(5): 490-492, 496 (2004);
    Dai W and Li M, Zhonghua Yan Ke Za Zhi 33(6): 413-416 (1997);
    Dickerson JE et al., Experimental Eye Research 66(6): 731-738 (1998);
    Duncan KG et al., Graefes Archive of Clinical and Experimental Ophthalmology 237(3): 231-240 (1999);
    Fan BJ et al., Investigative Ophthalmology and Visual Science 49(5): 1886-1897 (2008);
    Fatma N et al., Free Radicals Research 43(9): 783-795 (2009);
    Fautsch MP et al., Investigative Ophthalmology and Visual Science 46(8): 2848-2856 (2005);
    Filla MS et al., Investigative Ophthalmology and Visual Science 47(5): 1956-1967 (2006);
    Fleenor DL et al., Investigative Ophthalmology and Visual Science 2003 Aug; 44(8): 3494-3501 (2003);
    Fuchshofer R et al., Investigative Ophthalmology and Visual Science 47(3): 794-801 (2006);
    Fuchshofer R et al., Investigative Ophthalmology and Visual Science 48(2): 715-726 (2007);
    Fuchshofer R et al., Experimental Eye Research 88(6): 1020-1032 (2009);
    Fukuchi T et al., Nippon Ganka Gakkai Zasshi 101(3): 265-271 (1997);
    Gasiorowski JZ and Russell P, Experimental Eye Research 88(4): 671-675 (2009);
    Haque MS et al,. Current Eye Research 17(12): 1110-1117 (1998);
    Hardy KM et al., Journal of Biological Chemistry 280(32): 28917-28926 (2005);
    He X and Li M, Zhonghua Yan Ke Za Zhi 37(1): 50-52 (2001);
    He X and Li M, Zhonghua Yan Ke Za Zhi 33(6): 406-409 (1997);
    Hoffman EA et al., Investigative Ophthalmology and Visual Science 50(3): 1313-1318 (2009);
    Howard GC et al., Archives of Biochemistry and Biophysics 333(1): 19-26 (1996);
    Husain S et al., Journal of Pharmacology and Experimental Therapeutics 320(1): 258-265 (2007);
    Ishibashi T et al., Investigative Ophthalmology and Visual Science 43(12): 3691-3697 (2002);
    Jin M and Wu J, Zhonghua Yan Ke Za Zhi 38(5): 298-301 (2002);
    Jumper MD et al., Ophthalmic Research 30(5): 314-320 (1998);
    Junglas B et al., Experimental Eye Research 88(6): 1065-1075 (2009);
    Kageyama M et al., Journal of Ocular Pharmacology and Therapeutics 12(4): 433-440 (1996);
    Kashiwagi K et al., Journal of Glaucoma 10(4): 271-276 (2001);
    Keller KE et al., Investigative Ophthalmology and Visual Science 48(3): 1164-1172 (2007);
    Keller K et al., Investigative Ophthalmology and Visual Science #### (2009);
    Kelley MJ et al., Investigative Ophthalmology and Visual Science 48(7): 3126-3137 (2007);
    Kim JW, Korean Journal of Ophthalmology 21(1): 39-44 (2007);
    Kirstein L et al., Genes Cells 5(8): 661-676 (2000);
    Kohmoto H et al., Current Eye Research 13(3): 197-202 (1994);
    Leung YF et al., Molecular Vision 9: 425-439 (2003);
    Li G et al., Molecular Vision 13: 2282-2288 (2007);
    Li J et al., Investigative Ophthalmology and Visual Science 37(13): 2778-2782 (1996);
    Li XY et al., Zhonghua Yan Ke Za Zhi 42(11): 977-979 (2006);
    Li Z and Zhang H, Journal of Huazhong University of Science and Technology Medical
    Sciences 24(5): 486-489 (2004);
    Lin S et al., Current Eye Research 32(1): 43-50 (2007);
    Liton PB et al., Molecular Vision 15: 326-334 (2009);
    Liu X et al., Experimental Eye Research 72(6): 711-717 (2001);
    Liobet A et al., Investigative Ophthalmology and Visual Science 40(1): 113-125 (1999);
    Luna C et al., Food Chemistry and Toxicology 47(1): 198-204 (2009);
    Luna C et al., Molecular Vision 15: 534-544 (2009);
    Lutjen-Drecoll E Functional morphology of the trabecular meshwork in primate eyes.
    Progress in Retinal and Eye Research 18(1): 91-119 (1999);
    Matsumoto Y and Johnson DH Trabecular meshwork phagocytosis in glaucomatous eyes. Ophthalmologica 211(3): 147-152 (1997);
    Michael I et al., Investigative Ophthalmology and Visual Science 49(9): 3981-3987 (2008);
    Miller AM et al Lactate treatment causes NF-kappaB activation and CD44 shedding in
    cultured trabecular meshwork cells. Investigative Ophthalmology and Visual Science 48(4): 1615-1621 (2007);
    Mitton KP et al., Biochemical Biophysical Research Communications 235(1): 69-73 (1997);
    Miyamoto N et al Nipradilol and timolol induce Foxo3a and peroxiredoxin 2 expression and protect trabecular meshwork cells from oxidative stress. Investigative Ophthalmology and Visual Science 50(6): 2777-2784 (2009);
    Nakamura Y et al Signaling mechanism of TGF-beta1-induced collagen contraction mediated by bovine trabecular meshwork cells. Investigative Ophthalmology and Visual Science 43(11): 3465-3472 (2002);
    Nguyen TD et al Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. Journal of Biological Chemistry 273(11): 6341-6350 (1998);
    Obazawa M et al Analysis of porcine optineurin and myocilin expression in trabecular meshwork cells and astrocytes from optic nerve head. Investigative Ophthalmology and Visual Science 45(8): 2652-2659 (2004);
    Oh DJ et al Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Investigative Ophthalmology and Visual Science 47(9): 3887-3895 (2006);
    Pang IH et al Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Investigative Ophthalmology and Visual Science 44(8): 3485-3493 (2003);
    Peterson JA et al Heparin II domain of fibronectin uses alpha4beta1 integrin to control focal adhesion and stress fiber formation, independent of syndecan-4. Journal of Biological Chemistry 280(8): 6915-6922 (2005);
    Pfeffer BA et al A selective glucocorticoid receptor agonist (SEGRA) induces decreased myocilin protein and gene expression in cultured monkey trabecular meshwork cells when compared to traditional ocular steroids. Investigative Ophthalmology and Visual Science #### (2009);
    Polansky JR et al Regulation of TIGR/MYOC gene expression in human trabecular meshwork cells. Eye 14(Pt 3B): 503-514 (2000);
    Rhee DJ et al The matricellular protein SPARC is expressed in human trabecular meshwork. Experimental Eye Research 77(5): 601-607 (2003);
    Rosenthal R et al Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Experimental Eye Research 80(6): 837-845 (2005);
    Rozsa FW et al., Molecular Vision 12: 125-141 (2006);
    Sakai H et al., Journal of Cellular Physiology 213(3): 775-784 (2007);
    Sanka K et al., Investigative Ophthalmology and Visual Science 48(5): 2105-2114 (2007);
    Sato T and Roy S, Investigative Ophthalmology and Visual Science 43(1): 170-175 (2002);
    Savaskan E et al., Ophthalmic Research 36(6): 312-320 (2004);
    Sawaguchi S et al., Investigative Ophthalmology and Visual Science 35(1): 251-261 (1994);
    Schlunck G et al., Investigative Ophthalmology and Visual Science 49(1): 262-269 (2008);
    Sharif NA and Xu SX., Experimental Eye Research 63(6): 631-637 (1996);
    Shearer T and Crosson CE, Experimental Eye Research 73(1): 25-35 (2001);
    Shearer TW and Crosson CE, Investigative Ophthalmology and Visual Science 43(9): 3016-3020 (2002);
    Shen F et al., [Yan Ke Xue Bao 17(4): 209-212 (2001);
    Sherwood ME and Richardson TM, Experimental Eye Research 1988 Jun; 46(6): 881-895 (1988);
    Shuman MA at al., Investigative Ophthalmology and Visual Science 29(3): 401-405 (1988);
    Sohn S at al., Investigative Ophthalmology and Visual Science 43(12): 3680-3685 (2002);
    Steely HT et al., Investigative Ophthalmology and Visual Science 33(7): 2242-2250 (1992);
    Takahashi H et al., Current Eye Research 20(2): 81-84 (2000);
    Takahashi H et al., Biochemical Biophysical Research Communications 248(1): 104-109 (1998);
    Taniguchi F et al., Investigative Ophthalmology and Visual Science 41(8): 2070-2075 (2000);
    Tao W et al., Current Eye Research 17(1): 31-38 (1998);
    Thieme H et al., Ophthalmic Research 37(6): 293-300 (2005);
    Tiwari V et al., Journal of Virology 79(20): 13173-13179 (2005);
    Tripathi RC et al., Experimental Eye Research 64(3): 335-341 (1997);
    Ueda J et al., Journal of Histochemistry and Cytochemistry 48(10): 1321-1330 (2000);
    Usui T et al., British Journal of Ophthalmology 87(3): 357-360 (2003);
    Vittal V et al., Investigative Ophthalmology and Visual Science 46(8): 2857-2868 (2005);
    Webb JG et al., Experimental Eye Research 76(3): 283-289 (2003);
    Webb JG et al., Journal ofd Ocular Pharmacology and Therapeutics 22(5): 310-316 (2006);
    Webb JG et al, Experimental Eye Research 89(2): 126-132 (2009);
    Wentz-Hunter K et al., Journal of Cellular Physiology 200(1): 45-52 (2004);
    Wentz-Hunter K et al., Journal of Cellular Physiology 190(1): 46-53 (2002);
    Wordinger RJ et al., Investigative Ophthalmology and Visual Science 39(9): 1575-1589 (1998);
    Wordinger RJ et al., Investigative Ophthalmology and Visual Science 41(12): 3833-3841 (2000);
    Worthen DM and Cleveland PH., Investigative Ophthalmology and Visual Science 23(2): 265-269 (1982);
    WuDunn D, Experimental Eye Research 88(4): 718-723 (2009);
    WuDunn D, Current Eye Research 22(5): 394-397 (2001);
    Xue W et al., Investigative Ophthalmology and Visual Science 47(3): 997-1007 (2006);
    Yu AL et al., Investigative Ophthalmology and Visual Science 49(11): 4872-4880 (2008);
    Yue BY et al., Experimental Cell Research 187(1): 65-68 (1990);
    Zhang X et al., Experimental Eye Research 82(6): 968-973 (2006);
    Zhang X et al., Investigative Ophthalmology and Visual Science 44(12): 5301-5308 (2003);
    Zhao X et al., Investigative Ophthalmology and Visual Science 44(5): 1945-1952 (2003);
    Zhao X et al., Investigative Ophthalmology and Visual Science 45(11): 4023-4034 (2004);
    Zhong L et al., Journal of Ocular Pharmacology and Therapeutics 19(5): 425-436 (2003);
    Zhou L et al., Investigative Ophthalmology and Visual Science 37(1): 104-113 (1996);
    Zhou L et al., In Vitro Cellular and Developmental Biology Animals 35(3): 144-149 (1999);
    Zhou L et al., Current Eye Research 17(2): 211-217 (1998);
    Zhou L et al., Current Eye Research 19(5): 395-402 (1999);
    Zhou Q et al., Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29(3): 394-397 (2007);
  • The following represents a listing of the references cited in Example 2:
    • 1. Starner W D, Seftor R E, Snyder R W, et al. Cultured human trabecular meshwork cells express aquaporin-I water channels. Current eye research. 1995; 14:1095-1100.
    • 2. Alvarado J, Murphy C, Polansky J, et al. Age-related changes in trabecular meshwork cellularity. investigative ophthalmology & visual science. 1981; 21:714-727.
    • 3. He Y, Leung K W, Zhang Y H, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Investigative ophthalmology & visual science. 2008; 49:1447-1458.
    • 4. Verfallie C M. Adult stem cells: assessing the case for pluripotency. Trends in cell biology. 2002; 12:502-508.
    • 5. Beltrami A P, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114:763-776.
    • 6. Tropepe V, Coles B L, Chiasson B J, et al. Retinal stem cells in the adult mammalian eye. Science. 2000; 287:2032-2036.
    • 7. Coles B L, Angenieux B, Inoue T, et al. Facile isolation and the characterization of human retinal stem cells. Proc Natl Acad Sci USA. 2004; 101:15772-15777.
    • 8. Arsenijevic Y, Villemure J G, Brunet J F, et al. Isolation of multipotent neural precursors residing in the cortex of the adult human brain. Exp Neurol. 2001; 170:48-62.
    • 9. Oshima K, Senn P, Heller S. Isolation of sphere-forming stem cells from the mouse inner ear. Methods Mol. Biol. 2009; 493:141-162.
    • 10. Jiang Y, Jahagirdar B N, Reinhardt R L, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002; 41:41-49.
    • 11, Goodell M A, Brose K, Paradis G, et al. Isolation and functional properties of rnurirxe hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183:1797-1806.
    • 12. Gonzalez P, Epstein D L, Luna C, et al. Characterization of free-floating spheres from human trabecular meshwork (HTM) cell culture in vitro. Experimental eye research. 2006; 82:959-967.
    • 13. McGowan S L, Edelhauser H F, Pfister R R, et al. Stem cell markers in the human posterior limbus and corneal endothelium of unwounded and wounded corneas. Molecular vision. 2007; 13 :1984-2000.
    • 14. Zhang X, Ognibene C M, Clark A F, et al. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Experimental eye research. 2007; 84:275-284.
    • 15. Du Y, Funderburgh M L, Mann M M, et al. Multipotent stem cells in human corneal stromia. Stem cells (Dayton, Ohio). 2005; 23:1266-1275.
    • 16. Du Y, Carlson E C, Funderburgh M L, Birk D E, Pearlman F, Guo N, Kao W W Y, Funderburgh J L. Stem Cell Therapy Restores Transparency to Defective Murine Corneas. Stem Cells. 2009.
    • 17. McKenna K C, Xu Y, Kapp J A. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8-h T cells. J Immunol. 2002; 169:5630-5637.
    • 18, Sarkadi B, Orban Ti, Szakacs G, et al. Evaluation of ABCG2 expression in human embryonic stem cells: crossing the same river twice? Stem cells (Dayton, Ohio). 28:174-176.
    • 19. Zhou S, Schuetz J D, Bunting K D, et al. The ABC transporter BcrpIIABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature medicine. 2001; 7:1028-1034.
    • 20. Martin C M, Meeson A P, Robertson S M, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Developmental biology. 2004; 265 :262-275.
    • 21, Yin L, Castagnino P, Assoian R K. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchyrnal transition. Cancer research. 2008; 68:800-807.
    • 22. Yoshida S, Shimmura S, Nagoshi N, et al. Isolation of multipotent neural crest derived stem cells from the adult mouse cornea. Stem cells (Dayton, Ohio). 2006 ; 24:27 14-2722.
    • 23. Sivak J M, Mohan R, Rinehart W B, et al. Pax-6 expression and activity are induced in the reepithelializing cornea and control activity of the transcriptional promoter for matrix metalloproteinase gelatinase B. Developmental biology. 2000; 222:41-54.
    • 24. Akinci M A, Turner H, Taveras M, et al. Molecular profiling of conjunctival epithelial side-population stem cells: atypical cell surface markers and sources of a slow-cycling phenotype. investigative ophthalmology & visual science. 2009; 50:4162-4172.
    • 25. P. Challa P G, P. B. Liton, et al. Gene expression profile in a novel cell type in primary cultures of human trabecular meshwork. Investigative ophthalmology & visual science. 2003; 44:E-Abstract 3164.
    • 26. Kelley M J, Rose A Y, Keller K E, et al. Stem cells in the trabecular meshwork: present and future promises. Experimental eye research. 2009; 88:747-751.
    • 27. Stainer W D, Snyder R W, Smith B L, et al. Localization of aquaporin CHIP in the human eye: implications in the pathogenesis of glaucoma and other disorders of ocular fluid balance. Investigative ophthalmology & visual science. 1994; 35:3867-3872.
    • 28. Liton P B, Luna C, Challa P, et al. Genome-wide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle glaucoma tissue. Molecular vision. 2006; 12:774-790.
    • 29, Vittitow 7, Barras T. Genes expressed in the human trabecular meshwork during pressure-induced homeostatic response. Journal of cellular physiology. 2004; 201:126-137.
    • 30. Liton P B L Y, Luna C, et al. Identification of genes differentially expressed by Chitinase 3-like 1 in human trabecular meshwork cells. IOVS, 2009; 50:4859.
    • 31. Alexander J P, Samples J R, Van Buskirk E M, et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Investigative ophthalmology & visual science. 1991; 32:172-180.
    • 32. Zhou S, Morris J7, Barnes Y, et al. Berp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:12339-12344.
    • 33. Scharenberg C W, Harkey M A, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst. 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002; 99:507-512.
    • 34. Kim M, Turnquist H, Jackson J, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hetta.atopoietic stem cells. Clin Cancer Res. 2002; 8:22-28.
    • 35, Telford W G, Bradford J, Godfrey W, et al. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem cells (Dayton, Ohio). 2007; 25:1029-1036.
    • 36. Mathew G, Timm E A, Jr., Sotomayor P, et al. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell cycle (Georgetown, Tex. 2009; 8:1053-1061.
    • 37. Bill A. Editorial: The drainage of aqueous humor. Investigative ophthalmology. 1975; 14:1-3.
    • 38. Johnson D H, Richardson T M, Epstein D L. Trabecular meshwork recovery after phagocytic challenge. Current eye research. 1989; 8:1 121-1 130.
    • 39. Du Y, Sundarraj N, Funderburgh M L, et al. Secretion and organization of a cornea-lice tissue in vitro by stem cells from human corneal stroma. Investigative ophthalmology & visual science. 2007; 48:5038-5045.
    • 40, Jung S E, Sea K Y, Kim H, et al. Expression of MUC1 on corneal endothelium of human. Cornea. 2002; 21:691-695.
    • 41. Ding X W, Wui J H, Jiang C P. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life sciences. 86:631-637.
    • 42. Stone E M, Fingert J H, Alward W L, et al. Identification of a gene that causes primary open angle glaucoma. Science (New York, N.Y. 1997; 275:668-670.
    • 43. Wang N, Chintala S K, Fini M E, et al. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nature medicine. 2001; 7:304-309.
    Example 3 MATERIALS AND METHODS Primary Cell Culture
  • De-identified human corneas were obtained from the Center for Organ Recovery & Education (Pittsburgh, Pa.). Donor human corneas including scleral rim and trabecular meshwork (TM) not usable for transplantation were used for experiments. Cells from three donors at ages of 23-, 41- and 55-year old were used in the experiments shown. For each cell population, every experiment was repeated at least once. After careful removal of the iris, a cut was made through the inner edge of Schwalbe's line and the TM tissue was peeled off. We processed TMSC as either explant culture or dissociated cell culture. For explant culture, the tissue was cut into pieces and put in a 25-cm2 culture flask. Stem cell growth medium (SCGM) was added and the culture was left undisturbed for 10-14 days. For dissociated cell culture, the dissected TM tissue was digested in 0.3 mg/ml collagenase type-L (Sigma-Aldrich, St. Louis, Mo.) in Dulbecco's modified Eagle's medium (DMEM) at 37° C. for 20-22 hours. After digestion, the cells were filtered through a 70 μm mesh and washed twice with DMEM. Cells were seeded at 2×104 cells/cm2 in SCGM. For both cultures, cells were passaged at 80-90% confluency by trypsinization and seeded at 2-5×103 cells/cm2 in SCGM or seeded for clonal expansion by limiting dilution at 30 cells in a 96-well plate (0.3 cells/well). On average, about 1-10 percent of the 96 wells had clones with small cells which were picked up for subcultivation at 2-3 weeks after seeding. Among them, about 1/3-1/2 could be continuously passaged up to 30-50 population doublings. At least 6 clones from 3 donors were used and repeated in this study. SCGM was modified from a corneal endothelial cell culture medium16 containing OptiMEM-1 (Invitrogen) supplemented with 5% fetal bovine serum (FBS) (Hyclone), 10 mg/ml EGF (Upstate Biotechnologies), 100 μg/ml bovine pituitary extract (Biomedical Technologies), 20 μg/ml ascorbic acid, 200 μg/ml calcium chloride, 0.08% chondroitin sulfate (Sigma-Aldrich), 100 IU/ml penicillin, 100 pg/ml streptomycin and 50 μg/ml (Sigma-Aldrich). Primary TM cells were cultured in DMEM without FBS or any growth factors.
    • Isolation of Stem Cells by Side Population (SP) Cell Sorting.
  • SP cell sorting was carried out as previously described (17-19) using DyeCycle Violet (DCV) dye (Invitrogen) with minor modifications. After 2-3 passages, 5×105 to 2×106 trypsinized cells were incubated at 1×106 cells/ml in pre-warmed DMEM with 2% FBS and 10 μM DCV for 100 minutes at 37° C. To inhibit DCV efflux, 1×105 to 5×105 cells were preincubated for 20 minutes with 25 μg/ml fumitremorgin C before DCV incubation. After staining, the cells were washed twice in Hanks' balanced salt solution (HESS) with 2% FBS and stored on ice. Immediately before sorting, 2 μg/ml propidium iodide was added to identify nonviable cells. Cells were analyzed on FACSAria flow cytometer high-speed cell sorter (BD Biosciences, San Jose, Calif.), using 405-nm excitation. Cells showing reduced fluorescence at both blue (450 nm) and red (670 nm), designated SP cells, were collected. A small proportion of non-SP cells were collected separately as control. Dead cells stained with propidium iodide were omitted from the population. The sorted SP and non-SP cells were cultured and passaged without cloning for further studies.
    • Flow Cytometry
  • Clonal passaged TMSC were trypsinized and cell suspensions were passed through a 40 μfilter-cap tube to remove debris. Antibodies used are listed in Table 3. For cell surface marker staining, fluorescent conjugated antibodies (CD73-PE, CD90-Alexa 647, CD166-FITC) or appropriate isotype controls were incubated with cells on ice for 30 minutes followed by washed in 1% bovine serum albumin (BSA) in PBS once and resuspended in the same buffer for flow analysis using FACSAria flow cytometer (BD Biosciences). 2 μg/ml propidium iodide was added to identify nonviable cells. For unconjugated antibody staining (Bmi1, AQP1, CHI3L1), cells were fixed in 1% paraformaldehyde on ice for 30 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes. Cells were blocked in 10% heat-inactivated goat serum and stained with primary antibodies followed by secondary antibodies, 30 minutes on ice each. After washing, cells were resuspended in 1% BSA for flow analysis.
    • Multipotential Differentiation of Clonal Isolated TMSC
  • Neural differentiation: Clonal TMSC were seeded onto 35 mm dishes coated with FNC 7 Coating Mix (AthenaES, Baltimore, Md.) at 1×104 cells/cm2 in neural differentiation medium (NDM) containing Advanced D-MEM with 10 mg/ml EGF, 10 mg/ml FGF2, 1 μM all-trans retinoic acid (17). The medium was changed every 3 days and fresh 1 μM all-trans retinoic acid was added each time. The cells were cultured for 1-2 weeks for neural induction.
    • Adipogenic Differentiation
  • Adipocytes were induced as previously described (20) with minor modifications. TMSC were seeded onto 1% gelatin (Sigma-Aldrich) coated 35-mm dishes at 2×104 cells/cm2 and cultured in adipogenic differentiation medium (ADM) for 7 days, switched to adipogenic maintenance medium (AMM) for 4 days, then cycled again through ADM (7 days) and AMM (4 days) before fixation for histology or lysis for RNA. ADM consists of DMEM with 10% FBS, 1 μM dexamethasone, 0.5 mM methylisobutylxanthine, 10 μg/ml recombinant human insulin, 200 μM indomethacin. AMM contains DMEM with 15% FBS, 10 μg/ml insulin for 4 days.
    • Corneal Keratocyte Differentiation
  • Keratocyte differentiation was carried out as previously described (19). In brief, 3×105 TMSC were collected in a conical-bottom 15-mL tube, centrifuged at 1500 rpm (400 g) for 5 minutes to form a pellet. The pellets were cultured in SCGM for 3 days and then changed into keratocyte differentiation medium (KDM) (Advanced D-MEM (Invitrogen) with 10 mg/mL fibroblast growth factor 2 and 0.5 mM ascorbic acid) which was changed every 3 days for up to 3 weeks. Pellets cultured in SCGM served as control.
    • TM Cell Differentiation
  • Bovine aqueous humor (AH) was collected from enucleated bovine eyes by inserting a 27-gauge needle through the corneal limbus. AH was pooled and centrifuged at 10,000 g for 1 hour at 4° C. followed by filtering through 0.22 um (8) Steriflip Filter Units (50 ml) (Millipore, Billerica, Mass.). The AH was aliquoted and stored at −80° C. for later use. TM cell differentiation was induced by culturing TMSC 35-mm dishes in three different conditions: 50% AH in SCGM, 100% AH, or DMEM/F12 plus 10% FBS. The media were changed every 3 days for up to 10 days.
    • Phagocytosis Assay
  • Assessment of phagocytosis was performed following the procedures described by Zhang et al (21) with minor modifications. In brief, Alexa-488 conjugated Staphylococcus aureus bioparticles (from heat- or chemically killed S. aureus) were incubated with opsonizing reagent (purified rabbit IgG antibody) (Invitrogen) at 37° C. for 1 hour to enhance particle uptake. The cells were incubated with opsonized Alexa-488 conjugated S. aureus bioparticles at a ratio of 20 bioparticles per cell at 37° C. for 1 hour. After incubation, the cells were fixed with 4% paraformaldehyde solution for 15 minutes at room temperature (RT) and incubated with Alexa-546 goat-anti-rabbit IgG secondary antibody for 1 hour. The secondary antibody binds to the extracellular bioparticles opsonized with rabbit IgG, so the unphagocytosed bioparticles can be excluded when counting. Cell nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) at 1 μg/ml for 10 minutes. Cellular phagocytosis of bioparticles was visualized and imaged with an Olympus FluoView FV 1000 confocal microscope. The number of phagocytosed bioparticles was quantified by counting the cells and total bioparticles ingested by these cells. At least ten individual views per condition were counted and averaged. The data were analyzed statistically by one-way ANOVA followed by the Tukey post-test to assess the significance of differences between all groups.
  • Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
  • Cells were lysed with RLT buffer in the RNeasy mini kit (Qiagen, Valencia, Calif.) and RNAs were isolated following the manufacturer's instructions including treatment with DNAse I (Invitrogen) and concentration by ethanol precipitation. cDNAs were transcribed from the RNAs using SuperScript II reverse transcriptase (Invitrogen). qRTPCR of cDNAs was performed by direct dye binding (SYBR Green; Applied Biosystems) as previously described (17). Primers for SYBR assays were designed using online software (Primer 3; http://frodo.wi.mit.edu/) with the sequences shown in Table 4. Amplification of 18S rRNA was performed for each cDNA (in triplicate) for normalization of RNA content. A negative control lacking cDNA was also included in each assay. Relative mRNA abundance was calculated as the Ct for amplification of a gene-specific cDNA minus the average Ct for 18S expressed as a power of 2 (2−ΔΔCt). Three individual gene-specific values thus calculated were averaged to obtain mean±SD.
    • Histology
  • Cells cultured directly on 35-mm tissue culture dishes were rinsed briefly in PBS, fixed in 4% paraformaldehyde at RT for 15 minutes, rinsed in PBS, and stored at 4° C. in 50% glycerol and 50% PBS (v/v) until staining. Cells cultured as pellets were rinsed and fixed in 4% paraformaldehyde and embedded in optimal cutting temperature embedding compound (OCT, Tissue-Tek OCT, Electron Microscopy Sciences, Hatfield, Pa.) and cut into 8 μm sections, stored at −20° C. until staining. Nonspecific binding was blocked with 10% heat-inactivated goat serum. Sections were incubated overnight at 4° C. with primary antibodies (shown in Table 3). After three washes, anti-mouse Alexa-488 or -10 546, anti-rabbit Alexa-546 or -647 secondary antibodies and nuclear dye DAPI were added and incubated for 2 hours at RT. Samples were imaged using a confocal microscope (Olympus) with a 40× oil objective.
    • Oil Red O Stain for Adipogenic Differentiation
  • Oil red O (Sigma-Aldrich) was prepared at 0.5% in isopropanol, diluted to 0.3% in water and filtered before use. Cells were stained with oil red O for 20 minutes and rinsed with 60% isopropanol followed by hematoxylin stain for nuclei. Bright-field micrography was performed with a 40× objective.
    • Immunoblotting
  • Cells were lysed directly in 1×SDS sample buffer, heated at 95° C. for 5 minutes, and sonicated until solubilized. Protein concentration was determined by Bio-Rad DC Protein Assay (Bio-Rad, Hercules, Calif.) and then β-mercaptoethanol was added to a final concentration of 1% to the lysates and heated at 70° C. for 20 minutes. An equal amount of protein was loaded to precast 4-20% gradient (Bio-Rad) and electrophoresis was performed for 1 hour at 200V. Protein was transferred to PVDF membrane (Millipore) and blocked for 1 hour at RT in blocking buffer (1% gelatin in PBS). Membranes were incubated with primary antibodies diluted in blocking buffer with 0.1% Tween-20 followed by incubation with IRDye 680LT goat-anti-mouse, IRDye 800CW goat-anti-rabbit or IRDye donkey-anti-goat secondary antibodies for Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebr.). Fluorescent signal was visualized with LI-COR substrate followed by detection and capture of 16-bit images with an Odyssey Infrared Imager (LI-COR Biosciences).
    • Results Side Population (SP) Cells Express Stem Cell Markers
  • We previously isolated SP cells from human corneal stroma using the DNA-binding dye Hoechst 33342 17, 22 which is excited by ultraviolet light. Here we employed DyeCycle Violet Dye which is excited by violet light rather than ultraviolet laser in order to isolate SP cells from TM tissue. Both dyes can be actively effluxed by ATP-binding cassette transporter proteins and will generate an SP cell population (18, 23). To confirm the dissected TM tissue was not contaminated with adjacent corneal stromal tissue, the expression of TM specific markers AnkG (15) and CHI3L1 (24); corneal stromal marker keratocan (KERA) (25); and AQP1, expressed in both keratocytes (26) and TM (27), were compared on the TM tissue and the adjacent stromal tissue by qRT-PCR. FIG. 8A shows unfractionated cells from TM contain a small but significant side population which was collected by fluorescence-activated cell sorting (FACS). The percentage of SP cells ranged from 0.1-1.5% of the total population across multiple sorts. The isolated SP and non-SP cells were further expanded in SCGM and at passage-eight, gene expression was analyzed by qRT-PCR (FIG. 8B). The expression of stem cell genes ABCG2, Notch1, MUC1 and AnkG of SP cells was approximately 1.5 to 2-fold higher than that of non-SP cells. The expression of TM genes AQP1, MGP and CHI3L1 was approximately 4-fold lower in SP cells compared to non-SP cells. SP cells had almost no MYOC or ELAM-1 expression. The differences between SP and non-SP cells are statistically significant (p<0.05). FIG. 8C confirms that the isolated TM tissue which generated the SP cells was TM and not cornea. The isolated TM expressed AnkG (12) AQP1 and CHI3L1 but not the corneal gene KERA. In contrast, corneal stroma expressed AQP1 and KERA, but not AnkG nor CHI3L1.
    • Clonal Cultured TMSC are Distinct from Primary TM Cells
  • TMSC isolated by clonal growth and expanded in SCGM were initially compared with unfractionated primary TM cells cultured in medium without FBS or any growth factors. Immunofluorescent staining shows clonal TMSC were positive for stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; but not TM cell markers TIMP3, CHI3L1, AQP1, MGP or MYOC (FIGS. 9A-9E). In contrast, primary TM cells expressed these TM cell markers but not stem cell markers (FIGS. 9F-9J). qRT-PCR result (FIG. 9K) shows clonal TMSC, compared to primary TM cells, have significantly increased expression of stem cell genes (ABCG2, Notch1, MUC1, AnkG), decreased expression of TM genes (AQP1, MGP, CHI3L1), and decreased expression of MYOC. The differences of each transcript between the two groups are statistically significant (p<0.05).
  • Flow cytometry was used to assess the purity of clonal passaged TMSC. FIG. 10 revealed passage-four TMSC enriched with stem cell markers CD73, CD90, CD166 and Bmi1 (>95%) and lowered in TM markers AQP1 and CHI3L1 (<10%). This experiment was repeated on passage-two and passage-six TMSC with similar results.
    • Passaged TMSC are Multipotent
  • One of the characteristics of adult stem cells is multipotency, the ability to differentiate into a number of different cell types. We examined this property of the cloned TMSC by culturing them in different conditions. When TMSC were cultured in neural differentiation (13) medium containing EGF, FGF, and retinoic acid, expression of neurofilament protein, β-tubulin III and GFAP was observed (FIGS. 11A-11C), whereas MUC1 expression disappeared (FIG. 11D). In contrast, TMSC cultured in SCGM were MUC1 positive (FIG. 11H) without neural marker expression (FIGS. 11E-11G). Analysis of mRNA levels (FIG. 11I) confirmed significantly upregulated transcript of both neurofilament and GFAP after induction (p<0.05).
  • Under conditions inducing adipocytes, oil red O stained distinct intracellular lipid deposits in the induced TMSC (FIG. 12B) which were not present in TMSC cultured in SCGM (FIG. 12A). mRNA levels for adipocyte markers ap2 and Leptin were significantly increased (p<0.05) after induction in ADM/AMM compared to TMSC in SCGM (FIG. 12C).
  • When TMSC were cultured as pellets in a medium shown to induce keratocyte phenotype (19), TMSC secreted corneal stromal specific extracellular matrix components keratan sulfate (FIG. 13A) and keratocan (FIG. 13B), similar to the pellets from human corneal stromal stem cells (FIGS. 13E-13F). When TMSC were cultured as pellets in SCGM, however, they formed fragile aggregates, little extracellular matrix, and did not stain for keratan sulfate and keratocan (FIGS. 13C-13D). FIG. 13G shows increased mRNA expression of keratocan (KERA) and ALDH after keratocyte induction. The upregulation is significant (p<0.05).
    • TMSC Differentiate into TM Cells with Phagocytic Function
  • TM cells function to maintain aqueous humor outflow and proper intraocular pressure with phagocytic activity and secretion of specific enzymes and extracellular matrix (4). TM cell number decreases with age and affects intraocular pressure (6-9). We examined if TMSC can differentiate into TM cells. Clonal TMSC were incubated in several media in order to induce TM cell differentiation: 50% bovine aqueous humor in SCGM (SCGM/AH), 100% bovine aqueous humor (AH), or DMEM/F12 containing 10% FBS.
  • The expression of stem cell- and TM cell-markers was compared by immunofluorescence, qRT-PCR and Western blotting. FIGS. 14A-14E show TMSC cultured in SCGM retained expression of stem cell markers ABCG2, Notch1, OCT4, AnkG, MUC1; but not TM differentiation markers TIMP3, CHI3L1, AQP1, MGP, and not MYOC. When cultured in SCGM/AH (FIGS. 14F-14J), in AH (FIGS. 14K-140), or in 10% FBS (FIGS. 14F-14T), TMSC lost expression of stem cell markers but expressed the TM markers. Some induced TM cells were found to become MYOC positive (FIG. 14T, red).
  • qRT-PCR (FIG. 15A) revealed expression of ABCG2, Pax6, Notch1, MUC1, and AnkG to be decreased while expression of AQP1 and MGP increased upon TMSC differentiation in SCGM/AH, AH or 10% FBS. The expression of MYOC and ELAM-1 also increased after induction. Expression differences of all genes between TMSC in SCGM and induced cells in AH or in 10% FBS were statistically significant (p<0.05, oneway ANOVA followed by Dunnett's post-test). The differences between cells in SCGM and SCGM/AH were not consistently statistically significant. There were no statistical differences between cells in AH and 10% FBS.
  • Western blotting (FIG. 15B) identified ABCG2 and OCT4 expression in clonal TMSC but not in primary TM cells. A low level of ABCG2 was detected in cells cultured in SCGM/AH but not in cells in AH or 10% FBS. AQP1 and MGP were expressed in primary TM cells and induced cells but not in TMSC. CHI3L1 appeared as a doublet migrating at ˜39 kDa in primary and induced TM cells and weakly in TMSC. The lower molecular weight band may represent a glycosylation variant of the protein (28).
  • TM cells have phagocytic activity which eliminates debris, pigment, and other materials from the aqueous to maintain the outflow pathway (21, 29, 30). Phagocytic ability of the TMSC was assessed using fluorescently tagged S. aureus bioparticles comparing clonal TMSC, induced and primary TM cells (FIGS. 16A-16E). Ingested S. aureus bioparticles appear green. On average, 0.18 green particles per cell were ingested by TMSC in SCGM (FIG. 16F). In contrast, TMSC induced in SCGM/AH ingested 1.12 particles per cell; AH, 1.61; 10% FBS, 1.83, and primary TM cells had 2.11 particles per cell. ANOVA followed by Dunnett's test shows the increase in phagocytic activity by TSMC to be significant (p<0.0001) under all conditions; but none of the induced TSMC differed significantly from the activity of primary TM cells.
    • Discussion
  • In this report we describe the isolation and characterization of a population of stem cells from human TM. These cells can be isolated as a side population by FACS or by clonal growth. In culture they present a homogeneous population displaying antigenic markers previously characterized for mesenchymal stem cells (ABCG2, CD73, CD90, CD166 and Bmi1) as well as expressing gene products associated with pluripotent stem cells (Notch1, OCT4). Their stem cell character was confirmed by the ability of these cells to display phenotypic properties of cells from several different developmental lineages (neural, adipose, cornea) under culture conditions known to induce differentiation of multipotent stem cells. These cells are capable of differentiating into TM cells with phagocytic function and expressing TM markers AQP1, MGP, CHI3L1 and TIMP3 in the presence of aqueous humor or 10% serum. All of these indicate that these cells represent a resident population of adult stem cells in the human TM.
  • These results confirm and extend conclusions of previous studies suggesting stem cells in human TM. Challa et al described ‘novel’ cells in primary TM cultures expressing MUC-1 and AnkG (15). Kelley et al confirmed the expression suggesting it might be associated with a stem cell population (14). Gonzalez et al found cultured TM cells capable of forming free-floating neurospheres, a function associated with neural stem cells (12). More recently, McGowan et al observed cells expressing Oct-3/4, nestin, telomerase, PAX6, and Sox2 in the peripheral endothelium and TM of human corneas (13).
  • The above data confirm the presence of a stem cell population in TM which expressed MUC1, AnkG, PAX6, and Oct4. Expression of these markers clearly distinguish TMSC from typical mesenchymal stem cells. PAX6 is a homeobox gene essential to ocular development and is present in some adult ocular tissues but not generally present in TM31. PAX6 is present in corneal stromal stem cells (17, 32) but is not expressed by mesenchymal stem cells (33). MUC1 is a cell surface mucin associated with breast and other epithelial cancers (34). AnkG was recently described as essential for production of new neurons in the brain (35) and was described with higher expression in Schwalbe's cells that have been postulated to be responsible for cell regeneration in the TM (15). The expression of these three genes in the TMSC, therefore, defines markers distinguishing these cells from bone marrow-derived mesenchymal stem cells.
  • Similarly, the ability to differentiate to functional TM cells is a novel and, at current time, unique property of this cell population. The observation that TMSC differentiate to TM cells in the presence of fetal bovine serum suggests that differentiation to TM is the default lineage for these cells, implying that they are indeed a specialized population of stem cells, not mesenchymal stem cells from the vasculature or other tissues. The identification of cells that naturally differentiate to TM in vitro can be useful as a research tool to better understand steps in the developmental lineage of these rare cells. The ability to expand the numbers of TMSC provides access to large number of homogeneous TM cells for study in vitro, a facility not previously available from such a small tissue.
  • The above data show that TMSC express characteristic TM proteins after induction. These markers have essential roles in TM function and help to establish that TMSC can reestablish primary TM functions maintaining aqueous outflow. The water channel aquaporin 1 (AQP1) has been detected in the TM in vivo (27) as well as in cultured human TM cells and plays an important role in modulation of aqueous outflow (5). Matrix Glaprotein (MGP) has the ability to function in the TM as a calcification inhibitor36 and may be a key contributor to intraocular pressure homeostasis by regulating calcification and hardening of the TM (37). Aqueous humor contains chitinase 3-like 1 (CHI3L1) which has a protective role against inflammation, ECM remodeling and cell death in the outflow pathway (24). Myocilin expression in TM cells is induced upon treatment with dexamethasone, TGF-β or mechanical stretch and may lead to impaired outflow resistance (38). TM cells induced from TMSC with 10% serum also showed increased myoeilin expression (FIG. 15). This may be a result of the steroid content of fetal bovine serum or simply reflect the difference in myocilin expression between TMSC and TM cells (as observed in FIG. 9).
  • TM cells have phagocytic activity that is essential in maintaining normal aqueous outflow. We report here that TMSC after induction demonstrated phagocytic function almost as strong as primary TM cells. These are important findings that provide a biological source of differentiated TM cells for stem cell-based therapy on glaucoma.
  • TABLE 3
    Antibody Type Source Catalog#
    ABCG2 Mouse monoclonal Chemicon MAB4146
    Mucin1 Mouse monoclonal Santa Cruz Sc-7313
    Ankynn GG Mouse monoclonal Santa Cruz Sc-12719
    AQP1 Rabbit polyclonal Santa Cruz Sc-20810
    MGP Mouse monoclonal Santa Cruz SC-81546
    CH13L1 Goat polyclonal R&D AF2599
    TIMP3 Mouse monoclonal Santa Cruz Sc-101578
    MYOC Rabbit polyclonal Santa Cruz Sc-20976
    OCT4 Rabbit polyclonal Santa Cruz Sc-9081
    Notch 1 Mouse monoclonal BD Pharmingen 552466
    CD73 PE-conjugated eBioscience 12-0731-81
    CD90 Alex Fluor 6470- Biolegend 328115
    conjugated
    CD166 FITC-conjugated Biological KOO4-4
    Bmi1 Mouse monoclonal Millipore 05-637
    Neurofilament Mouse monoclonal Sigma N0142
    β-tubulin III Mouse monoclonal Chemicon MAB1637
    GFAP Mouse monoclonal Chemicon MAB360
    Keratan Sulfate Mouse monoclonal Kind gift from Dr.
    Bruce Katerson
    Keratocan Goat polyclonal Kind gift from Dr.
    Winston Kao
    α-tubulin Mouse monoclonal Sigma T5168
  • TABLE 4
    Seq.
    Id.
    Gene Name DNA Sequence No.
    18S  Forward: CCCTGTAATTGGAATGAGTCCAC 45
    Ribosomal  Reverse: GCTGGAATTACCGCGGCT 46
    RNA
    ABCG2 Forward: TGCAACATGTACTGGCGAAGA 47
    Reverse: TCTTCCACAAGCCCCAGG 48
    Pax6 Forward: CAATCAAAACGTGTCCAACG 49
    Reverse: TAGCCAGGTTGCGAAGAACT 50
    Notch1 Forward: AGTCTCTGCAGTGCTGGAAGTA 51
    Reverse: CTTGCAGTACTGGTCGTACAGG 52
    Muc1  Forward: CCATTCCACTCCACTCAGGT 53
    (Mucin 1) Reverse: CCACATGAGCTTCCACACAC 54
    AnkG  Forward: CATTCCTCCACGCAAGTGTA 55
    (AnkyrinG) Reverse: GTGGGTTGGCCAGTTTATGT 56
    AQP1  Forward: CTGCACAGGCTTGCTGTATG 57
    (Aquaporin Reverse: TGTTCCTTGGGCTGCAACTA 58
    1)
    MGP Forward: GCCGCCTTAGCGGTAGTAAC 59
    TCTCTGCTGAGGGGAATATGA 60
    CHI3L1 Forward: CCTTGACCGCTTCCTCTGTA 61
    GTGTTGAGCATGCCGTAGAG 62
    MYOC  Forward: AAGCCCACCTACCCCTACAC 63
    (Myocilin) Reverse: TCCAGTGGCCTAGGCAGTAT 64
    ELAM1 Forward: ACACCTCCACGGAAGCTATG 65
    Reverse: AATTGCAACCAGGTGTGTGTA 66
    MMP1 Forward: TGGACCTGGAGGAAATCTTG 67
    Reverse: AGAATGGCCGAGTTCATGAG 68
    Neurofilament Forward: GAGGAACACCAAGTGGGAGA 69
    Reverse: CTCCTCCTCTTTGGCCTCTT 70
    GFAP Forward: ACTACATCGCCCTCCACATC 71
    Reverse: CAAAGGCACAGTTCCCAGAT 72
    ap2 Forward: CATGGCCAAACCTAACATGA 73
    Reverse: AATTCCTGCCCAGTATGAA 74
    Leptin Forward: TCCTGGATTCCTTTCCTTCA 75
    Reverse: CAATCGAGGAGGGCAGAATA 76
    KERA  Forward: ATCTGCAGCACCTTCACCTT 77
    (keratocan) Reverse: CATTGGAATTGGTGGTTTGA 78
    ALDH Forward: CATTGGCACCTGGAACTACC 79
    Reverse: GGCTTGAGGACCACTGAGTT 80
  • The following is a list of references cited in Example 3.
    • 1. Gupta D. Glaucoma diagnosis and management: Lippincott Williams & Wilkins; 2004.
    • 2. Le A, Mukesh B N, McCarty C A, Taylor H R. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003; 44:3783-3789.
    • 3. Levkovitch-Verbin H. Animal models of optic nerve diseases. Eye (Lond) 2004; 18:1066-1074.
    • 4. Buller C, Johnson D H, Tschumper R C. Human trabecular meshwork phagocytosis. Observations in an organ culture system. Investigative ophthalmology & visual science 1990; 31:2156-2163.
    • 5. Stainer W D, Seftor R E, Snyder R W, Regan J W. Cultured human trabecular meshwork cells express aquaporin-1 water channels. Curr Eye Res 1995; 14:1095-1100.
    • 6. Alvarado J, Murphy C, Polansky J, Juster R. Age-related changes in trabecular meshwork cellularity. Invest Ophthalmol V is Sci 1981; 21:714-727.
    • 7. He Y, Leung K W, Zhang Y H, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci 2008; 49:1447-1458.
    • 8. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res 2005; 81:1-4.
    • 9. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984; 91:564-579.
    • 10, Daley G Q, Scadden D T. Prospects for stem cell-based therapy. Cell 2008; 132:544-548.
    • 11. Verfallie C M. Adult stern cells: assessing the case for pluripotency. Trends Cell Biol 2002; 12:502-508.
    • 12. Gonzalez P, Epstein D L, Luna C, Liton P B. Characterization of free-floating spheres from human trabecular meshwork (HTM) cell culture in vitro. Exp Eye Res 2006; 82:959-967.
    • 13, McGowan S L, Edelhauser H F, Pfister R R, Whikehart D R. Stem cell markers in the human posterior limbus and corneal endothelium of unwounded and wounded corneas. Mol V is 2007; 13:1984-2000.
    • 14, Kelley M J, Rose A Y, Keller K E, Hessle H, Samples J R, Acott T S. Stem cells in the trabecular meshwork: present and future promises. Exp Eye Res 2009; 88:747-751.
    • 15. Challa P, Gonzalez P, Liton P B, Caballero M, Epstein D L. Gene expression profile in a novel cell type in primary cultures of human trabecular meshwork. Invest Ophthalmol Vis Sci 2003; 44:E-Abstract 3164.
    • 16. Mimura T, Joyce N C. Replication competence and senescence in central and peripheral human corneal endothelium. Investigative ophthalmology & visual science 2006; 47:1387-1396.
    • 17. Du Y, Funderburgh M L, Mann M M, SundarRaj N, Funderburgh J L. Multipotent stem cells in human corneal stroma. Stem Cells 2005; 23:1266-1275.
    • 18. Telford W G, Bradford J, Godfrey W, Robey R W, Bates S E. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 2007; 25:1029-1036.
    • 19. Du Y, Sundarraj N, Funderburgh M L, Harvey S A, Birk D E, Funderburgh J L. Secretion and organization of a cornea-like tissue in vitro by stem cells from human corneal stoma. Invest Ophthalmol Vis Sci 2007; 48:5038-5045.
    • 20. Patel A N, Park E, Kuzman M, Benetti F, Silva F J, Allickson J G. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant 2008; 17:303-311.
    • 21. Zhang X, Ognibene C M, Clark A F, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res 2007; 84:275-284.
    • 22. Du Y, Carlson E C, Funderburgh M L, et al. Stem cell therapy restores transparency to defective murine corneas. Stem Cells 2009; 27:1635-1642.
    • 23. Goodell M A, Brose K, Paradis G, Conner A S, Mulligan R C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797-1806.
    • 24. Liton P B L Y, Luna C, et al. Identification of genes differentially expressed by Chitinase 3-like 1 in human trabecular meshwork cells. IOVS 2009; 50:4859.
    • 25. Liu C Y, Birk D E, Hassell J R, Kane B, Kao W W. Keratocan-deficient mice display alterations in corneal structure. J Biol Chem 2003; 278:21672-21677.
    • 26. Ruiz-Ederra J, Verkman A S. Aquaporin-1-facilitated keratocyte migration in cell culture and in vivo corneal wound healing models. Exp Eye Res 2009; 89:159-165.
    • 27. Stainer W D, Snyder R W, Smith B L, Agre P, Regan J W. Localization of aquaporin CHIP in the human eye: implications in the pathogenesis of glaucoma and other disorders of ocular fluid balance. Invest Ophthalmol V is Sci 1994; 35:3867-3872.
    • 28. Recklies A D, Ling H, White C, Bernier S M. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005; 280:41213-41221.
    • 29. Bill A. Editorial: The drainage of aqueous humor. Invest Ophthalmol 1975; 14:1-3.
    • 30. Johnson D H, Richardson T M, Epstein D L. Trabecular meshwork recovery after phagocytic challenge. Curr Eye Res 1989; 8:1121-1130.
    • 31. Collinson J M, Quinn J C, Hill R E, West J D. The roles of Pax6 in the cornea, retina, and olfactory epithelium of the developing mouse embryo. Dev Biol 2003; 255:303-312.
    • 32. Funderburgh M L, Du Y, Mann M M, SundarRaj N, Funderburgh J L. PAX6 expression identifies progenitor cells for corneal keratocytes. Faseb J 2005; 19:1371-1373.
    • 33. Nagai A, Kim W K, Lee H J, et al. Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow. PLoS One 2007; 2:e1272.
    • 34. Mukhopadhyay P, Chakraborty 5, Ponnusamy M P, Lakshmanan I, Jain M, Batra S K. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 2011; 1815:224-240.
    • 35. Paez-Gonzalez P, Abdi K, Luciano D, et al. Ank3-dependent SVZ niche assembly is required for the continued production of new neurons. Neuron 2011; 71:61-75.
    • 36. Xue W, Comes N, Borras T. Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors. Investigative ophthalmology & visual science 2007; 48:3184-3194.
    • 37. Vittitow J, Borras T. Genes expressed in the human trabecular meshwork during pressure-induced homeostatic response. J Cell Physiol 2004; 201:126-137.
    • 38. Tamm E R. Myocilin and glaucoma: facts and ideas. Prog Retin Eye Res 2002; 21:395-428.
  • All description herein relating to compositions or methods of treatment also should be construed to define “uses” of the invention. For example, the invention includes use of a source of salicylic acid for the treatment of conditions identified herein or achieving a therapeutic goal identified herein (e.g., lowing blood glucose in a human in need thereof). Likewise, the invention also includes use of a source of salicylic acid for manufacture of a medicament for such treatments/purposes.
  • The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the Detailed Description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document.
  • In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. With respect to aspects of the invention described as a genus, all individual species are individually considered separate aspects of the invention. With respect to aspects described as a range, all subranges and individual values are specifically contemplated.
  • Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention. Additional features and variations of the invention will be apparent to those skilled in the art front the entirety of this application, and all such features are intended as aspects of the invention.
  • Various references are cited herein which are hereby incorporated by reference in their entireties.

Claims (44)

1. An isolated population of multipotent stem cells which are capable of differentiating into trabecular meshwork (TM) cells.
2. The isolated population of claim 1, comprising multipotent stem cells isolated from a TM.
3. The isolated population of claim 2, wherein the TM is a TM of a mammal.
4. The isolated population of claim 3, wherein the mammal is a human.
5. The isolated population of claim 2, wherein the TM is obtained from a tissue bank.
6. The isolated population of claim 2, comprising multipotent stem cells isolated from a filtering region of the TM.
7. The isolated population of claim 6, comprising multipotent stem cells isolated from a non-filtering region of the TM.
8. The isolated population of claim 1, wherein at least 90% of the cells of the population express a stem cell marker selected from the group consisting of ABCG2, Pax6, Nestin, AnkyrinG, Mucin1, CD73, CD90, CD166, Bmi-1, Oct4, CD 117, Notch1, KLF4, and a combination thereof.
9. The isolated population of claim 8, wherein at least 90% of the cells of the population express AnkyrinG and Mucin1.
10. The isolated population of claim 1, wherein the multipotent stem cells express at a reduced level, as compared to TM cells, a TM cell marker selected from the group consisting of MGP, AQP1, CHI3L1, NCAM, TIMP3, and a combination thereof.
11. The isolated population of claim 1, wherein the multipotent stem cells are capable of differentiating into TM cells, corneal keratocytes, neural cells, and adipocytes.
12. The isolated population of claim 1, wherein the multipotent stem cells are capable of differentiating into phagocytic TM cells.
13. A method of obtaining an isolated population of TM cells, comprising obtaining an isolated population of multipotent stem cells and culturing the isolated population of multipotent stem cells in a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor, to induce differentiation of the multipotent stem cells into TM cells.
14. The method of claim 13, wherein the isolated population of multipotent stem cells is in accordance with claims 1.
15. The method of claim 13, wherein the isolated population of multipotent stem cells is obtained by side population cell sorting of cells of a trabecular meshwork.
16. The method of claim 13, wherein the isolated population of multipotent stem cells is obtained by clonal expansion of cells of a trabecular meshwork.
17. The method of claim 13, wherein the isolated population of multipotent stem cells is obtained by selective expansion of stem cells of a trabecular meshwork.
18. The method of claim 13, wherein the isolated population of multipotent stem cells are cultured in a medium comprising aqueous humor or fetal bovine serum.
19. An isolated population of TM cells obtained through the method of claim 13.
20. The isolated population of TM cells of claim 19, wherein the TM cells express at an increased level, as compared to the multipotent stem cells from which the TM cells originated, a TM cell marker selected from the group consisting of MGP, AQP1, CHI3L1, NCAM, and TIMP3, and a combination thereof.
21. The isolated population of TM cells of claim 19, wherein the TM cells are phagocytic TM cells.
22. A composition comprising the isolated population of multipotent stem cells of claim 1, and a pharmaceutically acceptable carrier, diluent, or excipient.
23. A composition comprising the isolated population of TM cells of claim 19, and a pharmaceutically acceptable carrier, diluent, or excipient.
24. The composition of claim 22, further comprising a medium comprising factors present in fetal bovine serum, aqueous humor, or in both fetal bovine serum and aqueous humor
25. The composition of claim 24, wherein the cells are from a human and the aqueous humor is from a non-human.
26. The composition of claim 22, wherein the cells are in solution.
27. The composition of claim 22, wherein the cells are cryopreserved.
28. The composition of claim 22, formulated for administration to a subject by implantation or injection.
29. The composition of claim 22, formulated for sustained, continuous release.
30. The composition of claim 22, wherein the cells are in a matrix, capsule, or gel.
31. A method of decreasing intraocular pressure in an eye, comprising administering to a subject in need of decreasing intraocular pressure in the eye the composition of claim 22, in an amount effective to decrease the intraocular pressure in the eye.
32. A method of increasing cell density in a trabecular meshwork {TM} of an eye, comprising administering to a subject in need of increasing cell density in the trabecular meshwork of the eye the composition of claim 22, in an amount effective to increase cell density in the TM.
33. A method of increasing outflow of aqueous humor from an eye, comprising administering to a subject in need of increasing outflow of aqueous humor from the eye the composition of claim 22, in an amount effective to increase the outflow.
34. A method of treating or preventing a medical condition caused by or associated with decreased cell density in a trabecular meshwork of an eye, increased intraocular pressure in an eye, decreased outflow of aqueous humor from the eye, or a combination thereof, comprising administering to a subject with the medical condition the composition of claim 22, in an amount effective to treat the medical condition.
35. The method of claim 34, wherein the medical condition is glaucoma.
36. The method of claim 31, wherein the composition is injected into the eye of the subject.
37. The method of claim 36, wherein the composition is injected into the TM or Schlemm's canal of the eye.
38. The method of claim 31, wherein the composition is injected into the blood stream of the subject.
39. The method of claim 31, wherein the cells are in a matrix or capsule and the matrix or capsule is implanted into the anterior chamber, trabecular meshwork, or Schlemm's canal of the subject.
40. A kit comprising the composition of claim 22 and instructions for use.
41. The kit of claim 40, comprising a device for administration of the composition to a subject.
42. The kit of claim 40, comprising instructions for administration of the composition to a subject.
43. A device comprising the composition of claim 22.
44. The device of claim 41, which is a syringe, a matrix, a capsule, or an intravenous bag.
US13/361,908 2011-01-31 2012-01-30 Trabecular Meshwork Stem Cells Abandoned US20120237485A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/361,908 US20120237485A1 (en) 2011-01-31 2012-01-30 Trabecular Meshwork Stem Cells
US14/605,216 US10004766B2 (en) 2011-01-31 2015-01-26 Trabecular meshwork stem cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438163P 2011-01-31 2011-01-31
US201161462255P 2011-01-31 2011-01-31
US13/361,908 US20120237485A1 (en) 2011-01-31 2012-01-30 Trabecular Meshwork Stem Cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/605,216 Division US10004766B2 (en) 2011-01-31 2015-01-26 Trabecular meshwork stem cells

Publications (1)

Publication Number Publication Date
US20120237485A1 true US20120237485A1 (en) 2012-09-20

Family

ID=46828639

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/361,908 Abandoned US20120237485A1 (en) 2011-01-31 2012-01-30 Trabecular Meshwork Stem Cells
US14/605,216 Active 2032-02-19 US10004766B2 (en) 2011-01-31 2015-01-26 Trabecular meshwork stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/605,216 Active 2032-02-19 US10004766B2 (en) 2011-01-31 2015-01-26 Trabecular meshwork stem cells

Country Status (1)

Country Link
US (2) US20120237485A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120271288A1 (en) * 2011-03-04 2012-10-25 Nanyang Technological University Methods and systems for processing images of the anterior chamber angle of an eye
CN103159643A (en) * 2013-03-06 2013-06-19 左英龙 Technology for whole membrane extraction of L-glutamine fermentation broth
EP3012328A3 (en) * 2014-09-30 2016-05-25 Sysmex Corporation Methods for detecting oncogenic mutations
WO2016109457A1 (en) * 2014-12-29 2016-07-07 Orange County Glaucoma Compositions and methods for treating glaucoma
CN110699318A (en) * 2018-07-09 2020-01-17 广西慧宝源健康产业有限公司 T cell culture medium and culture method
CN111366525A (en) * 2020-03-12 2020-07-03 西安交通大学 A method and application for rapid detection of SARS-CoV-2 virus infection in isolated blood samples
CN112451676A (en) * 2020-11-23 2021-03-09 广州准优生物科技有限公司 Optic nerve repairing composition and its preparing method and use
CN115531417A (en) * 2022-11-14 2022-12-30 青岛海尔生物科技有限公司 Application of ITGA6 positive iPSC source trabecular meshwork cells in preparation of medicine for treating ocular hypertension disease and screening method
CN119925379A (en) * 2025-03-05 2025-05-06 中南大学湘雅医院 Application of BCL3 inhibitors in the preparation of drugs for treating glaucoma

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179420B2 (en) * 2016-04-27 2021-11-23 Rohto Pharmaceutical Co., Ltd. Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
WO2021178977A1 (en) * 2020-03-06 2021-09-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating ocular disorders
WO2023080413A1 (en) * 2021-11-02 2023-05-11 주식회사 디자인셀 Stem cell culture and pharmaceutical composition comprising exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Clark et al., Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Investigative Ophthalmology & Visual Science, Vol. 35 No. 1 (January 1994) pages 281-294. *
Du et al., Multipotent stem cells from trabecular meshwork becomes phagocytic TM cells. Glaucoma, Vol. 53 No. 3 (March 2012) pages 1566-1575. *
Kelley et al., Stem cells in the trabecular meshwork: Present and future promises. Experimental Eye Research, Vol. 88 (2009) pages 747-751. *
Kim et al., Human trabecular meshwork and ciliary body epithelial cells express MUC1 Mucin. Investigative Opthalmology & Visual Science. (2002) 43: E-Abstract 2461. *
Steely et al., The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Investigative Ophthalmology & Visual Science, Vol. 33 No. 7 (June 1992) pages 2242-2250. *
Zhang et al., Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptorbeta. Experimental Eye Research, Vol. 84 No. 2 (February 2007) pages 275-284. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120271288A1 (en) * 2011-03-04 2012-10-25 Nanyang Technological University Methods and systems for processing images of the anterior chamber angle of an eye
US8687866B2 (en) * 2011-03-04 2014-04-01 Nanyang Technological University Methods and systems for processing images of the anterior chamber angle of an eye
CN103159643A (en) * 2013-03-06 2013-06-19 左英龙 Technology for whole membrane extraction of L-glutamine fermentation broth
EP3012328A3 (en) * 2014-09-30 2016-05-25 Sysmex Corporation Methods for detecting oncogenic mutations
US9845507B2 (en) 2014-09-30 2017-12-19 Sysmex Corporation Methods for detecting oncogenic mutations
WO2016109457A1 (en) * 2014-12-29 2016-07-07 Orange County Glaucoma Compositions and methods for treating glaucoma
EP3240533A4 (en) * 2014-12-29 2018-07-11 Orasis Medical, Inc. Compositions and methods for treating glaucoma
CN110699318A (en) * 2018-07-09 2020-01-17 广西慧宝源健康产业有限公司 T cell culture medium and culture method
CN111366525A (en) * 2020-03-12 2020-07-03 西安交通大学 A method and application for rapid detection of SARS-CoV-2 virus infection in isolated blood samples
CN112451676A (en) * 2020-11-23 2021-03-09 广州准优生物科技有限公司 Optic nerve repairing composition and its preparing method and use
CN115531417A (en) * 2022-11-14 2022-12-30 青岛海尔生物科技有限公司 Application of ITGA6 positive iPSC source trabecular meshwork cells in preparation of medicine for treating ocular hypertension disease and screening method
CN119925379A (en) * 2025-03-05 2025-05-06 中南大学湘雅医院 Application of BCL3 inhibitors in the preparation of drugs for treating glaucoma

Also Published As

Publication number Publication date
US20150231180A1 (en) 2015-08-20
US10004766B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
US10004766B2 (en) Trabecular meshwork stem cells
JP4950661B2 (en) Neural tissue regeneration and repair using postpartum cells
US7531355B2 (en) Methods and compositions for smooth muscle reconstruction
RU2527182C2 (en) Method for inducing stem cell migration in fatty tissue
US20040235165A1 (en) In vitro differentiation of adult stem cells
US20110142807A1 (en) Mesenchymal Stem Cells and Uses Therefor
CN109104869A (en) Express mescenchymal stem cell of at least one kind of cell surface marker object in the group being made of CD201, CD46, CD56, CD147 and CD165 and preparation method thereof and pharmaceutical composition comprising above-mentioned mescenchymal stem cell and preparation method thereof
KR102128224B1 (en) Enhanced postnatal adherent cells and method for producing the same
EP3336176B1 (en) Improved umbilical cord-derived adhesive stem cells, preparation method therefor, and use thereof
JP2005515753A (en) Stem cell differentiation
EP1402005B1 (en) A method of purification of cells
Avercenc-Léger et al. Umbilical cord-derived mesenchymal stromal cells: predictive obstetric factors for cell proliferation and chondrogenic differentiation
JP7708909B2 (en) Cell population containing adhesive stem cells, method for producing same, and pharmaceutical composition
US20150104470A1 (en) Immune modulation by peri-lymphatic or intra-lymphatic cell therapy
WO2003089631A1 (en) Method for propagating stem cells and/or progenitor cells
KR20220152240A (en) Methods of treating inflammatory bowel disease II
KR101468123B1 (en) Compositions for Improving or Treating Muscle Atrophy Diseases Comprising Stem Cells Derived from Umbilical Cord
CN115361960A (en) Methods for treating chronic graft versus host disease
US20230172991A1 (en) Method for treating inflammatory bowel disease i
CN120641115A (en) Methods of treating inflammation with cellular compositions
WO2018186420A1 (en) Cell population including mesenchymal stem cells, production method therefor, mesenchymal stem cells, and pharmaceutical composition
KR102011634B1 (en) Enhanced postnatal adherent cells and use thereof
US20170333487A1 (en) Methods of cardiac repair
WO2017039251A1 (en) Enhanced postnatal adherent cell, and use for same
US20100086525A1 (en) Compositions and Methods for Altering Pancreas or Liver Function

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DU, YIQIN;FUNDERBURGH, JAMES L.;SCHUMAN, JOEL STEVEN;REEL/FRAME:028306/0037

Effective date: 20120502

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF PITTSBURGH;REEL/FRAME:035979/0307

Effective date: 20120517